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Abstract
The

enzyme

3-hydroxy-3-methylglutaryl

coenzyme-A

reductase

(HMGR),

which catalyzes the reduction of HMG-CoA to mevalonate using two equivalents of the
cofactor NAD(P)H, is part of the mevalonate pathway, found in all kingdoms of life. This
pathway is at the heart of natural product biosynthesis constituting one of the obligate routes
to producing the building blocks for isoprenoids, which represent the largest and most
diverse class of natural products. Natural products and its derivatives continue to provide
important compounds in the fields of drug development, biomedical engineering, and
commercially-driven products. Therefore, HMGR, which performs the rate-limiting step of
the mevalonate pathway garners significant attention in these fields. Understanding of the
mechanism of HMGR remains incomplete, with gaps pertaining to the role of a putative
C-terminal flap domain (CTD) responsible for helping to modulate the positioning of active
site residues as well as the flux of substrates, intermediates, and products during the reaction.
Moreover, investigation into structural determinants of cofactor specificity, which contribute
towards varied cofactor preferences observed among HMGR homologs, point to a cofactor
helix as being crucial, and warrants further analysis.
Here, class II HMGRs from Delftia acidovorans (DaHMGR) and Streptococcus
pneumoniae (SpHMGR) are used as case-studies in elucidating biophysical, kinetic, and X-ray
crystallographic features that aid in our understanding of the three-dimensional characteristics of
class II HMGR including its catalytic and oligomeric states in solution, the role of the CTD in the
mechanism and features governing cofactor specificity. We provide the first crystal structures of
i

DaHMGR alongside complementary kinetic studies showing it to be an NAD-preferring HMGR.
We observe that NAD-preferring HMGRs are able to form hexamers whereas NADP-preferring
HMGRs predominate as dimers. Structures obtained with the CTD in novel locations expands our
knowledge on this domain. We observe a flipped conformation of the CTD that appears to capture
an intermediate state. The importance of the cofactor helix is manifest through protein engineering
efforts that switch specificity by switching this motif between HMGRs. This work expands on the
current class II HMGR paradigm as it relates to structural and functional dynamics, providing
greater insight into this biologically important enzyme.

ii

“There is nothing like returning to a place that remains unchanged to find the ways in which you
yourself have altered.”
Nelson Mandela
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Chapter I: HMG-CoA reductase, a key enzyme in natural product synthesis
1.1.

Natural Products
An exciting field of research at the interface between chemistry and biology seeks to

elucidate and modify the structures of natural products to yield chemicals that have desired
functionality and utility across industry and medicine [1]–[10]. These natural products are
biological molecules that are produced in nature by living organisms to have some benefit in the
context of the respective organism. In their native environments, these compounds typically serve
as secondary metabolites that encompass a wide variety of physiological roles including
functioning as signaling molecules, such as hormones, or redox molecules in the form of electron
acceptors and donors [11]. When extracted, these compounds can also be used as fuels, fragrances,
flavors, medicine and in many other industries [12]. With such incredible diversity available on
our planet, nature has provided a seemingly endless reservoir of compounds to mine, interrogate,
and employ.
These natural product molecules offer unique chemical d iversity and bioactivity [13] and
it is not surprising that the functions of natural products are distinctly a result of their atomic
configurations. To this end, researchers can, for example, exploit specific chemical functional
groups that facilitate interactions between a drug and an enzyme, to improve drug efficacy. This
structure and function interdependence, therefore, equips researchers with the ability to modify or
develop certain features in chemical structures giving rise to molecules with novel applications, a
venture that is both scientifically inspiring and practically useful. As an example, in some natural
products, such as some heterocyclic alkaloids, the incorporation of nitrogen into its ring moiety
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gives the molecule high biological activity [14] as observed in cases such as or quinine, an antiparasitic medicine used to treat malaria.
While interest in natural products and their derivatives stems from the ability of these
compounds to constitute important chemicals such as med icine, nutrition, fragrances, and biofuels,
its aspirations are mediated by the success of its research and development. In this study, two major
areas of research that greatly benefit from such endeavors are discussed in Chapter Five and
involve its applications in drug development and metabolic engineering of commodity chemicals.
A prerequisite to being able to utilize these approaches, however, is for researchers to not only
know and understand the structure and function of these compounds of interest, but also to explore
efficient and cost-effective ways to produce them. The present study, therefore, aspires towards
expanding this knowledgebase to further the research and development in the above endeavors.

1.2.

Isoprenoid Biosynthesis
The field of natural product biosynthesis, whether it be for the benefit of medicine or to

produce other compounds of interest, is an attractive area of study and underscores the importance
of research aiming to shed light on the biosynthesis of these important biomolecules. An abundant
source of natural products is comprised of the isoprenoids, which compose the largest and most
structurally diverse class of natural products [11] and, unsurprisingly, these ubiquitous molecules
constitute a wide variety of functions as a result of their vast assortment of structures.

2

1.2.1. Isoprenoids
Even though they are often considered secondary metabolites, in contrast to primary
metabolites whose roles are critical to survival, isoprenoids are often essential to the organism
[15]. Table 1 provides the structures of a variety of isoprenoids and isoprenoid derivatives along
with their functions. What is most remarkable, however, is that despite the extensive diversity of
the structures of isoprenoids, all are built with the same isomeric five-carbon building blocks:
isopentenyl pyrophosphate (IPP) and dimethylallyl diphosphate (DMAPP).
The discovery that all isoprenoids are made from IPP and DMAPP is attributed to a German
chemist Otto Wallach who was the first person to characterize isoprenoids, called terpenes in the
late 1800’s and early 1900’s. By studying simple ten-carbon (C10 ) monoterpenes, he began to
develop the concept of an isoprene unit as a building block towards larger complex molecules [16].
His advances in terpene chemistry and its applications, won him the Nobel Prize in Chemistry in
1910 [16]. Research on terpenes was further developed by Leopold Ruzicka, a Croatian scientist
who also earned the Nobel Prize in Chemistry in 1939, who researched higher-order terpenes and
further developed the isoprene rule [16], [17]. This rule outlined the formation of isoprenoids
through condensation of C 5 isoprene units in a head-to-tail fashion [17].
Thanks to the above pioneers in this field, we now have a clearer understanding of how
polymerization of isoprene units occurs. As shown in the example in Figure 1A, DMAPP and IPP
can be condensed in a head-to-tail fashion to give a C10 intermediate, geranyl pyrophosphate
(GPP). Further polymerization using additional IPP building blocks can continue in the same
manner giving longer chain products, farnesyl pyrophosphate (FPP, C 15 ) or geranylgeranyl
pyrophosphate (GGPP, C 20 ). The steps of polymerization, as outlined in Figure 1B, include

3

ionization where the pyrophosphate leaves, carbon-carbon bond formation between IPP and
DMAPP, and elimination where deprotonation of a neighboring hydrogen neutralizes the
carbocation by the formation of a double bond.
These Cx intermediates can further undergo cyclization by terpene synthases via
carbocation chemistry, as shown in Figure 1B, to give drastically different C x terpenes, all of which
can be additionally modified using downstream enzymes giving rise to tens of thousands of unique
isoprenoid structures; this explains the diverse structures and far-reaching applications of these
molecules. There is also intrinsic reactivity within the carbocation intermediates that are generated.
While there are many modifying enzymes, this intrinsic reactivity affords isoprenoid
molecules the ability to undergo structural rearrangements without the need for additional enzymes
beyond the terpene cyclases. Hydride shifts, for example, would enable the rearrangement of the
positive charge on the molecule by the migration of a hydrogen and its electrons to the carbocation
which results in a new location of the carbocation thus giving the molecule different reactivity. A
methyl shift, as the name suggests, involves the migration of a methyl group (as a methyl anion,
CH3 – ) to a nearby carbon; this step is often coupled with hydride migrations. Pyrophosphate
migration is like a hydride migration in that its movement to a new location essentially moves the
carbocation with new reactivity.
The carbocation, in most cases, gives the molecule many opportunities for rearrangements
and when combined with finely tuned active sites of enzymes can generate a multitude of
molecules. The positive charge generated as well as the nature of the terpene cyclase active site
that contains the carbocation drive this phenomenon; the distribution of charges and the steric
considerations of the active site dictate the outcome of the structural rearrangements, and the
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ability to undergo these reactions are intrinsic to the intermediate. As mentioned, the fascinating
feature of this extensive class of molecules is that despite their diversity in structure, they all begin
with IPP and DMAPP as the foundational building blocks, which brings into focus the biosynthesis
of IPP and DMAPP.
1.2.2. Biosynthesis of isoprenoids
In the three domains of life, archaea, bacteria and eukaryotes, there are two major
biosynthetic pathways that produce the isoprenoid building blocks IPP and DMAPP [18]. The nonmevalonate pathway, also known as the 1-deoxy-D-xylulose 5-phosphate (DXP) pathway, is
responsible for synthesizing these isoprenoid building blocks from glycolytic intermediates
whereas the mevalonate (MEV) pathway utilizes acetyl-CoA; thus, as shown in Figure 2, the DXP
and MEV pathways both utilize substrates from central metabolism. As a point of distinction, these
pathways are independent pathways where the DXP pathway is found primarily in bacteria
whereas in eukaryotes and archaea the MEV pathway is responsible for producing IPP and
DMAPP; however there exists exceptions to this classification [18]. In some instances, for example
in plants, both pathways are expressed but differ in their localization, where the MEV pathway is
found in the cytosol and the DXP pathway in plastid s [18].
Further emphasized in Figure 2, throughout biology the paths towards the biosynthesis of
the important isoprenoid precursor, the isoprene unit, is limited to just two metabolic routes, which
is discussed below, and as such these pathways continue to inspire research that aims to understand
and augment these systems with a proven history of yielding important biomolecules.

5

1.3.

Non-mevalonate pathway (DXP Pathway)
While the mevalonate (MEV) pathways it the focus of this study, it is worthwhile to obtain

a brief overview of the alternative DXP pathway especially since there are some parallels between
the DXP and MEV pathways. Early 13 C-labeling experiments observed in bacteria showed that the
synthesis of certain isoprenoids was a result of a different route other than the mevalonate pathway
[19]. It would have otherwise been a simple assignment of the atomic arrangement of the molecule
using the isoprene unit, but the results suggested an alternative pathway. These

13 C-labeling

experiments showed that the isoprene units that were produced were labeled from glycolytic
intermediates and subsequently this finding lead researchers to distinguish the starting substrates
of the DXP pathway as d-glyceraldehyde 3-phosphate (G3P) and pyruvate and not acetyl
coenzyme A (acetyl-CoA) which is the starting substrate in the MEV pathway.
The first step in the DXP pathway begins with the condensation of pyruvate and (G3P)
which is catalyzed by 1-deoxy-D-xylulose-5-phosphate (DXP) synthase using thiamine
pyrophosphate as a cofactor and yields DXP. In step two, DXP reductoisomerase takes DXP and
converts it to 2-C-methylerythritol 4-phosphate (MEP) using nicotinamide adenine dinucleotide
phosphate (NADPH) as a cofactor and required divalent metal. This step is one that is heavily
studied and is a target for fosmidomycin [20] which is an antibiotic that can be used in the treatment
of malaria. Subsequently, MEP reacts with the nucleotide cytidine triphosphate (CTP) to produce
4-diphosphocytidyl-2C-methyl-D-erythritol (CDP-ME) with the release of pyrophosphate by the
enzyme 4-diphosphocytidyl-2C-methyl-D-erythritol cytidylyltransferase.
In step four, an ATP-dependent kinase, 4-diphosphocytidyl-2-C-methyl-D-erythritol
kinase, takes CDP-ME and converts it to 4-diphosphocytidyl-2-C-methyl-D-erythritol 2phosphate (CDP-MEP) by adding a phosphate group to a terminal hydroxyl group. The next
6

enzyme, 2-C-methyl-D-erythritol 2,4-cyclodiphosphate synthase, requires two divalent metals,
one of which is always a Zn2+, to help to align and polarize the substrate phosphate groups to
cleave off CMP and yield 2C-methyl-D-erythritol-2,4-cyclodiphosphate (MEcPP) [20]. In the
sixth step, 4-hydroxy-3-methylbut-2-en-1-yl diphosphate synthase catalyzes the reduction of
MEcPP to 4-hydroxy-3-methyl-2-(E)-butenyl-4-di phosphate (HMBDP) and requires electrons
which are believed to come from the [4Fe-4S] clusters of ferredoxin [21]. Another reduction step
occurs afterwards using 4-hydroxy-3-methylbut-2-enyl diphosphate reductase, an iron-sulfur
protein, and NADPH as a redox cofactor to yield mostly IPP and some DMAPP. Isopentenyldiphosphate isomerase can interchange IPP and DMAPP to keep the ratio of these molecules
suitable for downstream reactions. The last two steps are the least understood with alternative
players, such as flavodoxin reductase and flavodoxin, being implicated in some organisms [20].An
overview of the DXP pathway is outlined in Figure 3.
In general, the importance of the DXP pathway is like that of the mevalonate pathway.
Since it is the obligate route to isoprenoids in many species, and since isoprenoid molecules have
often been shown to be essential for the survival of some organisms, this pathway is an attractive
target for drug development of broad spectrum antimicrobial drugs targeting serious diseases,
including malaria and TB [20]. Of particular importance is the fact that the DXP pathway is absent
in humans, so the ability to discriminate between isoprenoid synthesis in human versus a DXPdependent pathogen is a promising area of study.
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1.4.

Mevalonate pathway
The mevalonate (MEV) pathway is the second pathway that is responsible for the

biosynthesis of IPP and DMAPP. The pathway’s starting substrate, acetyl-CoA, plays a central
role in the overall metabolism of the cell, and as a result, the MEV pathway is intimately integrated
into broader metabolism. The MEV pathway, therefore, is an important point of regulation
especially as it relates to the production of signaling molecules, such as hormones, that support the
homeostasis of the organism. For example, in a recent study, the MEV pathway was implicated in
the progression of certain cancers. In these cancers, including leukemia, lymphoma, breast and
prostate cancers, the MEV pathway was previously shown to be upregulated , and this study
proposed the disruption of the MEV pathway in order to disrupt specific essential cellular functions
thereby reducing unwanted cell proliferation [22].
An overview of the MEV pathway [23] is presented in Figure 4. Starting with three
equivalents of acetyl-CoA, the MEV pathway uses seven enzymes to yield IPP and DMAPP. In
step 1, acetoacetyl-CoA thiolase condenses two molecules of acetyl-CoA, yielding acetoacetylCoA, after which 3-hydroxy-3-methyl-glutaryl-coenzyme A (HMG)-CoA synthase (HMGS) then
adds on another acetyl-CoA, resulting in HMG-CoA. These first two steps are not unique to the
mevalonate pathway; for example, these steps are utilized in ketogenesis which uses HMG-CoA
to eventually create ketone bodies that the body can utilize as a form of energy. Step 3 of the MEV
pathway is catalyzed by HMG-CoA reductase (HMGR), which uses two equivalents of NAD(P)H
to reduce HMG-CoA to mevalonate with loss of coenzyme A. This HMGR-catalyzed synthesis of
mevalonate is the first committed step of the MEV pathway, which is how the pathway gets its
name. The HMGR-catalyzed reaction is also the rate determining step of the MEV pathway. In
Steps 4 and 5, mevalonate-5-kinase (MK) and 5-phosphomevalonate kinase (PMK) add two
8

phosphate groups sequentially from ATP, leaving a pyrophosphate group on the C5 position to
first yield mevalonate-5-phosphate and then mevalonate-5-pyrophosphate. In step 6, using one
molecule of ATP, mevalonate-5-phosphate decarboxylase (PMD) removes the carboxylate group,
giving isopentenyl pyrophosphate (IPP), the first major product of the MEV pathway. An
additional step catalyzed by isopentenyl pyrophosphate isomerase (IPPI) interchanges IPP to
dimethylallyl pyrophosphate (DMAPP), the second major product of this pathway.
As pointed out in Figure 1, the products of the MEV pathway, IPP and DMAP can
polymerize in a head-to-tail fashion, creating longer chain isoprenoid intermediates. Additional
enzymes, such as cyclases, can make modifications to further diversify the chemical structure of
products made from this pathway. Since it is an obligate pathway towards the building blocks of
these diverse structures, the MEV pathway is often studied in the context of biosynthetic platforms.
One study utilized clustered regularly interspaced short palindromic repeats (CRISPR)
interference to transcriptionally attenuate the translation of enzymes of the MEV pathway for the
purpose of increasing isoprenoid production in Escherichia coli [24]. Using this modified pathway,
the researchers were able to improve the production of (-)-α-bisabolol, a C15 isoprenoid that is
considered to have anti-inflammatory and skin-soothing properties, while optimizing protein
quantity and reducing toxic intermediates [24], [25] . For this reason, a greater understanding of
each enzyme of the MEV pathway is warranted and the next section will focus on one critical
enzyme in this system, HMG-CoA reductase.
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1.5.

HMG-CoA Reductase
HMGR catalyzes the rate-limiting step of the MEV pathway, converting HMG-CoA to

mevalonate using two equivalents of reducing cofactors nicotinamide adenine dinucleotide
(NADH) or nicotinamide adenine dinucleotide phosphate (NADPH) as shown in Figure 4 [26].
Figure 5 shows a detailed view of this four-electron redox reaction, outlining the substrate and
cofactors involved, the intermediates, and the products of the reaction that HMGR catalyzes.
Genes encoding HMGR have been found in all three domains of life with more than 150
HMGR homologs recorded that have evolved into two classes: class I HMGR is found in
eukaryotes and in some archaea, and class II HMGR is found in some bacteria and archaea [26].
The catalytic domain of class I is comparable to that of class II HMGR; however, class I HMGRs
have two additional domains that are not present in class II enzymes, namely the transmembrane
domain and the linker, which influence the localization of HMGR such that class I enzymes are
membrane-bound, with the catalytic domain being cytosolic [27]. Since class II HMGRs lack the
transmembrane and linker domains, they exist in the cytosol [27]. When comparing the catalytical
domain of class I with class II HMGRs, the overall structures look similar. Figure 6 shows the
comparison between the overall folds of class I HMGR and class II HMGR, using human and
Pseudomonas mevalonii HMGR homologs, respectively, and includes a schematic of the domains
found in each class of HMGR.
Despite the overall similarity between the structures of the catalytic domain of class I and
the class II HMGRs, there are several noteworthy differences between the classes. For example,
class I HMGRs have an additional loop containing residues that are implicated in catalysis in
addition to residues involved in HMG-CoA binding and oligomerization that reveal differences
between the classes [28]. Another difference between HMGR classes is that class I HMGRs
10

exclusively utilize NADPH while class II HMGR cofactor preference varies [29]. In class II
enzymes, HMGRs from Pseudomonas mevalonii (PmHMGR), Delftia acidovorans (DaHMGR),
and Burkholderia cenocepacia (BcHMGR) all prefer NADH whereas HMGRs from Enterococcus
faecalis (EfHMGR) and Streptococcus pneumoniae (SpHMGR) prefer NADPH [29]–[33]. Other
HMGRs, such as those from Archaeoglobus fulgidus (AfHMGR) and Listeria monocytogenes
(LmHMGR) appear to have diminished cofactor selectivity owed to their ability to utilize either
cofactor comparably [34], [35] . In spite of these differences, it is thought that their relatively high
degree of structural similarity is a result of divergent evolution [28].
Research into both class I and class II enzymes has aimed at targeting HMGR to control
downstream product formation. In an example involving class I HMGR, researchers targeted
human HMGR with the goal of regulating the biosynthesis of hormones since the MEV pathway
generates products that go on to become product hormones. The most well-known application of
this is the use of statin drugs to inhibit the function of class I HMGR, thus inhibiting the production
of the sterol cholesterol, and therefore establishing itself as a therapeutic target for regulating
cholesterol synthesis. In the 1980’s, Michael S. Brown and Joseph L. Goldstein, doctors in the
Department of Medicine at the University of Texas Southwestern Medical Center, related HMGR
inhibition with the downregulation of low-density lipoprotein to treat cholesterol-related
cardiovascular disease. This work eventually won the Nobel Prize in 1985, and two years later, the
pharmaceutical giant Merck put out the first FDA-approved statin inhibitor, Lovastatin. Since then,
statins, whose primary target and mode of action are through its inhibition of HMGR, have become
the bestselling class of pharmaceutical compounds of all time, generating tens of billions of dollars
in sales each year [36], [37] .
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In an example that involves class II HMGR, researchers introduced the MEV pathway of
Saccharomyces cerevisiae into engineered E. coli alongside additional enzymes that produce
amorphadiene, the isoprenoid precursor to the antimalarial drug artemisinin [31]. In this study, they
interchanged the exogenous class I HMGR from Saccharomyces cerevisiae (ScHMGR) with
several different class II HMGR homologs and observed the resulting titers of amorphadiene. The
authors point out that expression of exogenous pathways in this manner can lead to toxic
metabolites, cofactor imbalances or protein expression issues, all resulting in lower yields [31].
However, they found a 120% improvement in amorphadiene production, which was achieved by
varying one factor, the HMGR homolog, is a notable achievement considering the breadth of
possible complications one may confront in engineering heterologous expression systems.

1.6.

Goals for this research

So far, this chapter has introduced the importance of natural products in medicine and
industry, and homed in on isoprenoids, the largest and most diverse class of natural products. This
led to an overview of the two obligate pathways that produce the isoprene building blocks of
isoprenoids, with an emphasis on the mevalonate pathway. Within the mevalonate pathway,
HMGR, which catalyzes the first-committed step, was highlighted and in doing so put into context
this biologically important enzyme. Specifically, this introduction serves to underscore its value
as a central enzyme in the mevalonate pathway, a pathway that is often used and engineered to
generate the precursors for some of nature’s most important molecules.
Our focus now pivots towards the in-depth study of class II HMGRs which is the core of
the exploration presented in this research. In a broad sense, the vision for this study is to advance
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our knowledge into the mechanism of catalysis of class II HMGR in order to further characterize
this key enzyme. Using a variety of biochemical techniques that survey structural and functional
characteristics, and by investigating several different class II HMGR homologs, this work aims to
elucidate and interrogate HMGR catalysis especially in the areas of cofactor specificity and
structural mechanics.
In Chapter Two, a variety of biophysical experiments are described using class II HMGRs
from Delftia acidovorans (DaHMGR) and Streptococcus pneumoniae (SpHMGR). This will be
prefaced with a survey of the literature on class II HMGR with regards to how HMGR presents
itself in its native state among class II HMGRs. Topics such as oligomerization and the overall
three-dimensional fold will be investigated to fully appreciate the experimental findings revealed
in this chapter. Results will be described from techniques involved in isolating DaHMGR and
SpHMGR, including expressing and purification methods, as well as biophysical characteristics
obtained from small angle X-ray scattering (SAXS), analytical ultracentrifugation (AUC), and size
exclusion chromatography (SEC). X-ray crystallography will be also used to substantiate the
overall structural features.
In Chapter Three, we will explore the kinetic behavior of a previously uncharacterized
HMGR, DaHMGR, and we will complement these studies with atomic-level insight into
DaHMGR catalysis. We will consult the literature on class II HMGR with regards to the enzyme
mechanism, HMG-CoA and cofactor affinity, additional Michaelis-Menten kinetic parameters,
and an overview of the crystal structures that have been published thus far. The results presented
in this chapter include those from enzyme activity assays utilizing steady-state kinetics
experiments and X-ray crystallographic structures comparing apo and ligand bound structures.
Special attention will be given to the C-terminal domain (CTD) that facilitates enzyme catalysis
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through the analysis of novel structures of DaHMGR and additional crystal structures obtained
from SpHMGR mutagenesis studies showing the CTD in various conformations.
In Chapter Four, we will explore the structural features that govern cofactor specificity
among several class II HMGRs. To set this up, there will be a survey of the literature on class II
HMGR with regards to cofactor specificity and the structural motifs that govern these interactions.
Much attention will be dedicated towards an α-helix that has been shown to dictate cofactor
preference, which we term the “cofactor helix” of HMGR. Utilizing the knowledge gained from
the prior chapters, protein engineering will be utilized to generate modified HMGRs with altered
cofactor specificity. The results presented will involve enzyme activity assays and crystal
structures with cofactors bound of these modified HMGRs and will demonstrate the power of the
complementary nature of the function of these enzymes and the structure, on a residue-by-residue
basis, as well as on a secondary structure basis.
In the final chapter, Chapter Five, the potential applications of this research will be
explored, especially in metabolic engineering in HMGR-dependent natural product synthesis, and
drug development targeting HMGR. One of the hurdles of this exciting field is the need to
overcome bottlenecking to improve product formation [12]. When bioengineering microbial hosts
to produce desired products, whether it is for medicine or for other chemicals of interest, cofactor
requirements can be a source of bottlenecking [4]. To this end, knowing an enzyme’s specificity
for a cofactor is crucial in providing the optimal functioning of the pathway to prevent delay in the
intermediate steps. It is also conceivable that with sufficient knowledge of the basis of cofactor
affinity and specificity, one could alter this cofactor preference to either make the enzyme more
promiscuous for both NADPH and NADH, or to improve the affinity of its preferred cofactor and
therefore lower its bulk concentration requirement. In addition, with atomic-level insight of the
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active site architecture of specific HMGRs, antibiotics with high specificity can be developed to
target HMGRs in specific pathogens. In sum, these endeavors make the study presented here an
important resource in the promising field of HMGR-dependent isoprenoid natural product
biosynthesis and class II HMGR antibiotic development.
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1.7.

Tables and Figures
Table 1. Examples of isoprenoids. A few isoprenoid derivatives, their structures,
and their functions, illustrating the diversity within these molecules.

Compound
Limonene,

Structure

Function
- oil with chemo-preventative and antitumor
activity
- fragrance, flavor, and cosmetics
- clove oil, used in food
- herbal benefits for use related to
gastrointestinal, respiratory
- topical alleviation of toothache
- antimalarial
- treatment of multi-drug resistant strains of
malaria

[38]

eugenol,
[39]

artemisinin,
[40]

paclitaxel
(Taxol),
[41]

-

cancer drug
treats breast, lung and ovarian cancer
used in treatment of Kaposi’s sarcoma

betaCarotene,

-

-

vitamin A precursor
antineoplastic and chemo-preventive
activity
antioxidant
induces cell differentiation and apoptosis
of some tumor cell types
involved in mitochondrial electron
transport chain
potent antioxidant

-

part of cell membranes
vitamin D and steroid precursor
roles in brain synapses and immune system

[42]

-

ubiquinone1, [43]

cholesterol,
[44]
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Figure 1. Condensation of IPP and DMAPP building blocks. (A) DMAPP and IPP join in headto-tail fashion, yielding a monoterpene, GPP. (B) GPP is rearranged into cyclized monoterpenes.
The difference between reaction 1 and 2 in Figure 3B, is dictated by the site of deprotonation by a
basic sidechain.
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Figure 2. From acetyl-CoA to isoprenoids. Acetyl-CoA is implicated in most of the important
metabolic pathways of the cell as illustrated above. There are, however, two major pathways that
convert lead to isoprene units, which are the building blocks for isoprenoids, the largest and most
diverse class of natural products. The mevalonate and DXP pathways are, therefore, crucial
metabolic pathways in the synthesis of a wide range of important biomolecules.

18

Figure 3. DXP pathway. An overview of the steps of the non-mevalonate pathway, often referred
to as the 1-deoxy-D-xylulose 5-phosphate (DXP) pathway.
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Figure 4. Overview of the mevalonate pathway. Six enzymes convert acetyl-CoA to isopentenyl
pyrophosphate (IPP), with an additional enzyme interconverting IPP to DMAPP. P represents a
phosphate group. HMGR, the focus of this research, performs the reaction that is outlined in the
box on the right, converting HMG-CoA to mevalonate using 2 NAD(P)H.
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Figure 5. Overview of the HMGR reaction. A) Basic step-by-step overview of the reaction that
HMG-CoA reductase catalyzes. The precise order of steps remains unknown. NADH is used as a
representative cofactor, although cofactor usage among HMGRs vary. The entire molecules of B)
NADH and NADPH, and C) HMG-CoA are shown whereas it is truncated in A.
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Figure 6. Comparison between the structures class I and class II HMGR. A) Various views
of an overlay of the catalytic portions of a class I HMGR (human HMGR in green PDB 1DQA)
and a class II HMGR (P. mevalonii HMGR in purple PDB 1QAX) with the N and C termini
indicated. B) and C) show primary structure schematics with residue numbering indicated of the
various domains of human HMGR and P. mevalonii HMGR, respectively, adapted from Friesen
J., Rodwell V., Genome Biology. (2004). The domains are denoted as follows: N = N domain,
found in human HMGR, that connects the linker to the large domain; L = large domain; S = small
domain; cis = region that contains the cis-loop that facilitates HMG-CoA and NADP(H) binding,
flap = mobile C-terminal domain. As depicted in the schematic, the catalytic domains are
comparable, and class II HMGRs lack the linker and transmembrane domains. The large domain
includes the region that binds HMG-CoA, and the small domain contains the region that binds
NAD(P)H.
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Chapter II: Biophysical characterization of HMGR from Delftia acidovorans
and Streptococcus pneumoniae
2.1.

Summary
Investigating the structural and functional dynamics of an enzyme in vitro is often aided

by visualization of the protein using techniques such as X-ray crystallography or Cryo-Electron
Microscopy and is complemented by functional studies assessing the thermodynamic and kinetic
behavior of the protein of interest. While X-ray crystallography can provide atomic-level detail of
the structure, which is valuable when making claims about steps of the mechanism, a limitation of
this technique is that it requires the creation and optimization of protein crystals that necessarily
diffract to high enough resolution. Additionally, X-ray crystallography provides a static snapshot
of the protein embedded in the crystal lattice, potentially restricting the dynamic nature of the
protein. For this reason, complementary biophysical analysis using alternative techniques must be
consulted to substantiate and corroborate the claims being made.
Depending on the nature of the hypothesis, a more comprehensive understanding of the
protein must utilize approaches that appropriately addresses how an enzyme behaves in its native
environment. Often, this is accomplished in vitro by studying the protein in solution. In this
chapter, we will review the literature on class II HMGRs as it pertains to the overall structure by
examining both the static snapshots provided by X-ray crystallographic analysis as well as
dynamic, solution state studies. We will explore some of the methodology of these techniques in
detail to recognize the advantages and limitations as we begin to characterize class II HMGR in
vitro. HMGR proves to be an intriguing enzyme from a structural standpoint due the intricate and
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dynamic mechanism which it performs. These experiments were performed using HMGR from
the lesser characterized Delftia acidovorans (DaHMGR), as well as HMGR from Streptococcus
pneumoniae (SpHMGR).
Following an overview of the expression and purification of the two HMGRs, X-ray
crystallography will outline the overall structural features of these enzymes including the global
fold, and secondary structural motifs. Size Exclusion Chromatography (SEC) will reveal that these
proteins exist in different oligomerization states. SEC will show that SpHMGR exists as a dimer
in solution which is corroborated by the way the protein crystallizes in the crystal lattice. In
contrast, DaHMGR in the crystal structure forms a hexamer. However, as revealed by SEC,
DaHMGR will be shown to exist in an equilibrium between multiple oligomeric states, requiring
small-Angle X-ray Scattering, equipped with an SEC, to assess the oligomeric state of the
predominant species, and will suggest that DaHMGR exists in an equilibrium between dimer, and
a hexamer. Collectively, these results will begin to lay the foundation as to how class II HMGR
functions in the cell and more specifically will begin to address its varying tertiary states within
the context of catalysis.

2.2.

Introduction
Structure and function are inextricably linked across biology and this relationship is

particularly exhibited in protein folding. Thus, decades of research have sought to examine the
structure of proteins to visualize how they perform specific, life-giving functions. Meanwhile,
parallel work has been done to investigate how proteins, from their primary amino acid sequence,
fold into elaborate three-dimensional structures [1]. The most recent advances to this end has
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produced a computational tool, called AlphaFold 2, that is able to predict structures purely from
their amino acid sequence by utilizing machine learning that surveys physical and biological data
as part of its algorithm – a remarkable achievement [2]!
Among other factors, these computational methods consider the various protein folding
forces that facilitate the formation of its three-dimensional conformation. Noncovalent interactions
such as hydrophobicity, hydrogen bonding, Coulombic interactions, and van der Waals
interactions are at play and collectively aid in the thermodynamics of achieving a more stable
conformation [3]. There are also secondary structural interactions between the backbone of the
polypeptide chain, and further interactions between the side chains involved [3]. These interactions
not only facilitate the formation of the tertiary structure, but also quaternary structure where these
forces contribute towards protein-to-protein interactions in the form of oligomerization. The
formation of protein oligomers go on to have significant impact on the protein’s stability and
functionality [4]. For this reason, when studying the activity of a protein in vitro, attention must
not be limited to a static image of the overall fold; there should be tantamount awareness of the
forces that facilitate conformational changes and movements as well as those involved in
oligomerization dynamics.
In Chapter Three, there will be a focused study of the mechanism of HMGR and will
explore in detail the atomic-level level understanding of how HMGR works. This section,
however, will preface those endeavors by focusing on the overall quaternary structural features of
this enzyme and will use HMGRs from Streptococcus pneumoniae (SpHMGR) and Delftia
acidovorans (DaHMGR). Using these two homologs as case studies, two primary areas that will
be highlighted include 1) the overall three-dimensional dynamics, and 2) higher order oligomeric
states. Both topics rely on the aforementioned forces that modulate secondary, tertiary, and
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quaternary structure formation and movements and are discussed here. Also included, is a review
of the technique of small-angle X-ray scattering (SAXS) used in this section to grasp the
advantages and limitations of this approach in helping to unravel the fascinating structural
considerations of class II HMGR.
2.2.1. Overall three-dimensional fold of class II HMGR
The first crystal structure of a class II HMGR was determined in 1995 and was a model of
HMGR from Pseudomonas mevalonii (PmHMGR) determined at 3.0 angstroms [5]. PmHMGR, a
45 kDa protein, is like all HMGRs in that it is an obligate homodimer where two identical
monomers come together to make up a dimer complex required for the reaction. In their structure,
Lawrence et al. observed this obligate dimer in the asymmetric unit noting a large monomer-tomonomer interface of which a substantial portion is solvent-inaccessible [5]. This early model of
PmHMGR did not include the last 50 residues of the enzyme and it was believed that this region
was disordered in the crystal lattice [5]. Subsequently, PmHMGR structures at higher resolution,
revealed novel locations of these last 50 residues and was later termed the C-terminal flap domain
due to its perceived mobility during the course of the reaction[6].
The formation of the obligate homodimer includes two helices from each monomer, that
contribute towards a familiar dimerization motif made up of an antiparallel four-helical bundle
that constitute the core of the dimerization interface [5]. Dimerization allows the coming together
of the active site where the substrate of one monomer reacts with the cofactor of the adjacent
monomer. Figure 1 aids in highlighting the key overall structural features pertinent to this
chapter.
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Similarly observed in later structures of HMGR from Streptococcus pneumoniae
(SpHMGR), the first ~70 residues of each monomer contain an interlocking motif that intertwine
at residues 38-58 (SpHMGR numbering) and form an interlocked β-sheet [7]. A conserved
sequence, ENVIGX 3 I/LP where X represents variable residues, makes up an important part of this
dimerization motif[8]. Figure 2 shows a close-up of this dimerization interface. The dynamics of
how this interlocking conformation is achieved is not known. For example, as each monomer is
translated, do they fold independently, then undergo conformational changes to interlock with
another monomer? Or do two monomers fold simultaneously into a dimer? Regardless of the
method of dimerization, the nature of this motif suggests that there are concerted features that
ensure that the dimer form remains intact.
The reason for this may lie in the fact that this N-terminal interlocking region contains
important substrate binding residues, Glu50 and Asn51, such that these residues in one monomer
interact with HMG-CoA of the adjacent monomer [7]. This observation, that there is an extensive
interlocking interface with residues implicated in catalysis, supports the notion that the integrity
of dimerization is pertinent to enzyme activity, and that the dimer conformation is an obligate
active form.
Each HMGR monomer can be broken up into three domains: a large, a small, and a Cterminal flap domain [9]. The small domain, residues ~110-215, is made up of three anti-parallel
β-sheets that stack up against two helices in an arc-like fashion and is linked to the large domain
by two β-strands. The C-terminal flap domain, which extends from the opposite end of the
molecule as the small domain, is made up for a three helical bundle linked to the large domain by
a flexible strand and is made up of the last ~50 residues.
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The rest of the molecule constitutes the large domain and is made up of ten helices and two
sets of anti-parallel β-sheets. As noted by Lawrence et al., the large domain has a unique fold
where a long helix, greater than 20 residues, runs through the center of this domain and is located
within a wall of three separate substructures made up of a combination of helixes and β-sheets
with has an “arm” made up of the first ~60 residues at the N-terminus that extends away [5]. Figure
3 shows one monomer of SpHMGR as well as a corresponding two-dimensional topological
outline of the secondary structural features with corresponding residue numbers generated by
PDBSum [10].
When the monomers come together, without the C-terminal flap domain, they form a dimer
that was initially described as having a “T” shape [5]. The large domains of each monomer
primarily make up the central vertical component of the T whereas the small domains extend to
either ends of the horizontal component. The C-terminal domain has been located in several
distinct positions, as will be discussed in Chapter Three, and can span a wide area on the left or
right of the overall T shape. In total, the overall structure of the homodimer contains both novel
and previously observed structural motifs, an elaborate interlocking dimerization feature, and a
flexible domain, all of which make HMGR a fascinating enzyme to study from a structural
perspective. In addition to the dimerization motif discussed above, which points to the necessity
of the obligate homodimer, evidence also points towards higher order oligomerization in some
HMGRs and will be discussed next.
2.2.2. Higher order oligomerization
Since the early dissociation experiments conducted by Theodor Svedberg, which revealed
that some proteins exist as multimeric complexes, extensive research has been done to assess not
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only the role of oligomerization but also the forces that promote the coming together of protein
complexes as well as the evolutionary mechanisms that have produced its roles [11] [12]. Proteinprotein interactions rely on hydrogen bonding, salt bridges, and most notably, hydrophobicity, and
in the context of oligomerization, can form either hetero or homo oligomers if either different or
identical subunits come together, respectively [11], [13]. A significant amount of proteins form
homo oligomers and this phenomenon has physiological implications on enzyme activity and
stability but also on broader processes in the cell including pathway regulation, gene expression,
and signaling [12]. HMGR oligomerization presents an interesting case study on this topic since
there appears to be different oligomeric preferences among HMGR homologs.
2.2.2.1.

Class I HMGR
As pointed out by Istvan et al., early class I HMGR studies showed that mammalian

HMGR, specifically rat HMGR, had a molecular weight of 50 kDa on a denaturing gel but 200
kDa in a size exclusion experiment [8]. This offered initial hints that the protein might exist as a
multimer. This work, done by Brown et al., showed that at low temperatures the enzyme was
inactive but with the addition of high amounts of salt, at 4 M, the high ionic environment was able
to prevent the loss of activity [8], [14]. With this observation, they reasoned that the enzyme was
a multimer held together by hydrophobic forces that were disrupted at lower temperatures but
stabilized by electrostatic interactions with high salt [8], [14]. As previously mentioned,
hydrophobicity plays a key role in protein folding where non-polar amino acids prefer being buried
in the protein and polar amino acids being exposed to the solvent, and temperature and ionic state
have different effects on this process[14].
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Later work revealed that mammalian HMGR exists as a tetramer, as shown in Figure 4A.
Armed with the crystal structure of the catalytic portion of human HMGR (hHMGR), it was
observed that the aforementioned obligate dimers come together to form the tetramer and the
authors propose that this tetramer formation was more stable than its dimer form [8]. In their crystal
structure, Istvan et al. show that hHMGR forms tetramers with D2 symmetry, and note how the
monomers from each dimer, extensively wind around each other as shown in Figure 4B, forming
the active site that exists at the interface between two monomers similarly observed in PmHMGR
above [8].
In its tetrameric form, about half of the surface is total solvent-inaccessible of which ~40%
is involved in dimer formation and the rest involved in tetramer formation [8]. This extensive
interface, observed in the crystal structure, showing a large contact area between the dimers,
further substantiates the tetrameric form found in solution which was corroborated by analytical
ultracentrifugation experiments[8]. In the case of hHMGR, the soluble catalytic portion is part of
a larger assembly that includes a membrane region. It is believed that the soluble portion may
facilitate tetramerization at the membrane region, and that dissociation of the tetramer membrane
region exposes HMGR to protease activity leading to inactivation of the enzyme, thus serving as
a mechanism of control[8]. The importance of this characteristics is that oligomerization is
implicated in modulating the function of this enzyme, further emphasizing the significance of
understanding this phenomenon as it relates to HMGRs in other organisms.
2.2.2.2.

Class II HMGR
In their first crystal structure of a class II HMGR, PmHMGR, Lawrence et al. observed

that the dimer in the crystal structure was able to form a hexameric assembly made up of three
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dimers formed around a threefold crystallographic axis [5]. However, it remained unclear whether
this was a crystallographic artifact or whether a hexamer formation existed in solution.
Subsequently, Rogers et al., performed gel filtration and sedimentation experiments and concluded
that the active form in solution was indeed a hexamer. This hexameric form was later also observed
in the crystal structure HMGR from Burkholderia cenocepacia (BcHMGR) [15]. It is worth noting
that both PmHMGR and BcHMGR are NAD(H)-preferring HMGRs. HMGR from Bordetella
petrii (BpHMGR) has not been fully characterized, but initial studies suggest that it is NAD(H)preferring[16]. The Kung lab has solved structures of BpHMGR with various ligands bound
(Raining Huo and Yan Kung, unpublished) which crystalizes an entire intact hexamer in the
asymmetric unit.
Interestingly, using size exclusion chromatography, BcHMGR was shown to have
potentially two other oligomeric states, a nonamer and a larger unknown assembly, such that the
equilibrium between these species shifted based on the pH of its buffer and enzyme concentration
[15]. In the case of hHMGR, formation of the tetramer buried about half of the surface area
whereas in the hexameric assembly, Peacock et al point out that the hexamer buries a significantly
smaller surface area and is more hydrophilic [15]. Their analysis of the hexameric interface
revealed a “cylinder resting in the palm of a hand” configuration where a helix from one dimer
rests across a four-stranded β-sheet on the adjacent dimer, and Peacock et. al point out that, in the
case of BcHMGR, only a single salt bridge and two protein-protein hydrogen bonds hold this
interface together[15]. Another unique finding in this study was that there exists a hexamer-tohexamer interface, involving residues 8-17, containing an Arg11 that forms interactions with
coenzyme A(CoA) [15]. When they computational removed CoA and performed molecular
dynamic simulations, they observed that Arg11 no longer interacts with CoA and instead with
35

Asp237, suggesting a dissociation mechanism of the hexamer-to-hexamer interface. The authors
go on to propose that BcHMGR functionality can be described using the morpheein model of
allostery where its catalytic activity is dynamically controlled by distinct oligomeric protein
conformations[15], [17].
In 2018, the Kung Lab solved two structures of the NADPH-preferring HMGR from
Streptococcus pneumoniae (SpHMGR), one with HMG-CoA bound (PDB 5WPK) and one with
NADPH (PDB 5WPJ)[7]. The NADPH-bound structure formed two dimers in the asymmetric unit
whereas the HMG-CoA-bound structure formed a dimer. In addition, two other apo structures of
SpHMGR with no associated publication (PDB 3QAU and 3QAE) contain a single monomer in
the asymmetric unit but crystallographic symmetry can create the dimeric assembly. This would
suggest that SpHMGR exists as a dimer in the crystal lattice, but its solution state remains
uncharacterized. The Kung Lab also recently solved the structure of HMGR from Enterococcus
faecalis (EfHMGR) with no ligands bound and crystallized with a single monomer in the
asymmetric unit (Jingyi Ren and Yan Kung, unpublished) that is also able to create the dimer using
crystallographic symmetry. In a study of Listeria monocytogenes HMGR (LmHMGR), an HMGR
that can use both NADP(H) and NAD(H) but has a preference for NADP(H), size exclusion
chromatography revealed a mass of 84.9 kDa suggesting that it exists as a dimer in solution[18].
Taken together, oligomerization of numerous HMGRs appears to vary and warrants further
investigation into the contributing factors.
So far, this chapter has examined the overall three-dimensional fold of HMGR and
discussed the important features that have informed our structural perceptions of this intriguing
enzyme. Much of this work has relied on X-ray crystallography which provides static snapshots
of the enzyme as it is contained in the crystal lattice. X-ray crystallography, while potentially
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helpful in its ability to predict the solution state oligomerization of the protein, is not a solutionbased study and therefore is inconclusive in its assessments of how the protein might truly exist in
its native state. We subsequently explored the published evidence of HMGR oligomerization in a
variety of organisms, however, there is limited solution state analysis done that more definitely
describe HMGR oligomerization. As such, the goals of this section will begin to address these
areas. To preface these goals, however, the following section describes an important technique
used that will be utilized in this chapter, that will help inform the nature of the findings.
2.2.2.3.

Solution-state technique - SEC-SAXS
Small-Angle X-ray Scattering (SAXS) of proteins is a solution-based technique that can

provide insight into the structure of the protein as it exists in a given solution. Unlike traditional
X-ray crystallography that requires the production of crystals and yields a static snapshot of the
protein in the crystal lattice, SAXS has an inherent advantage of providing information that may
be more closer to the protein’s native structure since does not need to be confined to a crystal
lattice. [19]. SAXS cannot provide high resolution structural models to the same extent as X-ray
crystallography. It is, however, more suitable for providing high-precision data with regards to
size and shape [20]. For this reason, SAXS often complements X-ray crystallography when
assessing the structure and function of macromolecules. In this section, we will explore the
fundamentals of SAXS and detail the various data analytical techniques used to better understand
the results presented later in this chapter.
A SAXS experimental setup looks very similar to X-ray crystallography in that a high
intensity light source provides an incident beam targeted at the sample, causing a resultant
diffraction, in the case of crystallography, or scattering, in the case of SAXS, pattern on a detector
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downstream of the beam direction. In X-ray crystallography, the diffraction pattern, or spots, is
the result of constructive and destructive interference of the waves as they pass through repeated
units of the protein in the crystal lattice. In SAXS, the scattering waves constructively or
destructively interfere but due to the rotational averaging of the protein in solution, the resulting
scattering pattern observed on the detector is isotropic i.e., the scattering is radially symmetric that
is more intense closer to the center. The pattern provides intensity (I) as a function of the amplitude
of the scattering vector, q, where q =

4π sinΘ
λ

; the angle (<3 °) at which scattering occurs is at 2Θ

generated from the angle formed by extrapolating the incident beam and the scattered x-rays [20].
Figure 5 shows an outline of a traditional SAXS experiment.
In an experiment, the solvent scattering is subtracted from the scattering of the protein in
the solvent and yields plot of the scattering intensity versus the distance from the beam center.
This plot is a scattering profile that directly, and precisely, relates to the shape of the protein. It is
important to consider factors that influence monodispersity of the sample that must be taken into
consideration when interpreting data. If one has a single protein conformation versus this same
protein that exists in multiple oligomeric states, the scattering profile will give be different. A size
exclusion chromatograph (SEC) is sometimes equipped upstream of the scattering experiment such
that protein species can be separately assessed.
Structural information that can be obtained from the initial plot of scattering intensity
versus the magnitude of the scattering angle is not immediately intuitive and further analysis is
required to utilize the breadth of insight that can be achieved using this technique. One challenge
of SAXS is that it typically requires highly pure samples since scattering is very sensitive to all
moieties within a sample, including impurities and aggregation [20]. By including a Size-
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Exclusion Chromatography apparatus upstream, as well as the ability to customize the buffer
conditions to ensure protein purity, some of these concerns can be alleviated. In sum, SAXS can
be powerful technique that provides a wealth of information on solution state of proteins, without
any prior knowledge of the structure required or the formation of crystals.
2.2.3. Goals of this section
Prior to the work presented here on DaHMGR, the crystal structures of only three HMGRs
were reported – hHMGR, PmHMGR and SpHMGR –of which only the latter two are from class
II. The structure of a third class II HMGR, BcHMGR, was later solved. Considering how
ubiquitous and central this enzyme is across biology, additional structures of HMGR remains a
high priority. As such, one goal involves solving the crystal structure of apo-DaHMGR, to analyze
its overall architecture in the context of previously reported observations, and to ultimately add to
the above list of structurally characterized class II HMGRs. However, a necessary pre-requisite to
this goal is to have a feasible approach of isolating soluble DaHMGR protein with relatively high
concentrations and purity. In the case of DaHMGR, this required customization and optimization
of purification techniques and will be discussed in detail.
In the studies that do have crystal structures, there is limited complementary biophysical
analysis available. A preliminary evaluation of the available data suggests that oligomerization
among the various characterized HMGRs vary. Moreover, questions into how and why
oligomerization influences activity remain. Accordingly, the second goal of this section is to utilize
the aforementioned biophysical techniques to explore the oligomerization of class II HMGR using
DaHMGR and SpHMGR.
Importantly, in the case of DaHMGR additional work to complement this crystal structure,
using techniques such as SEC and SAXS, will be employed. Since the crystal structure of
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SpHMGR already exists, the goal then is to further investigate the biophysical characteristics of
this previously studied HMGR, using SEC. What are the oligomeric states of DaHMGR and
SpHMGR? Do they present themselves in predominantly one oligomeric state or an equilibrium
between multiple states? Are there patterns in the oligomerization between various HMGR
homologs that are related to their structure and/or function? Considering that, in the case of
hHMGR, oligomerization is a mode of regulation, greater insight into the mechanisms of
oligomerization may provide the basis for understanding the physiological relevance and the
driving forces behind them.

2.3.

Results

2.3.1. Protein Expression and Purification of DaHMGR and SpHMGR
Successful overexpression of DaHMGR and SpHMGR was observed by evaluating the
protein makeup of cells pre- and post-induction prior to purification. When purifying DaHMGR,
during early attempts, significant protein precipitation was observed during fractionation.
Fractions containing the highest amount of protein precipitated shortly after fractionation. Upon
further examination, it was also observed that during the incubation of protein with the Ni2+ resin
prior to fractionation, precipitation was evident. It was hypothesized that protein precipitation was
concentration dependent and required an amended purification protocol.
To further optimize DaHMGR purification, during fractionation, volumes of as low as 0.5
mL/fraction were collected to prevent batch precipitation of large amounts. This necessarily caused
some fractions to form precipitation, but other fractions that had moderate amounts of protein did
not precipitate. Subsequently, fractions were centrifuged at high speed and combined with other
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fractions with similar concentrations. It was observed that DaHMGR prefers concentrations at ~8
mg/mL or lower. This modified procedure allows for fractionation with greater control over the
elution profile which enables the ability to acquire soluble protein at feasible amounts. SpHMGR,
in contrast, purified without the above modifications and Figure 6 shows representative
purification gels suggesting relatively high homogeneity using the above DaHMGR and SpHMGR
purification protocols.
Since DaHMGR precipitated at high concentrations, buffer exchange into the storage
buffer was not trivial. Initially, using a centrifugal concentrator, protein precipitation was observed
due to the concentration gradient generated when centrifuging the protein in the concentrator. It
was reasoned that a traditional dialysis, with the protein in dialysis membrane rotating in storage
buffer, would be more appropriate. However, significant precipitation was observed using this
method too. This could possibly be due to local pockets of high concentration protein during
dialysis overnight, or it could be attributed to DaHMGR’s intrinsic instability over time. Thus, a
desalting column was successfully used to perform buffer exchange as outlined in the methods.
2.3.2. Overall structure of DaHMGR
Only the overall structure of DaHMGR is discussed here since the structure of SpHMGR
was previously reported and incorporated into the discussion. Apo DaHMGR crystallized with one
monomer in the asymmetric unit. Using crystallographic symmetry, the adjacent monomer that
forms the obligate homodimer can be generated. Electron density for residues from 3-376 were
observed and modeled in. No electron density for the C-terminal domain was observed, which is
made up of residues 378-429. The active site and cofactor-binding sites are unoccupied. The
structures of apo DaHMGR align well with other DaHMGR structures (discussed in Chapter
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Three) as well as with those of other class II HMGRs, with a root-mean-square deviation for Cα
atoms (rmsd) of 0.75–0.84 using the structure of cofactor-bound SpHMGR (PDB entry 5WPJ).
Figure 7 shows an overlay of apo DaHMGR and structures of HMGRs from other class II HMGRs.
2.3.3. Size Exclusion Chromatography (SEC)
2.3.3.1.

SpHMGR SEC
The size of SpHMGR expressed above is 49.2 kDa as a monomer, and therefore a dimer

would constitute 98.4 kDa. The elution profile of SpHMGR shows that a single peak at
approximately ~76 mL corresponds with a dimer. As shown in Figure 8, an overlay of protein
standards and the elution of SpHMGR, SpHMGR elutes between the 44 kDa and 158 kDa protein
markers and more convincingly resembles the size of a dimer.
2.3.3.2.

DaHMGR SEC
The size of DaHMGR expressed above is 48.1 kDa as a monomer, and therefore a dimer

and hexamer would be 96.2 and 288.6 kDa, respectively. The elution profile of DaHMGR reveals
four peaks as shown in Figure 9. The largest peak, which eluted at ~48 mL corresponds with a size
>670 kDa and likely represents aggregation. The peak at ~63 mL represents a peak that is markedly
larger than 158 kDa that may represent a hexamer and the peak at ~76 mL corresponds with a
dimer. A peak at 88 mL suggests the presence of a species between 17 and 44 kDa that likely
represents a contaminant. Upon examination of the SDS-PAGE gels, Figure 6, there is indeed a
band representing protein between 30-40 kDa. Thus, in its soluble state, DaHMGR likely exists in
an equilibrium between hexamers and dimers.
2.3.4. DaHMGR SEC-Small-angle X-ray scattering
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The size exclusion chromatograph of the sample revealed that there were multiply
overlapping peaks, but it was possible to deconvolute three species: aggregate, a larger species,
and a smaller species. Data from the larger and smaller species were processed separately. It is
worth noting that only two peaks were analyzed, which does not rule out the presence of other
species in the sample which would include a dimer. Only the two largest peaks were feasible for
SAXS analysis as determined by the collaborators from the Ando Lab, Cornell University who
assisted us with data analysis.
Depicted in the various plots on Figure 10, namely the Guinier, Kratky, and Logarithmic
plots, is the larger species analyzed with respect to a dimer, tetramer, and hexamer. In these plots,
the data is computationally compared to a theoretical fit of each of these oligomers. The larger
species does not appear to resemble a dimer. Of the two higher order oligomers chosen to compare
this species with, tetramer versus hexamer, the larger species more resembles a hexamer than a
tetramer.
As depicted in similar plots on Figure 11, the smaller species also does not resemble a
dimer. However, upon examining whether this species resembles a hexamer or tetramer, we
observed no significant differences. Since there is no evidence that a tetramer formation is a
feasible oligomerization state of class II HMGRs, we computationally simulated a dimer: hexamer
ratio of 40%:60%, respectively, and noted that this configuration fits the tetramer and hexamer
formations comparably as shown in Figure 12. This suggests, that instead of the smaller species
resembling a tetramer, it may exist in an equilibrium between dimer and hexamer. This agrees with
the SEC profile of DaHMGR in Figure 9.
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2.4.

Discussion
HMGR, a central enzyme found across all kingdoms of life, continues to be a gratifying

protein of interest owed to its fascinating structural and functional dynamics that promise fruitful
inquiry. Intriguing characteristics include structural features such as the mobile C-terminal flap
domain, the non-Rossmann dinucleotide binding domain, and the dimerization motif of the
obligate dimer. But despite its prevalence in biology, there are only a handful of crystal structures
available for class II HMGR. Moreover, there is a lack of complementary biophysical analysis of
how the protein behaves in solution. Characterizing a protein requires a multidisciplinary approach
and depending on the nature of the investigation, one technique might be preferred over another,
often requiring additional evidence that corroborates the conclusions.
In this chapter, one goal was to optimize the isolation of DaHMGR protein for X-ray
crystallography experiments. Subsequently, by acquiring the crystal structure of DaHMGR, the
overall three-dimensional fold was investigated in the context of previously solved structures of
class II HMGRs. However, as alluded to, X-ray crystallography is limited in its ability to provide
insight into questions about certain structural features of this enzyme including its native-state
oligomerization. Therefore, a second goal was to investigate the oligomerization of HMGR to
understand how this protein might exist in its native environment. This goal relied on solutionstate studies that were discussed earlier in this chapter. In this discussion, we now critically reflect
on and synthesize the observations gained from the above two goals, with the hope of further
characterizing the structural features of this intriguing enzyme.
During purification, DaHMGR was especially sensitive to concentration. Precipitation was
evident as early as during the lysis of E. coli expression cells and persisted throughout purification
steps. An additional screen of buffers suggested that high amounts of salt, NaCl, glycerol, and
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reducing agent, TCEP, all aided in stabilizing soluble protein and these conditions were utilized
throughout protein purification steps. Following fractionation of the protein during affinity
chromatography, the protein was collected and directly applied to a desalting column for the
purpose of buffer exchange. Following fractionation from the desalting column, protein was stored
for use. This protocol prevented centrifugation steps that are typically used during buffer exchange
or concentrating of the protein using a centrifugal filter. While the purification protocol benefited
from the additives and modified procedures above, higher concentrations of protein caused
precipitation whereas concentrations below ~ 8 mg/mL were more stable. Purification of
SpHMGR was done according to a previously reported protocol [7].
Following the successful isolation of DaHMGR, initial protein crystals for DaHMGR were
further optimized and diffracted to relatively high resolution and produced an apo model.
Unsurprisingly, this apo model had no density for the C-terminal domain (CTD) since the inherent
flexibility of this domain makes it difficult to capture a single static conformation. In the context
of catalysis, the observation that the CTD would be mobile without any ligands emphasizes that
closure of the CTD is associated with ligand-binding. This phenomenon would allow ligands to be
retained during the course of the reaction. There is, however, a crystal structure of SpHMGR (PDB
3QAU) that is both apo and has a resolved CTD, however, the CTD adopts an open conformation.
This would suggest that in apo form, a flexible and open conformation predominates such that
ligands are free to enter either cofactor or substrate sites. The role of the CTD is further investigated
in Chapter Three.
The remaining overall structure of apo DaHMGR resemble the structures of other class II
HMGRs. The conserved dimerization motif, ENVIGX 3 I/LP, which is ENVFGSFELP in
DaHMGR, indeed forms an intimate interlocking motif that aids in the formation of the
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homodimeric interface. Interestingly, whereas other structures of HMGRs observe this region as a
B-strand, apo DaHMGR does not form this secondary structure and instead appears as a long
strand. Despite this observation, when overlaying this motif with the same region of PmHMGR,
we observe that the side chains of the above residues align almost identically suggesting that the
integrity of this motif is still maintained. Figure 13 shows an overlay of the dimerization motif of
apo DaHMGR and apo PmHMGR.
Using crystallographic symmetry, a hexamer made up of monomers of apo DaHMGR can
easily be generated. Figure 14 shows the hexamer, which forms a trimer of dimers, of apo
DaHMGR comprising residues 3-376 in each monomer and excludes the CTD. The hexameric
interface is made up of a helix of one monomer that stacks up against an anti-parallel beta sheet.
This was later described by Peacock et al. as a “cylinder resting in the palm of a hand”
configuration where a helix from one dimer rests across a four-stranded β-sheet on the adjacent
dimer, as described earlier [15]. With the help of the crystal structure, these interactions can be
parsed out, residue-by-residue, and as pointed out by Peacock et al. a total of two potential salt
bridges and 8 hydrogen bond interactions exist at the hexameric interface of DaHMGR[15]. They
point out that, in comparison to BcHMGR and PmHMGR hexameric structures, DaHMGR has the
most interactions suggesting that its preference for the hexameric form is notably higher.
The following interactions at the hexameric interface of DaHMGR are worth noting.
Glu308 from one monomer appears to interact with the backbone of His125 and Gly126 of the
adjacent monomer. Gln133 of one monomer interacts with the neighboring monomer via the
backbone of Thr105, and the sidechain of Gln104. Peacock et al. also suggest that two potential
salt bridges exist between Asp123 of one monomer and Arg226 of the adjacent monomer as well
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as Glu320 of one monomer and Arg128 of the adjacent monomer [15]. Figure 15 depicts these
potential interactions at the hexameric interface of DaHMGR.
Using the crystal structure of DaHMGR determined from the present study, analyzed by
Proteins, Interfaces, Structures and Assemblies (PISA) analysis, Peacock et al. point out that, in
DaHMGR, the hexameric interface is the most stable assembly showing the hexamer as the most
stable conformation (ΔG diss = 15.6 kcal/mol). In contrast, PISA analysis of SpHMGR crystal
structure (using PDB 5WPJ) suggests that SpHMGR exists as a dimer (ΔGdiss = 83.9 kcal/mol).
While the above analysis of oligomerization provides great insight into the features that
promote these interactions and provides reasonable analysis of the above conclusions, X-ray
crystallographic snapshots cannot conclusively say how the protein exists in its native state.
Moreover, the crystal lattice may have captured one oligomeric state, but this does not provide
evidence for whether this is the only oligomeric state observe in solution. Thus, solution state
studies of DaHMGR and SpHMGR come into focus.
Using Size Exclusion Chromatography (SEC) to assess DaHMGR oligomerization, there
are four notable peaks that correspond to aggregation, a likely hexamer, a dimer, and a
contaminant. The sizes of the peaks suggest that the hexameric assembly predominates. This
suggests that DaHMGR exists in equilibrium between a dimer and hexamer, where a hexamer is
more abundant. When higher concentrations of DaHMGR are assessed, this equilibrium reveals
an even greater abundance of hexamers than dimers in solution (Ashley Yang and Yan Kung,
unpublished). Preliminary SAXS experiments, which assessed the solution state of DaHMGR also
pointed to a hexamer formation. In these experiments, a SEC was fixed upstream of the SAXS
experiment, separating the protein based on size prior to scattering experiments. Peaks that were
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chosen to be analyzed included the predominant two peaks, and inspection of these peaks with
Oligomer suggested that a hexamer is likely. The SAXS experiments do not rule out the presence
of other species in solution but confirms the likelihood of the hexamer being in solution.
Taken together, the crystal structures, PISA analysis, SEC elution profiles, and preliminary
SAXS experiments, all point towards DaHMGR existing in an equilibrium of multiple oligomeric
states, with a hexamer being especially favored state at higher concentrations. Interestingly, as
pointed out earlier, DaHMGR tends to precipitate at high concentrations as revealed through
aggregation peaks in SEC experiments and during protein purification. The physiological
relevance of this remains unknown. While the hexamer has been shown to be the most stable
assembly, by PISA analysis, it is unknown why higher concentrations, which favor hexamer
formation, leads to precipitation when the concentration goes above a certain threshold.
Regarding SpHMGR, the crystal structures determined here, PISA analysis, and SEC
elution profiles, all point towards SpHMGR existing as a dimer. Upon close inspection, there is a
marked difference in the types of residues that constitute the hexameric interface in DaHMGR
when compared to the aligned residues in SpHMGR. As shown in Figure 16, if one aligns the
adjacent monomers of the hexameric assembly with monomers of SpHMGR, there are several
steric clashes observed. In Figure 16, residues such as Asn121, Lys123, Leu124, and Glu127 all
appear to sterically clash with the adjacent monomer in the hexameric configuration. These
observations provide structural evidence that the hexameric formation is hindered in SpHMGR.
More specifically, one could look at each of the interactions observed at the hexameric
interface in DaHMGR outlined in Figure 15 and observe the lack of these attractive forces in
SpHMGR. The following interactions, noted above, are observed at the hexameric interface in
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DaHMGR: Gln133 interacts with the side chain of Gln104; Glu308 interacts with His125 and
Gly126; Asp123 interacts with Arg226; Glu320 interacts with Arg128. In SpHMGR serine and
threonine replace Gln133 and Gln104 found in DaHMGR. In DaHMGR the glutamine sidechains
can interact each other, whereas serine and threonine found in SpHMGR cannot. In SpHMGR,
asparagine and serine replace Asp123 and Arg226 found in DaHMGR. In the case of DaHMGR,
Arg226’s long side chain can extend closer to Asp123 to facilitate the sidechain interactions,
whereas asparagine and serine in SpHMGR are >7 Å away which would prevent sidechain
interactions. This is similarly observed in the interaction between Glu320 and Arg128 in
DaHMGR which is replaced by threonine and asparagine, respectively, in SpHMGR. While it is
possible that the sidechains of threonine and asparagine can interact, they are ~6 Å away from each
other. Collectively, the lack of stabilizing interacts and the steric clashes that hinder the hexameric
formation provide structural reasoning for why SpHMGR might not prefer the dimer formation
and exists as a dimer.
Further examination of the hexameric interface provides insight into the types of HMGR
homologs that prefer the hexameric formation with regards to cofactor specificity. As pointed out
by Peacock et al. PmHMGR, DaHMGR and BcHMGR all contain the interactions between Glu320
and Arg128 that stabilizes the hexameric interface. Sequence alignment of this region, shown in
Figure 20A, confirms that all the HMGRs whose oligomerization states have been shown to
include a hexamer contain this glutamate residue which interacts with the corresponding arginine.
These all appear to be NAD(H)-preferring HMGRs. In contrast, NADP(H)-preferring HMGRs,
which have been shown to form dimers, do not have this glutamate and have shorter residues such
as threonine and serine.
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There is now mounting evidence that oligomerization is directly related to cofactor
specificity. There appears to be a developing pattern where NAD(H)-preferring HMGRs, such as
PmHMGR, BcHMGR, BpHMGR and DaHMGR, can form hexamers, whereas NADPH)preferring HMGRS, such as EfHMGR and LmHMGR do not. Figure 20 shows a list of HMGRs,
their cofactor preference, and their associated oligomeric states. In addition, a phylogenetic tree
using the amino acid sequences of the above HMGRs generated using PhyML[22] reveals how the
NAD(H)-preferring and NADP(H)-preferring HMGRs are more closely related to each other as
revealed in Figure 20B. It appears that evolution has produced lineages that manifest itself through
cofactor preference and oligomerization in class II HMGRs. Importantly, the data obtained here
strengthens this paradigm and offers insight into the structural mechanisms that promote such
oligomeric dynamics.
In sum, this chapter provides structural and biophysical characterization of DaHMGR and
SpHMGR that sheds light on the overall structural features of class II HMGR, using X-ray
crystallography, as well as insight into the way the protein behaves in its native environment using
solution state studies. In doing so, the results from this chapter add to key areas when
characterizing HMGRs by extending existing knowledge about the structures of these enzymes as
well as taking steps towards areas that deserve more attention. With a greater awareness of the
overall structural features of this enzyme, a closer look at features that govern the mechanism is
presented in the next chapter.

2.5.

Future work

2.5.1. Stability of DaHMGR
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As pointed out, purification of DaHMGR is difficult due to its tendency to precipitate at
higher concentrations. While there is the possibility that by customizing the buffer constituents
during purification that the protein may be more stable, it is also likely that this phenomenon is
inherent to the way the protein behaves. It would be worthwhile to investigate this further by
attempting to manipulate the purification protocol as well as observe how purified protein behaves
in different environments. Is it just a matter of including the right stabilizing reagents to prevent
precipitation, or is there a fundamental feature of DaHMGR, which is related to its concentration,
that is more influential?
It would also be helpful to determine if protein, which has precipitated due to high
concentrations, can be resolubilized, and to determine whether the activity of this reconstituted
protein is affected. If the activity can be restored effectively, purification of DaHMGR and
downstream steps, including buffer exchange and concentrating of protein, can be more readily
and conveniently achieved. If, on the other hand, the activity of precipitated protein is irreversibly
diminished, then this would also inform interpretation of activity assays with regards to specific
activity. One must ensure that the amount of protein, which is crucial when calculating specific
activity, is accurately assessed with regards to how much soluble versus insoluble protein there is
present in a sample.
2.5.2. Oligomerization and activity
Since DaHMGR can exist in an equilibrium of hexamers and dimers, further analysis can
be done to investigate the factors that contribute towards the various oligomerization states which
could include investigating protein concentration, and the salt and pH of protein buffers. In
addition, further work can also be done to determine what, if any, influence oligomerization has
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on activity. Does a dimer perform differently than a hexamer? Are there cooperativity dynamics
with respect to binding of ligands and on overall activity that relate to the hexamer? To this end,
novel structures of NAD(H)- and NADP(H)-preferring class II HMGR homologs might provide
further inside into oligomerization dynamics. Ultimately, these questions would provide insight
into the physiological relevance of oligomerization in class II HMGRs.

2.6.

Materials and methods

2.6.1. Isolating DaHMGR and SpHMGR
2.6.1.1.

Genes
The DaHMGR and SpHMGR genes were inserted into pSKB3, a modified pET28b

plasmid which encodes an N-terminal TEV protease-cleavable hexahistidine tag and a kanamycin
resistance cassette, by previous members of the Kung Lab. Figure 17 details the DNA sequence
including the promoter and terminator as well as the restriction digestion sequences of both genes.
The plasmids were then transformed into chemically competent BL21(DE3)* E. coli by adding 1
µL of DNA into 50 µL of cells supplemented with 10 µL of 5xKCM (0.5 M KCl, 0.15 M CaCl 2,
0.25 M MgCl2 ) and water up to a total volume of 100 µL. The cell mixture was incubated on ice
for 30 minutes, heat-shocked at 42°C for 90 seconds, and cooled on ice for 2 minutes, after which
the cells were allowed to recover and proliferate at 37°C with shaking at 200 rpm for 1 hour. Then,
50 µL of the cell mixture was spread onto lysogeny broth (LB) agar plates containing kanamycin
(50 µg/mL), allowing the cells to grow at 37°C overnight, yielding single colonies of cells that
contained the plasmid with the gene encoding the proteins of interest. The target protein sequences
that are encoded by these genes are shown in Figure 18.
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2.6.1.2.

Protein Expression
Both DaHMGR and SpHMGR were expressed similarly as outlined here. A single colony

from the transformation was used to generate a starter culture containing LB with kanamycin (50
µg/mL), which was grown at 37°C overnight with shaking at 200 rpm. Then, 1 L of LB
supplemented with kanamycin (50 ug/mL) was inoculated with 1% (10 mL) of the starter culture,
grown at 37°C at 200 rpm until cells reached OD 600 ~0.6-0.8. Protein expression was induced using
isopropyl β-D-1-thiogalactopyranoside (IPTG) at a final concentration of 0.5 mM at 16-20°C at
200 rpm for 16-18 hours. The expression efficiency was assessed by PAGE. Cells were harvested
by centrifugation at 5,000 × g for 12 min, flash frozen in liquid nitrogen, and stored at -80°C.
2.6.1.3.

Lysis Buffer Screen for DaHMGR
Prior attempts within the Kung Lab at purifying DaHMGR proved unsuccessful due to

precipitation during the purification process. To determine a suitable lysis buffer, and therefore a
purification buffer system, several lysis buffers were assessed based on DaHMGR’s abundance in
the soluble layer (aqueous layer) after cell lysis and clarification as determined by SDS-PAGE.
The list of buffers used is shown below in Figure 19. The screen was performed by suspending
~0.2 mg cell pellet in 2 mL lysis buffer, sonicating at 25% amplitude using 3 cycles of the
following method: 5 second pulse, rest on ice for 2 minutes. The lysate was clarified by
centrifugation at 14,000 × g for 20 min at 4°C and the supernatant and pellet layers were run on
an SDS-PAGE gel to determine whether DaHMGR precipitated into pellet or remained soluble in
the aqueous layer. While DaHMGR showed similar solubility in many of the buffers, a Tris buffer
close to physiological pH was determined to be the most suitable. This optimized buffer, 50 mM
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Tris pH 7.8, 400 mM NaCl, 1 mM TCEP, and 10% glycerol, was the basis for all subsequent
protein purification are shown in Figure 6.
2.6.1.4.

Protein Purification

2.6.1.4.1.

DaHMGR

Cells were thawed and resuspended in lysis buffer supplemented with lysozyme, 1 U/mL
Pierce Universal Nuclease and 1.0 mM phenylmethanesulfonylfluoride (PMSF). To lyse the cells,
sonication was performed on ice at 40% amplitude using four cycles of the following method: 3
second pulse, 5 second rest, 1.5-minute total pulse time, allowing 2-3 minutes of rest between
cycles to prevent the sample from overheating. Clarification of the lysate was achieved by
centrifugation at ~37,000 × g for 30 min at 4°C to separate any insoluble protein and cell debris.
A column containing 2 mL Ni-nitrilotriacetic acid (Ni-NTA) resin per liter of cell culture was preequilibrated with 3 column volumes (CV) of lysis buffer. The clarified supernatant was incubated
with the resin at 4°C with gentle rotating for 5-7 minutes (longer incubation times caused protein
precipitation), after which 10 CV of lysis buffer, and 10 CV of wash buffer was passed through
the column. DaHMGR was eluted using elution buffer in ~1 mL fractions. Fractions with highest
purity and concentration assessed by SDS-PAGE were collected in preparation for buffer exchange
and storage.
Initial attempts using various buffer exchange methods, using dialysis, or using a
centrifugal concentrator, caused precipitation of the protein. Precipitation was also observed when
protein concentration was attempted using a centrifugal concentrator. To overcome these
challenges, buffer exchange was performed using a desalting column collecting the fractions with
the highest concentration for further use without any subsequent concentration steps. A PD-10 (Ge
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Healthcare) column was pre-equilibrating with storage buffer and the purified protein was then
applied to the column and eluted with storage buffer in ~ 1 mL fractions, which were assessed by
SDS-PAGE, and fractions with the highest concentration and purity were pooled to obtain final
concentrations of 5-8.5 mg/mL as determined by the A280 using a calculated extinction coefficient
of 21,500 M-1 cm-1 and a molecular weight of 48.1 kDa. Aliquots of DaHMGR were flash-frozen
in liquid nitrogen and stored at -80°C.
2.6.1.4.2.

SpHMGR

The purification for SpHMGR followed the published protocol by Miller et al [7] and
followed a similar protocol as for DaHMGR above with the following modifications: the buffers
can be found on Figure 6; fractionation when eluting from the Nickel column was done in ~ 3 mL
volumes, and the fractions with highest concentration and purity were combined; buffer exchange
was performed using a centrifugal filter. Final concentrations of protein, as determined by the A280
using 38,900 M-1 cm-1 and a molecular weight of 49.2 kDa, was ~10 mg/mL. Aliquots of SpHMGR
were flash-frozen in liquid nitrogen and stored at -80°C.
2.6.2. Crystallization
2.6.2.1.

DaHMGR
The Materials and Methods section in Chapter Three provides greater depth into the initial

high throughput crystallization experiments that yielded crystal hits. These initial crystal hits of
DaHMGR, with NADH bound, contained citrate in the substrate binding site due to the
crystallization buffer being made up of 100 mM citrate. Following the acquisition of DaHMGRbound NADH and citrate, we sought to acquire additional structures of DaHMGR without citrate
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bound. This was done by replacing citrate in the crystallization condition with other buffers,
adjusting pH, and including other precipitating reagents. By modifying the crystallization buffer
to Bis-Tris pH 5.5-6.5 and adding polyethylene glycol 3350 ~18-19%, we were able to acquire
crystals of apo DaHMGR that were suitable for diffraction experiments. This apo structure was
optimized to contain 100 mM Bis-Tris pH 5.5, 600 lithium sulfate, and 18% PEG 3350. For
diffraction experiments, the crystals were soaked in a cryoprotectant solution that contained a 1:1
volume ratio of the crystallization solution and a solution containing 16% ethylene glycol, 16%
glycerol, 18% sucrose, and 4% glucose before being flash-cooled in liquid nitrogen.
2.6.2.2.

X-ray Data Collection, structure determination, and refinement
X-ray diffraction data were collected at the Advanced Photon Source (APS). Data was

indexed, merged, and scaled using MOSFLM in space group P321 with a single molecular in the
asymmetric unit. Since the NADH/citrate structure was determined first, and that the apo structure
crystallized with a different unit cell and space group, P65 22 versus P321 respectively, molecular
replacement was used to solve the apo structure with the NADH/citrate structure as the search
model in Phaser in the PHENIX suite. Iterative rounds of reciprocal space refinement were
performed, with real space refinement done in Coot. The final data collection and refinement
statistics of this structure, at 1.93 Å resolution, is presented in Table 1.
2.6.3. Small-angle X-ray Scattering
2.6.3.1.

Sample preparation
Samples of DaHMGR were transported on ice to the Cornell High Energy Synchrotron

Source (CHESS). Precipitation was observed during transit, most likely because the protein was
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no longer frozen for an extended time. Prior to injection, samples were centrifuged at high speed
and resulted in a protein concentration of ~4.7 mg/mL as assessed by A 280 .
2.6.3.2.

SEC-SAXS data collection
Samples were run on a SAXS beamline at Cornell High Energy Synchrotron Source

equipped with a SEC upstream. The SEC column was a Superdex 200, 5/150 (2.945 mL column
volume). DaHMGR storage buffer, 50 mM Tris pH 7.8, 400 mM NaCl, 1 mM TCEP, and 10%
glycerol, was used as the running buffer with a flow rate of 0.17 mL/min. Data collection was
performed as follows: 1,000 frames, 2 sec exposure (to increase signal). Data was analyzed using
Primus, Oligomer, and FOXS with the help of members of the Nozomi Ando Lab, Cornell
University.
2.6.4. Size Exclusion Chromatography
The SEC column was a HiLoad 16/600 Superdex 200 prep grade column (GE Healthcare
Life Sciences) equilibrated with storage buffer (DaHMGR = 400 mM Tris pH 7.8, 400 mM
NaCl, 1 mM TCEP, 10% glycerol, SpHMGR = 50 mM Tris (pH 7.8), 200 mM NaCl, and 10%
glycerol) using an Akta Pure chromatography system (GE Healthcare Life Sciences). Injection
volumes and concentrations were as follows: DaHMGR, ~3 mg/mL, 0.75 mL injection volume;
SpHMGR at ~10 mg/mL, 0.75 mL injection volume. Protein standards were run in buffers
resembling the storage buffer utilized for each protein. Elution was monitored by absorbance at
A280 .
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2.7.

Tables and figures

Figure 1. PmHMGR crystal structure in a ternary complex. PmHMGR dimer (PDB 1QAX)
bound to NAD+ and HMG-CoA with one monomer colored green and the other blue highlighting
the active site and the orientation of the ligands. A) Two views in surface representation with
ligands represented as spheres with C atoms of HMG-CoA colored green, the N atoms colored
blue, the O atoms colored red, the P atoms colored orange, and the S atoms colored yellow. B)
Two views in cartoon representation with ligands represented as balls. C) Zoom in on the active
site with ligands represented as sticks in blue (NAD+) and green (HMG-CoA) and specific atoms
colored similarly to the spheres.
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Figure 2. Dimerization motif of SpHMGR. SpHMGR (PDB 5WPJ) homodimer with monomers
colors blue and red. A close-up of the dimerization interface is highlighted, with the conserved
ENVIGX 3 I/LP sequence in sticks colored by chain and the N atoms colored blue, the O atoms
colored red.
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Figure 3. Overview of the structure of one monomer of SpHMGR. A) Three different views
of one monomer of the crystal structure of SpHMGR (PDB 5WPJ chain B) shown in cartoon
representation. Secondary structures are colored similarly to the topological outline shown in C.
B) Schematic generated by PDBSum that shows the residue numbers and predicted secondary
structures of SpHMGR. C) Topological depiction of SpHMGR generated by PDBSum .
60

Figure 4. Crystal structure of human HMGR. A) The tetrameric conformation, made up of two
dimers, with three monomers colored shades of gray and one monomer in orange. The termini of
the orange monomer are noted. In balls are HMG, NADP+ and CoA bound. B) A dimer, with one
monomer colored gray and another orange, showing the interface as well as the location o, the
ligands depicted as sticks.
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Figure 5. SAXS overview. An outline of SAXS from experimental setup to data collection.
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Figure 6. Purification of DaHMGR and SpHMGR. On the left are SDS-PAGE gels representing
the following fractions collected during purification using Ni-NTA affinity chromatography: FT =
flowthrough, W = wash, 1-9=fractions. On the right outlines the makeup of the various buffers
used throughout Ni-NTA purification and storage. Purification with respect to A) SpHMGR and
B) DaHMGR.
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Figure 7. Overlay of DaHMGR and various class II HMGRs. Several views containing an
overlay of the main body of the protein, excluding the C-terminal domain, of DaHMGR and
various other HMGRs. Apo DaHMGR in green (PDB 6eeu), apo PmHMGR in light gray (PDB
4I64), and apo SpHMGR in dark gray (PDB 3QAU), are all shown in cartoon representation. The
overall structures align well with no significant structure differences.
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Figure 8. Size Exclusion Chromatography (SEC) of SpHMGR. SEC elution profile of
SpHMGR. In gray represents protein standards with the peaks corresponding to the size of
proteins used. In green represents the elution profile of DaHMGR.
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Figure 9. Size Exclusion Chromatography (SEC) of DaHMGR. SEC elution profile of
DaHMGR. In gray represents protein standards with the peaks corresponding to the size of proteins
used. In maroon represents the elution profile of DaHMGR. The y-axis, which represents
absorption at A 280 are on the left and right for the protein standards and DaHMGR, respectively.
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Figure 10. SAXS analysis of the larger species of DaHMGR. A) Guinier plot, B) Kratky plot,
and C) Logarithmic plot of the larger species eluted in the SEC-SAXS experiment. The dots
represent the data, and the fits represent a theoretical fit of the oligomer noted on the top (dimer,
tetramer, and hexamer).
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Figure 11. SAXS analysis of the smaller species of DaHMGR. A) Guinier plot, B) Kratky plot,
and C) Logarithmic plot of the smaller species eluted in the SEC-SAXS experiment. The dots
represent the data, and the fits represent a theoretical fit of the oligomer noted on the top (dimer,
tetramer, and hexamer).
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Figure 12. SAXS analysis of the smaller species of DaHMGR with additional dimer: hexamer
fits. A) Guinier plot, B) Kratky plot, and C) Logarithmic plot of the smaller species eluted in the
SEC-SAXS experiment. In addition to analyzing the data with respect to a tetramer and hexamer,
a dimer: hexamer ratio of 40%:60%, respectively, was used. The dots represent the data, and the
fits represent a theoretical fit of the oligomer noted.
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Figure 13. Comparison between dimerization motif of PmHMGR and DaHMGR. A) Apo
PmHMGR (PDB 4I64) as a dimer shown in surface representation with one monomer in light gray
and its adjacent monomer in dark gray. The dimerization motif of PmHMGR (dark blue and light
blue) and DaHMGR (dark green and light green) are depicted as cartoon. B) Close up of an overlay
of the dimerization motif shown as a cartoon of PmHMGR and DaHMGR. Dark blue and light
blue represent adjacent monomers of PmHMGR, and dark green and light green represent adjacent
monomers of DaHMGR. C) The sidechains of B are shown as sticks. Coloring of atoms are as
follows: O = red, N = blue, C = color of respective cartoon representation. In PmHMGR, the
dimerization motif makes up a β-sheet whereas in DaHMGR a strand is observed.
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Figure 14. Hexameric assembly of DaHMGR. Hexamer, formed through crystallographic
symmetry of DaHMGR (PDB 6EEU). Each monomer that makes up the hexamer are colored
differently. A) Surface representation of hexamer. B) Cartoon representation of hexamer. C)
Surface representation of the hexamer with a dimer colored in purple and red. D) The same as C)
with the corresponding dimer shown in cartoon representation.
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Figure 15. Hexameric interface of DaHMGR. Specific interactions between adjacent monomers
that constitute the hexameric interface which include interactions proposed by Peacock et al.
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Figure 16. Comparing residues at the hexameric interface in DaHMGR with the aligned
sequences of SpHMGR. A) and C) represent an overlay of adjacent monomers of SpHMGR with
the hexameric interface observed in DaHMGR modeling the nature of this interface if SpHMGR
were to form hexamers. B) and D) represent the hexameric interface of DaHMGR. A) and B)
shown one monomer in cartoon representation with selected residues shown in sticks and the
adjacent monomer in surface representation colored gray. C) and D) show cartoon representation
of a both monomers with selected residues shown in sticks. Atom coloring is as f ollows: O = red,
N = blue, C = colored with respect to the cartoon representation. From this, one observes that in
SpHMGR (A and C) there exists steric clashes that would not favor the hexamer formation, unlike
those observed in DaHMGR (B and D).
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taatacgactcactatagggcatATGGTCGCCGATTCTCGCCTGCCGAACTTTCGTGCATTGACGCCTGCTCAG
CGTCGCGATTTTTTGGCAGATGCGTGTGGATTATCCGATGCTGAGCGTGCGCTGCTGGCTGCGCCAGGCGCGCT
GCCGCTTGCCTTGGCGGACGGCATGATCGAAAATGTGTTTGGGAGTTTTGAGCTGCCGCTGGGCGTTGCCGGCA
ATTTTCGGGTCAATGGACGTGATGTGCTGGTCCCGATGGCAGTGGAAGAGCCTTCTGTCGTTGCCGCAGCGAGC
TATATGGCGAAATTAGCCCGCGAAGACGGCGGCTTTCAGACATCGTCTACATTGCCACTGATGCGTGCCCAAGT
GCAAGTGCTGGGTGTCACTGACCCTCATGGCGCCCGTCTGGCGGTTTTACAAGCGCGTGCACAGATCATTGAAC
GCGCGAACTCTCGCGATAAAGTATTAATCGGTTTAGGGGGCGGTTGTAAAGATATCGAGGTACACGTGTTTCCG
GATACTCCGCGCGGCCCGATGCTGGTCGTGCATCTGATTGTTGATGTCCGTGACGCGATGGGTGCCAACACCGT
TAATACGATGGCGGAATCGGTGGCCCCGCTGGTTGAAAAAATCACCGGTGGCTCTGTCCGTCTGCGCATTCTGA
GTAACCTGGCAGATCTGCGCCTGGCGCGTGCCCGCGTGCGTCTGACCCCGCAGACGCTGGCAACCCAAGACCGT
AGCGGTGAAGAAATTATCGAAGGCGTGCTGGATGCGTATACGTTCGCAGCAATCGACCCGTACCGTGCTGCAAC
CCATAACAAAGGTATTATGAATGGCATCGATCCGGTGATTGTTGCCACCGGTAATGACTGGCGTGCAGTGGAAG
CAGGCGCTCACGCGTATGCCAGTCGCTCCGGTTCATACACGTCCCTGACCCGTTGGGAAAAAGATGCAGGTGGC
GCTCTGGTTGGCTCAATTGAACTGCCGATGCCGGTCGGTCTGGTGGGTGGCGCAACCAAAACGCATCCGCTGGC
ACGTCTGGCACTGAAAATCATGGATCTGCAGTCCGCACAGCAACTGGGTGAAATTGCCGCAGCTGTGGGTCTGG
CACAGAACCTGGGCGCTCTGCGTGCACTGGCTACCGAAGGTATCCAACGCGGCCACATGGCACTGCACGCTCGT
AATATTGCGCTGGTTGCGGGTGCCACGGGCGATGAAGTTGACGCAGTCGCTCGTCAGCTGGCGGCCGAACACGA
TGTTCGCACCGACCGTGCACTGGAAGTCCTGGCAGCTCTGCGTGCGCGTGCCtaaggatccccgctgagcaata
actagc

Codon optimized gene of HMGR from Delftia acidovorans (DaHMGR)
taatacgactcactatagggcatATGAAGATTAGCTGGAATGGTTTTAGCAAGAAGAGCTATCAAGAACGTCTG
GAACTGCTGAAGGCGCAAGCGCTGCTGAGCCCGGAACGCCAGGCGAGCCTGGAGAAGGACGAACAAATGAGCGT
GACCGTTGCGGATCAGCTGAGCGAGAACGTGGTTGGCACCTTCAGCCTGCCGTATAGCCTGGTGCCGGAAGTGC
TGGTTAACGGTCAAGAATACACCGTGCCGTATGTTACCGAGGAACCGAGCGTGGTTGCGGCGGCGAGCTACGCG
AGCAAGATCATTAAACGTGCGGGTGGCTTTACCGCGCAGGTTCACCAGCGTCAAATGATCGGTCAGGTGGCGCT
GTATCAAGTTGCGAACCCGAAGCTGGCGCAAGAAAAAATTGCGAGCAAGAAAGCGGAGCTGCTGGAACTGGCGA
ACCAGGCGTACCCGAGCATCGTGAAGCGTGGTGGCGGTGCGCGTGATCTGCACGTTGAGCAAATCAAAGGCGAA
CCGGACTTCCTGGTGGTTTACATTCACGTGGATACCCAGGAAGCGATGGGTGCGAACATGCTGAACACCATGCT
GGAAGCGCTGAAGCCGGTTCTGGAGGAACTGAGCCAGGGCCAAAGCCTGATGGGTATCCTGAGCAACTATGCGA
CCGACAGCCTGGTGACCGCGAGCTGCCGTATTGCGTTTCGTTATCTGAGCCGTCAGAAGGATCAAGGCCGTGAG
ATCGCGGAAAAAATTGCGCTGGCGAGCCAGTTTGCGCAAGCGGACCCGTATCGTGCGGCGACCCACAACAAAGG
CATCTTTAACGGCATCGATGCAATTCTGATCGCGACGGGCAATGACTGGCGCGCCATTGAAGCGGGCGCACACG
CCTTTGCGAGCCGCGATGGTCGTTATCAAGGTCTGAGCTGCTGGACCCTGGACCTGGAACGCGAGGAACTGGTC
GGTGAGATGACGCTGCCGATGCCAGTGGCAACCAAAGGTGGTAGCATTGGCCTGAACCCGCGCGTGGCCCTGAG
CCATGATCTGCTGGGTAACCCGTCTGCCCGTGAACTGGCGCAAATTATTGTGAGCATCGGTCTGGCGCAAAATT
TCGCGGCACTGAAAGCCCTGGTTAGCACCGGTATTCAGCAGGGCCACATGAAACTGCAGGCGAAATCTCTGGCA
CTGCTGGCCGGCGCATCTGAGAGCGAAGTTGCCCCGCTGGTTGAACGTCTGATTAGCGACAAGACCTTTAACCT
GGAGACCGCACAACGTTACCTGGAAAATCTGCGCAGCtaaggatccccgctgagcaataactagc

Codon optimized gene of HMGR from Streptococcus pneumoniae (SpHMGR)

Figure 17. Codon-optimized DaHMGR and SpHMGR genes. T7 promoter and terminator and
restriction sites are shown in addition to the start and stop codons for each gene. Underlined = T7
promoter and terminator sequences. NdeI and BamHI are restriction sites, ATG and TAA are start
and stop codons respectively.
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MGSSHHHHHHDYDIPTTENLYFQGHMVADSRLPNFRALTPAQRRDFLADACGLSDAERALLAAPGALPLALADG
MIENVFGSFELPLGVAGNFRVNGRDVLVPMAVEEPSVVAAASYMAKLAREDGGFQTSSTLPLMRAQVQVLGVTD
PHGARLAVLQARAQIIERANSRDKVLIGLGGGCKDIEVHVFPDTPRGPMLVVHLIVDVRDAMGANTVNTMAESV
APLVEKITGGSVRLRILSNLADLRLARARVRLTPQTLATQDRSGEEIIEGVLDAYTFAAIDPYRAATHNKGIMN
GIDPVIVATGNDWRAVEAGAHAYASRSGSYTSLTRWEKDAGGALVGSIELPMPVGLVGGATKTHPLARLALKIM
DLQSAQQLGEIAAAVGLAQNLGALRALATEGIQRGHMALHARNIALVAGATGDEVDAVARQLAAEHDVRTDRAL
EVLAALRARA

Amino acid sequence of HMGR from Delftia acidovorans (DaHMGR)
MW: 48.1 kDa
Ext. Coeff: 21,500 M-1 cm-1
pH: 6.24

MGSSHHHHHHDYDIPTTENLYFQGHMKISWNGFSKKSYQERLELLKAQALLSPERQASLEKDEQMSVTVADQLS
ENVVGTFSLPYSLVPEVLVNGQEYTVPYVTEEPSVVAAASYASKIIKRAGGFTAQVHQRQMIGQVALYQVANPK
LAQEKIASKKAELLELANQAYPSIVKRGGGARDLHVEQIKGEPDFLVVYIHVDTQEAMGANMLNTMLEALKPVL
EELSQGQSLMGILSNYATDSLVTASCRIAFRYLSRQKDQGREIAEKIALASQFAQADPYRAATHNKGIFNGIDA
ILIATGNDWRAIEAGAHAFASRDGRYQGLSCWTLDLEREELVGEMTLPMPVATKGGSIGLNPRVALSHDLLGNP
SARELAQIIVSIGLAQNFAALKALVSTGIQQGHMKLQAKSLALLAGASESEVAPLVERLISDKTFNLETAQRYL
ENLRS

Amino acid sequence of HMGR from Streptococcus pneumoniae (SpHMGR)
MW: 49.2 kDa
Ext. Coeff: 38,900 M-1 cm-1
pH: 6.08

Figure 18. DaHMGR and SpHMGR amino acid sequences. Underlined is the TEV protease
cleavage site which proceeds the hexa-histidine tag used for purification during Ni-NTA affinity
chromatography. Underlined = TEV protease cleavage site.
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Figure 19. Lysis buffer screening conditions for DaHMGR purification. On the bottom are
conditions A through G which vary by type of buffering reagent, pH, and salt content. On top is
an SDS-PAGE gel of the pellet versus supernatant fractions when cells containing overexpressed
DaHMGR was lysed and centrifuged using the respective buffers.
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Figure 20. Oligomerization observed in various characterized HMGRs. A) A table showing
the relationship between cofactor preference and oligomerization among class II HMGRs.
Additionally, a sequence alignment of a region encompassing a glutamate residue that is conserved
among NAD(H)-preferring HMGRs which form hexameric interface. This glutamate interacts
with an arginine for the adjacent monomer and is involved in stabilizing hexameric interface. In
NADP(H)-preferring HMGRs, this glutamate is replaced with smaller residues. B) A phylogenetic
tree created with PhyML showing how cofactor preference is manifested in various HMGR
homologs.
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Table 1. X-ray Data Collection and Refinement
Statistics.
apo DaHMGR
6EEU

PDB ID
Data Collection
Beamline
Wavelength (Å)
Space group
Unit cell
a=b, c (Å)
Resolution (Å)
Wilson B (Å2)
Total reflections
Unique reflections
Multiplicity
Completeness (%)
Mean I/σ(I)
Rmerge
Rmeas
CC1/2

APS, 24-ID-E
0.9792
P321
100.54, 75.86
57.20–1.93 (1.99–1.93)
20.59
138,912 (9,597)
33,218 (2,243)
4.2 (4.3)
98.9 (100.0)
8.1 (2.0)
0.117 (0.823)
0.134 (0.941)
0.994 (0.602)

Refinement
Rwork
Rfree
r.m.s.d. bonds (Å)
r.m.s.d. angles (°)
Number of atoms
Average B factors (Å2)
All atoms
Protein
NADH/citrate/mevalonate
Water
Ramachandran analysis
Favored (%)
Allowed (%)
Outliers (%)
MolProbity Clashscore
Statistics for the highest-resolution shell shown in parentheses.
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0.1597 (0.2325)
0.1980 (0.2845)
0.006
0.794
3,097
22.95
21.7
N/A
31.76
98.12
1.88
0
1.62
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Chapter III: Kinetic, and structural characterization of HMGR from
Delftia acidovorans and Streptococcus pneumoniae
3.1.

Summary

After exploring the native state and global structural dynamics of HMGR from Delftia
acidovorans (DaHMGR) and Streptococcus pneumoniae (SpHMGR) in Chapter Two, we now
venture into greater depth to further probe the function of the enzyme on an atomic level by
exploring the finer details of catalysis. This chapter will begin to unravel the specifics of the
mechanism as revealed by structural and functional characteristics of HMGR through studying the
X-ray crystallographic crystal structures bound with various ligands as well as the steady-state
kinetic parameters of substrate and cofactor. There will be specific focus geared towards the role
of the C-terminal flap domain (CTD), introduced in Chapter Two, and how it facilitates HMGR
catalysis. Attention will be given to the numerous positions the CTD assumes in various apo and
ligand-bound states to substantiate and expand our understanding of the role that this domain has
in the mechanism.
This research yielded the first crystal structures of DaHMGR, in apo form as well as ligandbound forms, complemented by steady-state kinetics revealing this enzyme as an NADHpreferring HMGR and depicting a novel “flipped” conformation of the CTD. Novel structures of
DaHMGR and SpHMGR, in addition to mutant constructs of SpHMGR, that are discussed in
Chapter Four, will be partially incorporated into this chapter only as it pertains to the role of the
CTD since they provide additional insight into this domain. The relatively high-resolution crystal
structures will confirm the importance of conserved cofactor and substrate binding site
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architecture. They will also corroborate prior research detailing unique observations found in
NADH-preferring HMGRs and will reveal a novel location of the C-terminal flap domain which
has direct implications for catalysis. With relatively high-resolution structures, greater detail into
HMG-CoA catalysis will inform both the order of reactivity as well as the roles of various residues
involved. In the end, this chapter will propose a modified reaction mechanism as well as validate
the importance of structural motifs that dictate cofactor specificity.
Portions of this chapter were published in:
E. R. Ragwan, E. Arai, and Y. Kung, “New Crystallographic Snapshots of Large Domain Movements
in Bacterial 3-Hydroxy-3-methylglutaryl Coenzyme A Reductase,” Biochemistry, vol. 57, no.
39, pp. 5715–5725, Oct. 2018, doi: 10.1021/acs.biochem.8b00869.

3.2.

Introduction

HMGR is classified as an oxidoreductase, more specifically, an NAD(P)-dependent
oxidoreductase. Oxidoreductases belong to a large class of enzymes that encompasses almost one
third of all enzymatic activities and utilizes a range of both organic and inorganic substrates such
as alcohols, amines, and metals [1]. These enzymes perform redox reactions as follows: A− + B
→ A + B− where A represents a substrate that is oxidized during the reaction while B represents
a substrate that is reduced; depending on the enzyme, the reverse reaction can also be catalyzed
[1]. NAD(P)-dependent oxidoreductases, can reduce or oxidize a substrate by facilitating the
donating or accepting of a hydride, respectively, using the cofactor, NAD(P)(H), as the hydride
reservoir.
Oxidoreductases typically have a catalytic domain and a cofactor binding domain. The
catalytic domain, which binds the substrate, assumes distinctive active site architecture depending
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on the enzyme’s substrate. The cofactor binding domain, however, often comprises common
structural motifs, such as the Rossmann fold, which allow these enzymes to accommodate the
nucleotide binding domain of NAD(P). In Chapter Four we will discuss the specifics of cofactor
binding as it pertains to the structural nuances that govern the between NADH and NADPH, which
in the case of HMGR involves a non-Rossmann fold. However, in this section, some attention will
be given to the nature of cofactor binding in the context of the mechanism of catalysis.
In 2013, Haines et al. published “The Increasingly Complex Mechanism of HMG-CoA
Reductase” and emphasized that despite the diversity of tools utilized to study this enzyme,
ranging from biochemical to computational techniques, the details and certainty of the mechanism
remains incomplete [2]. This complexity is due to the nature of the reaction where HMGR
performs a four-electron reduction of HMG-CoA to mevalonate, which requires two cofactors,
multiple intermediates, and a means to control the steps of the sequence of the reaction. The overall
mechanism is as follows: HMG-CoA binds and is reduced to mevaldyl-CoA using one equivalent
of NAD(P)H. Then, mevaldyl-CoA is cleaved to form mevaldehyde and CoA, while NAD(P)+
and CoA are removed, as a second NAD(P)H binds to facilitate conversion of mevaldehyde to
mevalonate, after which NAD+ and the final product, mevalonate, can be released.
Since 2013, further insight into the mechanism has been expounded on, and will be
discussed here, but there are still questions that persist about the order of events and contributions
of residues and conformations. In this section, we will highlight 1) the active site architecture and
mechanistic proposals, and 2) the C-terminal flap domain (CTD) in its role during the course of
the reaction. In doing so, we will illustrate how the research presented here provides marked
improvements in our understanding of this enzyme, but we will also gain an appreciation for the
uncertainties that remain. Since research into HMGR falls at the juncture between evaluating
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existing work and the need for further investigation, HMGR continues to be a relevant case study
in enzymology, especially in the field of oxidoreductases, that promises fruitful inquiry.
3.2.1. Active site architecture and mechanism
The sequence identities within class II HMGRs are ~50%, and contain conserved active
site residues, and as pointed out in Chapter Two, possess similar overall folds [2]. Figure 1 shows
the sequence alignment of a variety of class II HMGRs, noting the highly conserved regions. The
active site, made up of two monomers, is at the apex of a “V” shape where the substrate of one
monomer and cofactor of the adjacent monomer meet at a buried core that exists at the
homodimeric interface and extend towards the solvent in different directions, as discussed in
Chapter Two [3]. The conserved active site residues have been the center of attention with regards
to proposed mechanisms. In early studies, done in yeast HMGR, unspecified acidic and basic
residues were suggested as being crucial for catalysis [2], [4]. Additional work highlighted the
importance of a yet-to-be identified acidic residue and a cationic histidine [2], [5]. Based on the
sequence alignment of class II HMGRs and with the knowledge that a conserved acidic and
histidine residue was important for catalysis, site-directed mutagenesis studies homed in on Glu83
and His381 [2], [6], [7].
The advancement in biochemical tools contributed to acquiring greater details about the
mechanism. The first crystal structure, described in Chapter Two, showed a well-defined HMG
pocket to accommodate the substrate and revealed a “shallow” surface groove with fewer
stabilizing interactions with the CoA moiety [2]. Additional higher resolution structures of
PmHMGR describe specific hydrogen bonds and water mediated interactions involved in substrate
binding. For example, in a structure of HMG-CoA-bound PmHMGR, Steussy et al. highlights
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hydrogen bonds between the protein and both ends of HMG-CoA [8]. In their structure, they
propose that at one end of the HMG-CoA binding pocket Arg11 makes a hydrophobic interaction
between the CoA adenine and its sidechain carbons and they observe a hydrogen bond between
the imine side group and the adenine phosphate [8]. At the well-defined HMG pocket, on the other
end, two hydrogen bonds between Arg261 imine groups interact with the carboxyl group of HMG,
and between both ends, the authors suggest that there are water-mediated interactions involved,
albeit affording torsional flexibility in the central region [8].
Similar types of interactions that anchor bond ends of HMG-CoA are observed in HMGCoA-bound SpHMGR where Ser9 and Gly7 make backbone and side chain interactions between
the 3’-phosphate of the adenosine ribose, and Arg257 coordinates the carboxylate at the other end
[3]. In addition, Ser85 of PmHMGR has been shown to stabilize reaction intermediates by
interacting with the first amide bond of CoA[8]. Figure 2 depicts both ends of the binding pocket
of HMG-CoA highlighting some of the important direct interactions between HMG-CoA and
residues of PmHMGR and SpHMGR.
There are also conserved regions within the cofactor binding site that pertain to cofactor
specificity. These interactions will be discussed in detail in Chapter Four but for the purpose of
the reaction mechanism there are additional noteworthy residues that are implicated in catalysis.
At the active site, well conserved asparagine, lysine and aspartate residues typically serve to
coordinate the region around the nicotinamide ring of the cofactor and have been shown to be
important for catalysis [2], [3]. More specifically, as observed in NADPH-bound SpHMGR,
Asn212 hydrogen bonds with the amide group of the nicotinamide ring, and Asp279 hydrogen
bonds with the 2-hydroxyl group of the nicotinamide’s ribose [3]. As pointed out in the HMG-
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CoA-bound PmHMGR, Lys267 is positioned to be able to stabilize the negative charge
intermediates including carboxylate groups from the active site Glu and Asp mentioned above [2].
In total, there have been several proposed mechanisms that have developed chronologically based
on the incremental knowledge gained from additional studies.
3.2.2. Role of the C-terminal domain in catalysis
As pointed out in the overview of the reaction, the series of steps involved in the reaction
is complex. Substrate and cofactor must bind to generate the first intermediate, mevaldyl-CoA,
followed by the exchange of the oxidized cofactor with a reduced one without the release of the
mevaldyl-CoA. Once mevaldyl-CoA is converted to mevaldehyde, HS-CoA needs to be released
while mevaldehyde needs to be retained. Finally, mevaldehyde is converted to the product,
mevalonate, and both the product and the second used cofactor are released. It is not known, for
example, when HS-CoA is released, and the precise order remains elusive.
Of importance is the fact that HMGR intermediates mevaldyl-CoA and mevaldehyde are
not released during the catalytic cycle [9], suggesting a mechanism by which these intermediates
are retained in the active site until mevalonate is formed. In contrast, the cofactors NAD(P)H and
NAD(P)+ do need to enter and exit at specific times within the reaction cycle, suggesting a
mechanism that timely controls cofactor exchange. Taken together, these two important
mechanistic features of retaining HMG-CoA intermediates while modulating the entry and exit of
cofactors provide the rationale for what is observed in HMGR crystal structures, where a flexible
C-terminal domain (CTD) that is near both the substrate and cofactor sites acts as a flap to help, at
least in part, to control these steps. This flexible CTD flap completes a fascinating feat of
engineering encompassing a range of motion that gives it the ability to cover either or both of the
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substrate and cofactor sites in a specific order that regulates the entry and exist of the respective
ligand.
The initial insights regarding the CTD was gained through the work done by Taberno et al.
where they determined the structures of two non-productive ternary complexes, PmHMGR with
HMG-CoA/NAD+ and mevalonate/NADH of which the former structure depicted the CTD
covering the active site [10]. The authors described the former structure as being involved in a
substrate-induced closing of the CTD. In this closed conformation, the CTD ensures that the
catalytic His381, which was previously identified as a catalytically important cationic residue, is
positioned appropriately in the active site. In addition, the authors propose that as a result of the
closed conformation, a hydrophobic pocket, made up of residues Ile213, Leu371, and Ile377,
covers the hydride transfer reaction, thereby sheltering it from the solvent [10]. The closed
conformation is further stabilized by interactions between residues within the CTD of one
monomer and the small domain of the adjacent monomer[10]. Figure 3 shows the position of the
CTD as it covers the active site, along with the accompanying positioning of the catalytically
important histidine that is enabled by the CTD adopting this closed conformation.
A structure of apo SpHMGR (PDB 3QAU), without an associated publication, was
deposited in the Protein Database, and upon inspection of the structure revealed a novel location
of the CTD. In contrast to the closed conformation found in the above ternary complex of
PmHMGR with HMG-CoA/NAD+ that covers the active site, this apo structure revealed an open
conformation where the CTD was flipped away from the active site[3]. This conformation
repositions the catalytically important histidine away from the active site. In a subsequent structure
determined by the Kung Lab of NADPH-bound SpHMGR, two additional open conformations
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were observed[3]. Neither of the open conformations align directly over each other and it was
speculated that crystal contacts with adjacent molecules may have given rise to these slightly
varied positions [3]. However, the take-away from these various open and closed conformations is
that it appears that the CTD flap domain closes for the purpose of positioning the histidine into the
active site, sheltering the hydride transfer reaction and when opened cofactor exchange can occur.
Figure 4 shows the various open conformations observed till this point.
Yet another location of the CTD was observed in an HMG-CoA-bound SpHMGR that was
described as being in a partially closed conformation [3]. Whereas in the closed conformation the
CTD covered the active site, and in the open conformation it was flipped away, this partially closed
conformation located the CTD away from the cofactor-binding site but still covering the substratebinding site [3]. In the closed conformation, with both substrate and cofactor bound in a dead -end
complex, the CTD covered the entire active site, including both substrate and cofactor sites. This
contrasts with the SpHMGR structure that has only substrate bound which reveals the partially
closed conformation that only covers the substrate site.
This partially closed conformation would allow cofactor exchange without the release of
substrate intermediates, which corroborates prior studies that show that reaction intermediates are
not released during the course of the reaction. Figure 5 shows all the conformations of the CTD
determined from PmHMGR and SpHMGR structures. What is revealed through all these structures
showing the CTD in various location is that the CTD is mobile, spanning various locations for the
integrity of the reaction. While the order of events remains unclear, an evolving paradigm of how
the CTD facilitates the reaction, that is optimized by preventing intermediates from being released,
and the mechanism by which two equivalents of cofactors are used in this sequence, is becoming
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clearer, but further work will continue to expand our understanding of this fascinating, dynamic
enzyme.
3.2.3. Goals of this section
As observed in the above chronological unraveling of the mechanism of HMGR, additional
studies done on different homologs incrementally added and expounded on prior assumptions.
Thus, this work serves to add to the growing body of knowledge that can both corroborate prior
research and extend our understanding. For this reason, we utilize a previously less characterized
HMGR, from Delftia acidovorans (DaHMGR), with the desire to provide novel crystal structures
and complementary biochemical data to further our understanding of class II HMGR. The vision
was birthed out of the need to clarify the importance of active site residues and to understand the
role of the CTD more fully as it traverses through different conformations during the course of the
reaction.
More specifically, one goal sought to characterize DaHMGR using steady-state kinetics
and X-ray crystallography. Several HMGRs have been kinetically characterized as revealed in
Table 4 which outlines a variety of kinetic parameters determined for HMGRs that have been
published thus far. This table provides the following: the organism from which the HMGR comes
from; and any steady-state kinetic parameters obtained for substrate, product, or cofactor.
However, prior studies on DaHMGR are limited in biochemical characterization. Of the limited
published biochemical data, DaHMGR was featured in one study using engineered E. coli strains
where HMGRs from several different species were expressed alongside the remaining MEV
pathway enzymes from Saccharomyces cerevisiae. The pathway was engineered to produce
amorphadiene, the isoprenoid precursor to the antimalarial drug artemisinin, and out of the HMGR
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homologs tested, the greatest yield was achieved when using DaHMGR [11]. Despite this
intriguing observation, a more thorough kinetic characterization of the steady-state kinetics using
HMG-CoA and NAD(P)H, is lacking. Thus, this goal seeks to utilize steady-state activity assays
to assess substrate and cofactor affinity and in doing so hope to determine its cofactor preference.
With the knowledge of its cofactor preference, the next step in this goal of characterizing
DaHMGR seeks to crystallize DaHMGR with its preferred cofactor to observe the interactions
with the cofactor. Prior to this work, structures of only two class II HMGRs, PmHMGR and
SpHMGR, were determined. These two structures, one of the NADH-preferring PmHMGR and
one of the NADPH-preferring SpHMGR, have provided some structural basis for cofactor
specificity. By determining the structure of DaHMGR with its preferred cofactor, one is able to
assess prior hypotheses about the structural determinants that confer cofactor specificity. This will
aid the work done in Chapter Four that aims to utilize this knowledge to generate modified HMGRs
with modified cofactor preferences.
A second goal of this section involved solving crystal structures of DaHMGR and
SpHMGR that capture the conformation of the CTD. By locating the CTD, with or without ligands
bound, this study will add to the limited number of structures that depict the CTD in their models.
The hope is that we will eventually be equipped with the understanding of how the CTD behaves
as it accommodates and facilitates each step of the mechanism. Incidentally, while studying
cofactor specificity, which is the focus of Chapter Four, additional SpHMGR mutant constructs
generated crystal structures containing additional insight related to the C-terminal domain (CTD).
Since the CTD is one of the focuses of the present chapter, the crystal structures from these
SpHMGR mutant constructs will be partly incorporated into the Discussion of this chapter but
only as they pertain to the C-terminal domain (CTD), with the hope of expanding our
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understanding of the role of the CTD during the mechanism. In sum, this section continues from
Chapter Two in characterizing HMGR but specifically exploring the mechanism utilizing
structural and functional data.

3.3.

Results

3.3.1. Activity assays
The activity of DaHMGR was monitored by the decrease in absorbance at A 340 nm since
the oxidation of NAD(P)H to NAD(P)+ causes a loss of absorbance at this wavelength. The initial
rate, V 0 , is determined by the slope of the line of absorbance versus time at the interval in which
the fastest activity is observed. The activity of DaHMGR begins to slow down as the concentration
of the substrate and cofactor decline and become depleted.
In Figure 6, steady-state parameters were determined based on a non-linear regression
fitting the Michaelis-Menten equation done in GraphPad Prism 6.0 with respect to NADH and
NADPH and HMG-CoA. The Km for HMG-CoA using its preferred cofactor, was calculated to be
7.34 µM. The kcat which was calculated by dividing the Vmax by the molar enzyme concentration,
was determined to be 22.29 s-1 and the kcat/KM, 3.04 x 106 M-1 s-1 [12].
With regards to cofactor preference, a clear preference for NADH is observed. The Km is
determined to be 28.48 µM, the kcat is 16.58 and the kcat/KM is 5.82 x 105 M-1 s-1 . While DaHMGR
is capable of using NADPH, when NADPH was assessed, the enzyme did not reach Vmax at the
concentrations that were measurable using the detection limit of the instruments used, showing
low activity for NADPH. As observed by a linear relationship between initial rate versus NADPH
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concentration in Figure 6, despite increasing the concentration of NADPH as high as 500 µM, the
enzyme never reaches a maximum velocity. Thus, steady-state parameters are not determined [12].
Table 5 shows a summary of the novel kinetic parameters determined for DaHMGR.
Inhibition by citrate with respect to HMG-CoA was observed when supplementing steadystate kinetics varying HMG-CoA with 0-355 mM Citrate. Double-reciprocal pots with linear fits
show no difference in the y-intercepts of the linear fits with and without citrate suggesting
competitive inhibition as shown in Figure 6. The apparent KM after supplementing the reaction
with citrate was increased, and as such a Ki of 170 mM was calculated.
3.3.2. Crystal structures
3.3.2.1.

Apo DaHMGR
The initial apo DaHMGR crystallized with one monomer in the asymmetric unit such that

its catalytically related adjacent monomer is generated by crystallographic symmetry. Only density
for the residues 3-376 was observed and was modeled with the protein chain. The CTD,
presumably disordered, makeup the remaining residues, 377-429. An overlay of this apoDaHMGR and the remaining structures presented in this chapter are shown in Figure 7 revealing
no significant differences in the overall structure of the main domain which excludes the CTD.
The data collection and refinement statistics of this structure are provided in Chapter Two.
3.3.2.2.

Mevalonate-bound DaHMGR
Similar to the apo structure above, mevalonate-bound DaHMGR crystallized with one

monomer in the asymmetric unit and did not have density for the CTD. Density consistent with
mevalonate was observed and was modeled into the structure. A Polder mFo – DFc omit density
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map with respect to mevalonate calculated in Phenix[13] is shown in Figure 8, which includes the
interactions between mevalonate and the surrounding residues within the active site. An overlay
of mevalonate-bound DaHMGR and the remaining structures presented in this chapter are shown
in Figure 7 revealing no significant differences in the overall structure of the main domain.
3.3.2.3.

NADH- and mevalonate-bound DaHMGR
Similar to the above apo and mevalonate-bound structures, NADH- and mevalonate-bound

DaHMGR crystallized with one monomer in the asymmetric unit and did not have density for the
CTD. Density consistent with NADH and mevalonate was observed and was modeled into the
structure. Polder mFo – DFc omit density maps with respect to NADH and mevalonate calculated
in Phenix[13] are shown in Figure 9. An overlay of NADH- and mevalonate-DaHMGR and the
remaining structures presented in this chapter are shown in Figure 7 revealing no significant
differences in the overall structure of the main domain which excludes the CTD.
3.3.2.4.

NADH- and citrate-bound DaHMGR
DaHMGR, bound to citrate and NADH, crystallized with three molecules in the

asymmetric unit. Chains A and B form a homodimer, whereas chain C forms a homodimer with a
second chain C monomer (C’) through crystallographic symmetry. Density for the CTD was
observed in chain B and C, whereas the CTD of chain A was unresolved. The CTD is observed in
a similar location as the previously described closed conformation observed in the ternary complex
of PmHMGR (PDB 1QAX) however it appears to be turned upside-down. The linker region, which
connects the main domain to the CTD, allows the three helices of the CTD to be oriented such that
there is a ~180° in-place rotation of the CTD, a conformation we term the “flipped conformation.”
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The final model contains the following residues: chain A contains residues 2-377, chain B
contains residues 2-428, and residues C contains residues 2-429. Polder mFo – DFc omit density
maps with respect to citrate and NADH calculated in Phenix[13] are shown in Figure 10 and Figure
11, respectively, which includes the interactions between citrate and NADH and the surrounding
residues in the active site. An overlay of NADH- and citrate-bound DaHMGR and the remaining
structures presented in this chapter are shown in Figure 7 revealing no significant differences in
the overall structure of the main domain which excludes the CTD. The root-mean-square deviation
for deviation for Cα atoms (rmsd) of 0.75–0.84 when compared to the structure of cofactor-bound
SpHMGR (PDB entry 5WPJ)[12].
3.3.2.5.

Citrate-bound DaHMGR
For this experiment, DaHMGR was crystallized with HMG-CoA but there was no electron

density for the CoA moiety of HMG-CoA. Instead, density consistent with citrate, which was part
of the crystallization reagent, with a final concentration of ~50 mM citrate, was observed, in a
similar manner as described previously. This citrate-bound DaHMGR structure crystallized with
two monomers in the asymmetric unit that form the catalytic homodimer. Density for residues 3429 were observed in both chains, however, density for the CTD in Chain A was poorer than the
density observed for the CTD in Chain B. Crystal packing analysis suggest that the CTD of Chain
B has more interactions with symmetry-related monomers than the CTD of Chain A which may
be the reason poorer density is observed for the latter.
The CTD adopts the flipped conformation previously observed in the NADH- and citratebound DaHMGR. Notably, the crystallization parameters between the citrate-bound structure and
the NADH- and citrate-bound structure, are different. For example, the space group, the respective
crystal contacts, the number of molecules observed in the asymmetric unit, all differ between these
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two structures, however they both produce structures that have the CTD in a flipped conformation.
Figure 12 shows an overlay of CTD of the citrate-bound DaHMGR and NADH- and citrate-bound
DaHMGR.
3.3.2.6.

Citrate- and NADPH-bound SpHMGR
Apo and ligand bound structures of SpHMGR have been previously reported, however a

novel crystal morphology in a previously unreported space group was obtained during
crystallization screening involving SpHMGR mutants discussed in Chapter Four. Using those
conditions, a structure of wildtype SpHMGR co-crystallized with NADPH was determined. This
crystal formed the homodimer in the asymmetric unit. In both chains, density for residues 3-424
were observed and modeled in. Density for NADPH and citrate, which was part of the precipitation
reagent during crystallization experiments, was observed and modeled in. Polder mFo – DFc omit
density maps with respect to NADPH and citrate for one chain were calculated in Phenix are shown
in Figure 13.
The CTD adopts a conformation that resembles the “flipped” conformation that was
previously observed in citrate- and NADH-bound DaHMGR. The CTD occupies the same region
as the closed conformation found in the ternary complex of PmHMGR (PDB 1QAX) but the
orientation of the three helices that make up the CTD are flipped. The catalytic histidine, which
point towards the active site during distinct steps in the mechanism, is now flipped outwards
toward the solvent.
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3.4.

Discussion
HMGR, an NAD(P)-dependent oxidoreductase, is a fascinating enzyme that exemplifies

how the structure of these biologically important enzymes accomplish its complex function. Its
intrigue stems from to its ability to catalyze the four-electron reduction of HMG-CoA to
mevalonate, using two cofactors that individually need to enter and leave at specific times during
the reaction mechanism. Moreover, the enzyme can control the flux of ligands, from substrate to
product, by preventing unnecessary loss of intermediates, thus achieving a highly efficient process.
To date, research has revealed important facets of the active site as well as the role of a
flexible flap domain, named the C-terminal domain (CTD), that contributes towards its mechanism
of catalysis, which is owed to studies done on several HMGRs that incrementally added to our
understanding of how HMGR works. With gaps in our understanding remaining, this research
sought to characterize a lesser-studied HMGR, from Delftia acidovorans (DaHMGR), with two
main goals: 1) to kinetically characterize HMGR with respect to substrate and cofactor and solve
crystal structures of its preferred cofactor bound; 2) to solve crystal structures that contain the CTD
to substantiate its role in the mechanism. Additional structures of SpHMGR and SpHMGR
mutants, which are the focus of Chapter Four, were also consulted as they pertain to the role of the
CTD.
Regarding the first goal to kinetically characterize DaHMGR, one specific aim was to
quantify the cofactor preference of DaHMGR for either NADH or NADPH. Here, using steadystate kinetics, the evidence shows DaHMGR as an NADH-dependent enzyme, with a Km of 28.48
±1.39 µM and kcat of 16.58 ±0.24 s-1 for a catalytic efficiency of 5.82 x 105 M-1 s-1 . These kinetic
parameters are comparable with respect to various characterized HMGRs. For example, Kmvalues
for various HMGRs range from 12.9-160 µM as listed on Table 4. Catalytic efficiency is also
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within reported ranges as compared to, for example, SpHMGR which has a kcat/ Km of 2.4 x 105
M-1 s-1 .
While DaHMGR can utilize NADPH, the enzyme did not reach maximal velocity using
the range of NADPH used here, further showing DaHMGR’s preferred utility of NADH over
NADPH. Another specific aim was to perform steady-state kinetics to reveal the affinity of
DaHMGR to HMG-CoA. Here, we present DaHMGR kinetics with respect to HMG-CoA to have
a Km of 7.34 µM and kcat of 22.29 ±0.48 s-1 for a catalytic efficiency of 3.04 x 106 M-1 S-1 when
using its preferred cofactor. Of the class II HMGRs that have been investigated, DaHMGR has the
lowest Km, suggesting a relatively high affinity for DaHMGR to HMG-CoA.
With the knowledge that DaHMGR prefers NAD(H), we solved the crystal structure of
DaHMGR with NADH bound. We confirm an important motif that was previously hypothesized
to directly contribute towards cofactor specificity. It was previously proposed that a short α-helix
found only in class II HMGR termed the “cofactor helix” plays a crucial role in determining
cofactor specificity [3]. At least three important residues in positions one, three and seven of this
helix are involved in governing cofactor specificity. In NADH-preferring HMGR, for example in
PmHMGR, these three residues are made up of an aspartate that is conserved among NADHpreferring HMGRs and two hydrophobic leucine residues. The two hydrophobic residues in the
third and seventh position stack against the aromatic adenine ring. More importantly, the aspartate
sidechain hydrogen interacts with the 2-hydroxyl of the NAD ribose.
This aspartate likely contributes towards selectivity by preventing the 2’-phosphate of its
non-preferred cofactor, NADPH, from binding. In contrast, for NADPH-preferring HMGRs, like
in SpHMGR, a tyrosine is observed instead of aspartate of the cofactor helix and residues serine
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and arginine, occupy positions three and seven. Instead of nonpolar residues found in NADHpreferring HMGRs, serine and arginine making hydrogen bonding and pi-pi stacking interactions
with the ribose phosphate group and adenine respectively. A summary of the cofactor helix as a
structural motif that confers cofactor specificity is as follows: DX(V/L)XXXL for NADH and
YXSXXXR for NADPH, where “X” indicates variable amino acids. In the crystal structure
presented here, DaHMGR contains the cofactor helix sequence DKVLIGL. Figure 14 shows the
cofactor helices that constitute the developing model used to explain cofactor specificity, which
alongside the kinetic data obtained here, agrees with previous hypothesis of the important role in
dictating cofactor specificity of the cofactor helix. Further work into the cofactor specificity, and
engineering efforts are explored in the next chapter.
A second goal of this section in further characterizing DaHMGR and elucidating the
mechanism of catalysis among class II HMGRs was to solve crystal structures with resolved CTDs.
In many structures of HMGRs, there is no density for this domain because it is a highly flexible
and dynamic domain. HMGR is believed to be active in its crystal form [8], so the flexibility of
the CTD in the context of its native function persists in the crystal lattice, thus making it difficult
to procure crystal structures of HMGR that have resolved CTDs. However, in this study, we were
successful in obtaining several structures of DaHMGR and SpHMGR and SpHMGR mutants that
reveal novel locations of the CTD.
In one structure of NADH-bound DaHMGR which contained citrate in the active site –
citrate was part of the crystallization reagents –we reveal a surprising new orientation of the CTD
of class II HMGR. Prior to this discovery of this new orientation, the CTD was previously observed
in either an open, closed, or partially closed conformation, depending on what ligands were bound.
In the structure of apo-SpHMGR with no ligands bound, the CTD assumed an open conformation,
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allowing entry of substrate and cofactor. In the structure of with NADPH-bound SpHMGR, the
CTD was in a similar open conformation, which suggests that cofactor binding alone does not
trigger closing of the CTD. In the structure of HMG-CoA-bound SpHMGR, the CTD was located
in a partially closed conformation where the CTD interacts with CoA moiety of the substrate,
closing off the substrate-binding site while leaving the cofactor-binding site exposed. When HMGCoA and NAD+ were bound simultaneously to PmHMGR, a closed conformation where the CTD
covers the active site was observed. The novel location found in this study shows DaHMGR CTD
having a flipped conformation which further expands this paradigm.
It is worth pointing out that crystal packing interactions appear to have allowed the capture
of the CTD in this flipped conformation whereby symmetry-related monomers stack up against
the CTD to stabilize it. This observation may question the physiological relevance of the CTD in
this conformation. However, it is important to consider that the crystal packing interactions that
contribute towards stabilizing the CTD in two different structures, namely the citrate-bound
DaHMGR structure and the NADH- and citrate-bound structure, are different. In NADH- and
citrate-bound DaHMGR, the crystal packing interactions that stabilize the CTD are primarily made
up of the CTD of one monomer and the CTD from a symmetry-related monomer. However, in
citrate-bound DaHMGR, the CTD from one monomer is stacked up against two CTDs from two
adjacent symmetry-related monomers in a vastly different orientation. Moreover, in citrate-bound
DaHMGR, the way the CTD of chain A stacks up against two CTDs from the adjacent monomer
is different from the way chain B stacks up against two CTDs from its adjacent monomer. The
difference between the crystal packing interactions in both the above structures are depicted in
Figure 15.
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As noted in the Results, the two above structures are from entirely different crystal lattices,
and crystallized in different space groups, with different crystal packing, yet still reveal the CTD
in a flipped conformation. Even within two monomers of the same crystal structure (citrate-bound
DaHMGR), the crystal packing interactions that stabilize each CTD differ, despite the
conformation of the CTD remaining the same. This suggests that the flipped conformation of the
CTD may not simply be a crystallographic artifact. The observation that two completely different
crystal packing configurations captured the CTD in this conformation is evidence of this
conformation being intrinsic to the protein’s native function. Furthermore, as will be highlighted
later in this discussion, this flipped conformation is similarly observed in a different citrate-bound
HMGR homolog.
According to the CTD movements previously observed, the CTD of NADH-bound
DaHMGR would be expected to assume an open conformation just as with NADPH -bound
SpHMGR. However, in the flipped conformation, the NADH-binding site and the substratebinding site are covered by the CTD, with Arg405 and Arg428 of the CTD interacting with the
cofactor. In this conformation, the catalytic histidine side chain is flipped out of the active site and
is pointing towards solvent. In addition, while the location of the three helical bundle of the CTD
is in the same general vicinity of the closed structure as observed in PmHMGR, the orientation of
the three helices is different than previously observed. In the closed structure, the first helix of the
CTD stacks up against the active site, with the catalytically important histidine pointing towards
the active site, as it lays on the surface of the opposite monomer. The two remaining helices are
positioned away from the active site on the outer surface, pointing towards the solvent. In the
flipped conformation of DaHMGR, the first helix is now on the outer surface of the protein, and
instead, the two subsequent helices lay on the surface of the protein. Figure 16 shows the location
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and orientation of the flipped conformation in comparison to the closed conformation observed in
PmHMGR.
What is reiterated by this observation is the inherent flexibility of the CTD and that the
CTD may assume multiple conformations that facilitate the progression of the reaction. In the
flipped conformation, crystal packing interactions have captured a snapshot of one possible
location that the CTD can assume when cofactor is bound. Thus, it is likely that there is no single
conformation for cofactor-bound HMGR but rather conformations that point to the inherent
mobility of this domain upon cofactor binding. The degree of flexibility of this domain is owed to
a linker region that connects the main domain of the protein to the mobile CTD. The linker region
is found preceding the three helical bundle that comprises the CTD and extends from a helix from
the main domain to the CTD. While occupying the same overall location, the linker region reveals
how it can afford the CTD’s ability to adopt various conformations and locations as shown in
Figure 17, including the novel flipped location revealed in this study. Interestingly, in the ternary
complex of NAD+- and HMG-CoA-bound PmHMGR, where the CTD adopts a closed
conformation, this linker regions forms part of a bent helix that connects the main domain to the
CTD. It is possible that the winding and unwinding of this helix contributes towards the flexibility
of this linker region and subsequently the positioning of the CTD.
In addition to highlighting the flexibility of the CTD, this flipped location may also provide
greater insight into the catalytic mechanism. Upon analysis of citrate bound to the active site, it
was proposed that citrate, which resembles the structures of intermediates mevaldehyde and
mevalonate, may be mimicking an intermediate step. As previously mentioned, NADH-bound
DaHMGR would be expected to have its CTD in an open conformation, allowing entry and exit
of both cofactor and substrate. However, in NADH-bound DaHMGR, both sites are closed off,
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thus suggesting an intermediary step where the CTD is preventing the release of an intermediate,
blocking off the binding site of the substrate/product. To further support the idea that citrate may
be mimicking an intermediate, we observe many of the same interactions between citrate and
DaHMGR that were also observed in a prior structure of mevalonate-bound PmHMGR[10]. As
such, the flipped conformation may in fact represent an intermediate mevaldehyde- or mevalonatebound structure.
It is important, therefore, to examine the resemblance of citrate to the intermediates.
Mevaldehyde contains a terminal carbonyl at a sp2-hybridized carbon, while mevalonate contains
a primary alcohol at a sp3-hybridized carbon. Figure 10 shows a comparison between the structures
of citrate and intermediates. Citrate, with a terminal sp2-hybridized carboxylate carbon, arguably
resembles mevaldehyde more closely, and if so, the citrate-bound DaHMGR presented here may
provide useful insight into the catalytic mechanism. Citrate was also found to inhibit the reaction
competitively with respect to HMG-CoA as shown in Figure 6.
Additionally, the flipped conformation confirms that while His381 plays an important role
in catalysis, its direct role is not during HMG-CoA reduction or mevaldehyde reduction but rather
in the protonation of CoA as it is cleaved. In this scenario, His381 would not need to be in the
vicinity of the active site in the subsequent steps when mevaldehyde is reduced to mevalonate
using the second cofactor. The citrate-bound DaHMGR indeed has His381 in the flipped
conformation located towards the solvent.
Incidentally, while pursing mutant constructs of SpHMGR related to cofactor preference
efforts which will be discussed in the next Chapter, crystal structures revealed locations of the
CTD that appear to corroborate some of the assertions made here. Two SpHMGR chimeric
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proteins, SpHMGR containing a DaHMGR cofactor helix with and without M185T mutations,
both bound with their newly preferred cofactor, NADH, reveal new locations of the CTD. The
CTD in both of these structures are in the general open location. This agrees with the above
observation that there is no single conformation and location of the CTD when only cofactor is
bound. Figure 18 shows the open conformations of these newly acquired structures overlayed with
a previous structure of SpHMGR in an open conformation.
An additional structure, of SpHMGR bound by NADPH and citrate, reveals the CTD in an
apparent flipped conformation. In this structure, the location of the CTD is in the general vicinity
of the previously observed closed conformation of PmHMGR, however, the orientation of the
helical bundle more resembles the flipped conformation of DaHMGR. In this flipped
conformation, the catalytically important histidine is indeed pointing away from the active site and
is solvent exposed. Similarly observed in the flipped CTD conformation in DaHMGR, the first
helix points towards the solvent, whereas the remaining two helices lay closer to the surface of the
protein. Figure 19 shows the comparison between the flipped conformations between DaHMGR
and SpHMGR. In both DaHMGR and SpHMGR flipped conformations, citrate is bound, and as
proposed above, may be a mechanistically relevant conformation in possibly mimicking an
intermediate step in the mechanism.
Taken together, the results presented thus far in this Chapter provide new insight into the
steps of catalysis and as outlined in Figure 20, the result is a proposed revised mechanism [12]. In
apo form, without any ligands bound, the CTD is flexible and disordered which is corroborated by
the apo-DaHMGR structure presented here as well as other apo-HMGRs structures. There are
many open conformations, but common among these, is the ability for substrate and cofactor to
bind. It is not known whether substrate or cofactor binds first and there are structures of only
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HMG-CoA bound and structures of only NADP(H) bound. Upon cofactor binding, however, it is
evident that the CTD remains flexible as confirmed by the several open conformations of NADPHbound SpHMGR and the NADH-bound DaHMGR structures presented here. If, instead, HMGCoA binds first, the CTD can adopt a partially closed conformation as observed in HMG-CoAbound SpHMGR which shows how HMG-CoA can be retained while allowing NADP(H) to
bind[12].
Once the ternary complex is formed, the CTD assumes a closed conformation as depicted
in NAD+- and HMG-CoA-bound PmHMGR. In this closed conformation, the CTD situates the
catalytic histidine (His381 in PmHMGR numbering) at the active site. As illustrated in Figure 20
of the mechanism, HMG-CoA is reduced to mevaldyl-CoA utilizing the first equivalent of cofactor
and it has been proposed that either Glu83 or Lys267 protonates the substrate carbonyl. Structures
of HMG-CoA-, and the mevalonate and citrate-bound structures presented here, all show
conserved positioning of these two residues as they interact with the oxygen atom of the carbonyl
[12].
Further mutational analysis of the roles of the above two catalytic residues, Glu83 and
Lys267, alongside structural analysis offer insight into the roles of these two residues. Mutation
of Lys267 to alanine significantly diminishes activity, but does not abolish it completely [10]. In
contrast, mutation of Glu83 to glutamine, essentially kills activity, and computational analysis has
suggested that transfer of a hydride from the cofactor is more favorable if Glu83 is protonated [6],
[14]. The revised proposed mechanism, therefore, suggests that Glu83 acts as the catalytic acid,
protonating the substrate carbonyl, whereas Lys267 acts to polarize the carbonyl, priming it for
the first reduction step. It is worth noting that this revised mechanism does not rule out Lys267 as
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being the source of protonation, but the structural and functional data thus far informs this proposal
[12].
Following this first reduction step, and once the intermediate mevaldyl-CoA is formed, it
is uncertain the order of the immediate steps that follow. Specifically, it is unclear the order of
steps as they pertain to the release of the used oxidized cofactor and the incorporation of the second
reduced cofactor, and the steps involved in the cleavage of mevaldyl-CoA to form mevaldehyde
and CoA. With evidence suggesting that a CoA-containing intermediate can remain bound to the
enzyme, and the observation that in the partially closed conformation of SpHMGR showing how
the CTD binds the CoA moiety while keeping the cofactor binding site open for exchange gives
credence to the presumption that the release of the oxidized cofactor and the acquisition of a
reduced cofactor, occurs while mevaldyl-CoA remains bound [3], [8]. Subsequently, this
intermediate is decomposed to mevaldehyde and CoA [12].
In the decomposition of mevaldyl-CoA to mevaldehyde and CoA step, Glu83 may be
involved in deprotonating mevaldyl-CoA. From the citrate-bound DaHMGR and SpHMGR
structures presented here, which possibly mimic a mevaldehyde-bound HMGR, indeed Glu83 is
shown interacting with the corresponding oxygen atom of citrate. This suggests that Glu83 may
be protonated when this oxygen is deprotonated. Following cleavage of CoA, His381 from the
CTD of the opposite monomer likely protonates the thiolate moiety, which is then able to be
released, leaving behind mevaldehyde in the active site. In the citrate-bound flipped conformation
structure of DaHMGR, it is noted that the CTD would sterically clash with any bound CoA. As
shown in Figure 21, which is an overlay of HMG-CoA-bound PmHMGR and the citrate-bound
DaHMGR structure, the location of the CTD sterically clashes with CoA and would contradict
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CoA still being bound. As such, this flipped conformation suggests that CoA can be released once
mevaldehyde is formed and may not remain bound for the remainder of the reaction [12].
In the citrate-bound SpHMGR structure, the flipped CTD conformation does not appear to
sterically hinder CoA if CoA were bound. An overlay of HMG-CoA-bound SpHMGR and citratebound SpHMGR reveals that CoA can still be present. The steric clashes shown above in the case
of the flipped CTD conformation of DaHMGR are not observed in the flipped conformation of
SpHMGR. In this case, it is possible that CoA can be retained and released at a later step in the
mechanism. However, while the citrate-bound SpHMGR conformation of the CTD includes the
possibility that CoA can being released later in the mechanism, based on the flipped structure of
DaHMGR, CoA is likely released once mevaldehyde is formed.
At this point in the mechanism, the second cofactor and mevald ehyde are bound, therefore
one would expect that the enzyme can undergo a conformation change to adopt the closed
conformation of the CTD which would enable the reduction of mevaldehyde to mevalonate. In the
citrate-bound DaHMGR mimicking mevaldehyde binding, the mevalonate bound -DaHMGR, as
well as prior mevalonate-bound PmHMGR structures, show Glu83 or Lys267 interacting with the
analogous oxygen atom. This suggests that one of these two residues protonates mevaldehyde as
it forms mevalonate alcohol. As discussed above, regarding the roles of Glu83 and Lys267 in
protonating a prior intermediate, we propose Glu83 as the protonating residue. Following this step,
the CTD can become flexible and mobile, and can adopt an open conformation, which would allow
the release of mevalonate and oxidized cofactor. This final step leaves the active site empty and
exposed to the solvent for reprotonation of active site residues, and ultimately, ready for substrate
and cofactor to bind for a new round of the mechanism[12].
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In this chapter, the biochemical and crystallographic data presented here illuminate the
structural and functional dynamics of the class II HMGR using DaHMGR and SpHMGR
homologs. Using DaHMGR, by solving its crystal structure bound to its preferred NADH cofactor,
we have confirmed the importance of a helical motif that appears to determine the cofactor
preference of the enzyme. Furthermore, the various crystal structures of apo, mevalonate-bound,
NADH- and citrate-bound DaHMGR, and citrate-bound DaHMGR as well as citrate-bound
SpHMGR, provides a snapshot into the flexibility of the CTD, adopting a novel flipped location
that contributes towards and expands the proposed HMGR mechanism. With citrate bound, this
research may also provide insight into the intermediary steps of the reaction cycle. Collectively,
this research makes considerable progress towards the hope of growing our understanding of the
catalytic mechanism and cofactor specificity of this biologically important enzyme.

3.5.

Future work

3.5.1. Additional kinetic characterization
While this study makes significant strides in characterizing the kinetic behavior of
DaHMGR, additional functional studies are warranted. Steady-state kinetics to expand the
Michaelis-Menten parameters of DaHMGR with respect to the oxidized cofactors as well as
mevalonate and CoA are examples of work that needs to be explored. Since the KM of HMG-CoA
is relatively low compared to other HMGRs, suggesting that the affinity of the substrate is high in
the forward reaction converting HMG-CoA to mevalonate, it would be worthwhile to determine if
DaHMGR also binds the reverse direction substrates with similar affinity. Also, as will be
discussed in Chapter Five, it is likely that DaHMGR prefers to operate in the reverse direction,
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thus steady-state kinetics to characterize its affinity to the oxidized form of NADH will be
insightful.
3.5.2. Additional structures with different ligands bound
The new work presented here unearths exciting directions for further characterization of
DaHMGR and therefore class II HMGR, including the hopes of obtaining additional crystal
structures of various ligands bound – either intermediates, substrate, or products, with or without
cofactors. This will further the insight into the structural dynamics required for catalysis. It will be
advantageous to have a library of structures that correspond to various points in the mechanism,
ideally the conformations of the CTD resolved. These structures include DaHMGR bound to:
HMG-CoA + NAD+, mevalonate + CoA + NADH, and NADP(H). Especially in light of the
flipped conformation with citrate possibly mimicking the mevaldehyde intermediate and its
implications on the mechanism, it would be desirable to solve the structure of DaHMGR or
SpHMGR

with

an

intermediate

bound,

for

example,

having

a

structure

of

DaHMGR+mevaldehyde. Such a structure would be helpful in discerning the physiological
relevance of the flipped conformation.
3.5.3. Understanding the forces that enable CTD motions
As the CTD traverses through the various locations, which so far have been depicted in
open, partially closed, flipped, and closed conformations, there are instances where residues of the
CTD interact with moieties of the rest of the protein complex. To further interrogate the importance
of such conformations, it would be worthwhile to pursue mutational analysis that perturbs these
interactions, to observe how catalytic activity is influenced. If these various locations are
mechanistically important, then mutating residues that are involved in the interaction between the
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CTD and the rest of the protein might diminish activity, and such an analysis would home in on
the significance of the various conformations and implicated residues.
Similarly, further interrogation into the role of the linker region that connects the CTD to
the rest of the protein would be helpful in determining its part in accommodating or even promoting
the ability of the CTD to adopt various locations. Based on Figure 17, in the partially closed
conformation of the CTD, the linker region is comprised partly of a helix. In the closed
conformation, the linker region is almost entirely helical. Whereas in the other conformations, the
linker region does not form a distinct secondary structure. Thus, it appears that the winding and
unwinding of this linker region may contribute towards the opening and closing of the CTD. One
could pursue investigation into this phenomenon by, for example, disrupting helical formation by
introducing a residue such as proline, and observe the consequences on catalysis.

3.6.

Materials and methods
DaHMGR protein expression and purification are outlined in the Materials and Methods

of Chapter Two. In this section, the Materials and Methods associated with DaHMGR kinetic and
structural analysis are detailed. In addition, as mentioned above, the crystal structures of various
SpHMGR mutant constructs, which are the focus of Chapter Four, contain novel insight into the
conformations of the CTD and therefore will be included in the Discussion of this chapter, however
the Materials and Methods for those structures are outlined in Chapter Four.
3.6.1. In vitro enzyme activity assays
Steady-state kinetics to acquire Michaelis-Menten parameters, K m and kcat, were conducted
by monitoring the enzyme-catalyzed oxidation of NAD(P)H via a decrease in absorbance at 340
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nm, using an extinction coefficient of 6200 M−1 cm−1 . For assessing cofactor parameters, HMGCoA was kept constant at saturating concentrations while varying the concentration of NAD(P)H,
and for assessing substrate parameters, NAD(P)H was kept at saturating concentrations while
varying HMG-CoA concentration. K m was calculated using a non-linear regression fit of the graph
of initial rate versus substrate concentration to the Michaelis-Menten equation in GraphPad Prism
7[15], and kcat was determined by dividing V max by the molar enzyme concentration. Experiments
were conducted in triplicate using a microplate reader. The reaction mixtures were prepared as
shown Table 3, with the reaction being initiated by the addition of HMG-CoA.
3.6.2. Citrate inhibition assays
To assess inhibition with respect to HMG-CoA, the above steady-state kinetics with the
same reaction mixtures when assessing HMG-CoA parameters were conducted by including 0,
188, and 350 mM Sodium Citrate (pH 7.4). Double reciprocal plots were used to analysis the
nature of inhibition and to determine the Ki.
3.6.3. Crystallization
3.6.3.1.

NADH- and citrate- bound DaHMGR
To attempt crystallization of DaHMGR, sparse-matrix screening was performed using a

Crystal Gryphon crystallization robot (Art Robbins) with ~500 different crystallization conditions
by sitting-drop vapor diffusion. Three different enzyme mixtures using DaHMGR at 8.5 mg/mL
were prepared for this screen: DaHMGR alone, DaHMGR with 1 mM NADH, and DaHMGR with
1 mM HMG-CoA + 1 mM NAD+. Crystals were identified in many conditions, and using Izit dye,
these crystals were believed to be protein crystals, however a majority developed an irregular shape
not suitable for X-ray diffraction (see Figure 22). Condition 63 of Crystal Screen HT (Hampton
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Research) which contains 0.5 M ammonium sulfate, 0.1 M sodium citrate tribasic dihydrate pH
5.6, and 1.0 M lithium sulfate monohydrate showed promising crystals and subsequent
optimization of this condition was performed. The initial crystals were flat semi-circles that grew
into overlapping clusters. Optimization of these conditions involved varying the pH (from pH 5 to
pH 7) of citrate buffer and varying concentrations of lithium sulfate (200 mM to 1200 mM) using
hanging-drop vapor diffusion at room temperature. Optimal three-dimensional hexagonal crystals
were obtained at 0.1 M sodium citrate pH 5.0, 500 mM ammonium sulfate and 4-800 mM lithium
sulfate.
In preparation for X-ray diffraction, the optimized hexagonal crystals were cryoprotected
using 0.5 M ammonium sulfate, 0.1 M sodium citrate tribasic dehydrate pH 5.0, 600 mM lithium
sulfate, 26% glycerol or ethylene glycol supplemented with the same concentrations of ligands in
the co-crystallization before being flash-cooled in liquid nitrogen. As discussed in the results, this
yielded the first crystal structure of DaHMGR, with citrate and NADH bound.

3.6.3.2.

Apo DaHMGR, mevalonate-bound DaHMGR, and NADH- and mevalonate-bound
DaHMGR, and citrate-bound DaHMGR
Following the acquisition of citrate- and NADH-bound DaHMGR, we sought to acquire

additional structures of DaHMGR. As alluded to in the Materials and Methods section of Chapter
Two, this was done by modifying the crystallization condition with other buffers, adjusting pH,
and including other precipitating reagents. By modifying the crystallization buffer to Bis-Tris pH
5.5-6.5 and adding polyethylene glycol 3350 ~18-19% we were able to acquire crystals of apo and
mevalonate-bound DaHMGR that were suitable for diffraction experiments (See Figure 22).
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The apo structure was described in Chapter Two. 1 mM mevalonate was added in a similar
condition as apo –100 mM Bis-Tris (pH 6.5), 600 mM lithium sulfate, and 19% PEG 3350 –to
obtain the mevalonate-bound structure. These crystals were soaked in a cryoprotectant solution
composed of the crystallization solution with 1 mM mevalonate, 1 mM NAD +, and 21% sucrose
before being flash-cooled in liquid nitrogen to acquire the NADH- and MEV-bound structures.
During subsequent high-throughput screens using DaHMGR, a novel crystal morphology
was obtained. These crystals, which looked like cubes, were crystallized with 1 mM HMG-CoA,
and were looped directly from the screens without optimization for crystallization experiments.
The condition belonged condition B2 of Wizard Cryo Screen from Hampton Research and
contained 100 mM Sodium phosphate dibasic/Citric acid pH 4.2, 200 mM Ammonium Sulfate,
10% (v/v) glycerol and 20% (v/v) PEG 300. As will be discussed, HMG-CoA was not bound,
instead citrate was observed at the HMG-CoA binding site, similarly observed in the NADH- and
citrate-bound DaHMGR above. This citrate-bound DaHMGR, however, crystallized in both a
different morphology and space group than all prior structures.
3.6.3.3.

Citrate- and NADPH-bound SpHMGR
During crystallization screening exploring cofactor specificity, outlined in Chapter Four,

crystals of SpHMGR mutants that formed in a previously unreported space group were found.
Utilizing similar conditions, SpHMGR was co-crystallized with 10 mM NADPH in 100 mM
citrate pH 5.0, 17% PEG 3350 and yielded hexagonal-shaped crystals. Crystals were looped
without cryoprotectant, and flash-frozen for data collection.
3.6.3.4.

X-ray Data Collection, structure determination, and refinement
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X-ray diffraction data were collected at the Advanced Photon Source (APS). For the
DaHMGR with both citrate and NADH bound, the data were indexed, merged, and scaled using
MOSFLM[16] in space group P65 21 2 with three molecules in the asymmetric unit at 2.14 Å
resolution. Using the PHENIX [13] suite, Phaser [17] was used to determine the structure by
molecular replacement using the structure of PmHMGR (PDB entry 1QAX) with the substrate,
cofactor and C-terminal domain removed as the search model. Electron density for the C-terminal
domain was observed in only chains B and C. Using Coot [18], a poly-alanine sequence was built
first, prior to refinement in Phenix, and sequence-specific residues subsequently modelled in.
Electron density for NADH was also observed; Phenix.elbow [19] was used to generate NADH
restraint files that was used in the refinement of NADH in the structure. Electron density consistent
with citrate, which was part of the crystallization buffer, was found in the active site and modelled
in. Phenix.refine was used to perform reciprocal space refinement, with model-building in Coot.
X-ray data collection, structure determination and refinement were done similarly for the
apo, citrate- and mevalonate-bound structures. For these structures, however, instead of
PmHMGR, DaHMGR from the above NADH- and citrate-bound DaHMGR was used as the search
model for DaHMGR crystals, with the ligands removed, when the space groups were different
from the above. Apo, and mevalonate-bound crystals belonged to space group P321 and the
citrate-bound crystal belonged to space group P21 3. The same test set of reflections was preserved
for both apo and mevalonate-bound DaHMGR data sets. In addition, no density for the CTDs were
observed in the initial apo and mevalonate-bound structures, however, the citrate-bound DaHMGR
structure contained electron density for the CTD which was modeled as described above. For
SpHMGR, apo SpHMGR (PDB 3QAU) was used as a search model. These crystals formed in P
32 21 with two molecules in the asymmetric unit. Density for citrate, found in the crystallization
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reagent, and NADPH was observed and modeled in as well as for the CTD in both chains. Final
data collection and refinement statistics for published structures are listed on Table 1 and
unpublished structures are listed on Table 2.
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3.7.

Tables and figures
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Figure 1. Sequence alignment of class II HMGRs. A sequence alignment showing the conserved
residues between various class II HMGRs determined using Clustal Omega [20]. Red = small
hydrophobic resides including tyrosine (AVFPMILW). Blue residues = acidic residues (DE).
Magenta = basic residues (RK). Green = include hydroxyl, sulfhydryl, and amine groups
(STYHCNGQ).
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Figure 2. Overlay of HMG-CoA binding pocket. PmHMGR (PDB 4I6A) shown in green and
SpHMGR (PDB 5WPK) shown in cyan in cartoon representation and HMG-CoA in sticks.
Coloring of atoms are as follows: C colored green or cyan in PmHMGR or SpHMGR respectively,
N colored blue, O colored red, P colored orange, and S colored. A) adenine ring, solvent exposed
end of HMG-CoA and B) HMG moiety bound at the interior.
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Figure 3. Closed conformation of the C-terminal domain. PmHMGR bound by NAD+ and
HMG-CoA (PDB 1QAX) in a ternary complex, revealing the location of the CTD in a closed
conformation. Each monomer of the homodimer is colored a shade of gray and shown in surface
representation, with the CTD of one monomer, shown in yellow cartoon representation, covering
the active site. NAD+ and HMG-CoA are shown in sticks with the following coloring: C colored
green, N colored blue, O colored red, P colored orange, and S colored. The catalytically important
histidine, His381 from the CTD, is depicted in stick model, showing the vicinity of this residue to
the active site as a result of the CTD adopting this closed conformation. A) top view of the CTD
covering the active site. B) a side view of the CTD with respect to the rest of the complex. C)
Close up of the active site.

118

A

B

Figure 4. Open conformations of the C-terminal domain found in various SpHMGR
structures (PDB 3QAU and PDB 5WPJ). Each monomer of the homodimer is colored a shade of
gray and shown in surface representation, with the CTD in open conformations as observed in
SpHMGR structures shown in cartoon representation and colored differently. HMG-CoA and
NADP are modelled in from PmHMGR (PDB 1QAX) and SpHMGR (PDB 5WPJ) respectively, to
visualize the location of the active site with respect to the open conformation of the CTD. Ligands
are colored using the following: C colored green, N colored blue, O colored red, P colored orange,
and S colored. A) top view of the active site and B) a side view.
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Figure 5. Various conformations of the C-terminal domain of PmHMGR and SpHMGR
observed prior to the work done in this study. Each monomer of the homodimer is colored a
shade of gray and shown in surface representation. . HMG-CoA and NADP are modelled in from
PmHMGR (PDB 1QAX) and SpHMGR (PDB 5WPJ) respectively, to visualize the location of the
active site with respect to the open conformation of the CTD. Ligands are colored using the
following: C colored green, N colored blue, O colored red, P colored orange, and S colored . A)
top view of the active site and B) a side view. Open conformation of the CTD is made up of apoSpHMGR structures (PDB 5WPJ and 3QAU). Partially closed structure conformation of the CTD
is made up of the HMG-CoA-bound SpHMGR (PDB 5WPK). The closed conformation of the
CTD is made up of NAD+- and HMG-CoA-bound PmHMGR (PDB 1QAX). On the right, a
overlay of all the locations of the CTD of PmHMGR and SpHMGR. A) top view and B) side view.
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Figure 6. DaHMGR steady-state kinetics with respect to HMG-CoA, NADH and NADPH,
and citrate inhibition. A) Measuring the specific activity versus HMG-CoA concentration.
Concentrations of HMG-CoA ranging from 2 to 300 μM were used. B) Circles represent data with
NADH, and squares for NADPH. Concentrations of NADH ranging from 4 to 360 µM NADH
were used. Concentrations of NADPH ranging from 5-500 µM were used, but the enzyme did not
reach V max . Higher concentrations of NADPH could not be assessed due to its high absorbance
exceeding the detection limit of the instruments used. C) Competitive citrate inhibition with respect
to HMG-CoA with Double-reciprocal plots with linear fits showing citrate competitively binds
with respect to HMG-CoA.
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Figure 7. Overlay of all the DaHMGR structures presented in this chapter. Cartoon
representation of all the DaHMGR structures presented in this chapter, excluding the C-terminal
domain, which is only present in the NAD- and citrate-bound DaHMGR structure. Green = apoDaHMGR, blue = mevalonate-bound DaHMGR, magenta = NAD- and citrate-bound DaHMGR,
and yellow = NAD- and mevalonate-bound DaHMGR.
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Figure 8. Mevalonate-binding site of DaHMGR. A) Polder mFo – DFc omit density contoured
at 3.0σ shown surrounding mevalonate in green mesh, with mevalonate shown as sticks (C colored
pink and O colored red). B) The close-up of the substrate-binding site, with mevalonate from
DaHMGR (C colored pink), mevalonate from superimposed PmHMGR (PDB entry 1I6Y, C
colored teal), and DaHMGR residues (C colored gray) shown as sticks, with N colored blue and
O colored red. Dashed lines represent hydrogen bonding or salt-bridge interactions between
mevalonate and DaHMGR.
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Figure 9. Omit maps generated with respect to in NAD- and mev-bound DaHMGR. Polder
mFo – DFc omit density contoured at 3.0σ and colored brown surrounding A) mevalonate and B)
NAD with the ligands shown in sticks colored as follows: C colored green, N colored blue, O
colored red, and P colored orange.
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Figure 10. Substrate-binding site, showing citrate bound in DaHMGR. A) Polder mFo – DFc
omit density contoured at 3.0σ surrounding a citrate molecule shown in green mesh, with citrate
shown as sticks. B) Comparison between the structures of the substrate (S)-HMG-CoA,
intermediate (R)-mevaldehyde, product (R)-mevalonate, and citrate. Annotated colors in
parenthesis refer to the corresponding ligand coloring in panel C. C) Stereo view of citrate binding
in the structure of citrate- and NAD-bound DaHMGR superimposed with mevalonate in the
structure of mevalonate-bound DaHMGR and HMG-CoA in the structure of HMG-CoA-bound
SpHMGR (PDB 5WPK). Citrate (C colored pink), NADH (labeled, C colored pink), mevalonate
(C colored cyan), HMG-CoA (C colored green), and DaHMGR residues (C colored gray) are
shown as sticks, with N colored blue, O colored red, P colored orange, and S colored yellow.
Dashed lines represent hydrogen bonding or salt-bridge interactions involving citrate and
DaHMGR.
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Figure 11. NAD-binding site. A) Polder mFo – DFc omit density contoured at 3.0σ surrounding
NAD shown in green mesh, with NADH shown as sticks. B) Stereo view with NADH shown as
sticks (C colored pink) and DaHMGR residues shown as sticks (C colored gray), with N colored
blue, O colored red, P colored orange, and S colored yellow. A water molecule is shown as a red
sphere and labeled “W”. Dashed lines represent hydrogen bonding or salt-bridge interactions.

126

Figure 12. Comparing the flipped conformation of the C-terminal domain (CTD) observed
in two different structures of DaHMGR. In cartoon representation is an overlay of the CTD of
NAD- and citrate-bound DaHMGR shown in green and the CTD of citrate-bound DaHMGR
shown in cyan. In surface representation is the rest of the protein where each monomer of the
homodimer is colored in a different shade of gray. On top, are two different views of the overlay
of the CTDs showing how well they align.
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Figure 13. Polder omit maps generated with respect to citrate and NADPH bound by
SpHMGR. Polder mFo – DFc omit density contoured at 3.0σ and colored brown surrounding A)
citrate B) NADPH with the ligands shown in sticks colored as follows: C colored dark blue, N
colored blue, O colored red, and P colored orange.
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Figure 14. The cofactor helix that dictates cofactor specific among class II HMGRs. The
cofactor helices are shown in cartoon representation. Ligands and important residue are colored
using the following: C colored according to the rest of the molecule, N colored blue, O colored
red, and P colored orange. A) NAD-bound PmHMGR, B) NADP-bound SpHMGR, and C) NADbound DaHMGR.
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Figure 15. Different crystal packing that stabilizes C-terminal domain in various DaHMGR
structures that adopt the flipped conformation. Crystal structures are depicted in cartoon
representation illustrating the differences in crystal packing that facilitate the stabilization of the
CTD in the flipped conformation observed in various structures. A) In the NAD- and citrate-bound
DaHMGR structure, the CTD of one monomer stacks up against a CTD from a symmetry-related
monomer. In gray is the homodimer with the CTD of one monomer in black. In shades of orange
are the monomers of a symmetry-related homodimer. The CTD, shown in black, interacts with a
single adjacent monomer. B) In the citrate-bound DaHMGR structure, symmetry-related
monomers stack up against each other such that the CTDs of three monomers interact. On the left
is the crystal packing of the CTD of one chain and on the right is from another chain. Green and
blue represent a homodimer, and in black are their respective CTDs. This d epicts different interacts
that stabilize the CTD between the different chains.
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Figure 16. The C-terminal domain in the closed conformation versus the flipped
conformation as observed in PmHMGR and DaHMGR respectively. Surface representation of
the protein homodimer in gray together with cartoon representation of the CTD in the closed
conformation of NAD+- and HMG-CoA-bound PmHMGR (PDB 1QAX) and the flipped
conformation of the CTD in NAD-bound DaHMGR. Each helix of the CTD is colored a different
color as follows: first helix = orange, second helix = yellow, and blue helix = third helix. The
catalytic histidine, His381 PmHMGR numbering is shown at the active site in the closed
conformation versus solvent-exposed in the flipped conformation. Ligands are modeled in from
the ternary complex of PmHMGR (PDB 1QAX) and are shown in spheres with the following
coloring: C = green, N colored blue, O colored red, S = yellow. and P colored orange
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Figure 17. Linker region, that connects the main body of class II HMGR to the C-terminal
domain. In gray, surface representation of the main body of class II HMGR is depicted, with
cartoon representation of the region that links the main body to the CTD. The various colors
represent various structures as follows: Green = apo-SpHMGR, (PDB 3QAU). red and green =
NADP-bound SpHMGR (PDB 5WPJ), blue = HMG-CoA-bound SpHMGR (PDB 5WPK), yellow
= NAD+- and HMG-CoA-bound PmHMGR (PDB 1QAX), magenta = citrate- and NAD-bound
DaHMGR (PDB 6DIO).

132

Figure 18. Two new open conformations of the CTD found in SpHMGR mutants. Surface
representation of the main body of HMGR shown in gray. CTDs are shown in cartoon
representation. The open conformation of the CTD as observed in prior SpHMGR structures (PDB
5WPJ, PDB 3QAU), shown in different shades of gray. Yellow = NAD-bound
SpHMGR_DaHMGR-helix, and NAD-bound SpHMGR_DaHMGR-helix_M185T. Substrate and
cofactor are modeled in and shown in spheres to help situate the CTD with respect to the active
site.
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Figure 19. Flipped conformations of the C-terminal domain as observed in structures
obtained in this research. Surface representation shown in gray. Substrate and cofactor are
modeled into the active site and shown as spheres. The CTDs are shown in cartoon representation
and are colored as follows: darker blue, darker red, and darker green are the three helices from
proceeding from the N to C termini of NADP- and citrate-bound SpHMGR and lighter blue, lighter
red, and lighter green represent the analogous helices from NAD- and citrate-bound DaHMGR.
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Figure 20. Revised proposed mechanism. class II HMGR mechanism, as proposed by Ragwan,
E., Arai, E., Kung, Y., Biochemistry. 2018
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Figure 21. Steric clash between CoA moiety and the C-terminal domain in the flipped
conformation in DaHMGR. Surface representation (left) and cartoon representation (right) of
DaHMGR with the CTD in the flipped conformation. CoA, modeled in from HMG-CoA-bound
PmHMGR (PDB 1QAX) and shown as sticks. The steric clash between the CTD and the CoA
moiety is highlighted in yellow.
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Figure 22. Optimization of various DaHMGR crystals. In the panel on top, there are images of
various irregular crystals formed in many different crystallization conditions after initial highthroughput sparse matrix screening. The bottom right of the panel on top, is an image of the crystal
drop being dyed with Izit dye showing that these irregular crystals absorbed the dye which would
suggest that they were protein crystals. However, most of these could not be initially optimized
and were not ideal for X-ray diffraction experiment. A citrate condition was optimized, as shown
in the middle above, revealed a hexagonal crystal morphology. These crystals resulted in the first
published citrate- and NADH-bound structure (PDB 6DIO). The constituents of this condition
were further modulated to reveal a half-hexagonal crystal as depicted in the bottom image. These
crystals resulted in the additional structures published of apo-DaHMGR and mevalonate-bound
DaHMGR (PDB 6EEU and 6EEV respectively).
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Table 1. Data collection and refinement statistics for structures of DaHMGR that are published
in the Protein Database.

PDB ID
Data Collection
Beamline
Wavelength (Å)
Space group
Unit cell
a=b, c (Å)
Resolution (Å)
Wilson B (Å2)
Total reflections
Unique reflections
Multiplicity
Completeness (%)
Mean I/σ(I)
Rmerge
Rmeas
CC1/2
Refinement
Rwork
Rfree
r.m.s.d. bonds (Å)
r.m.s.d. angles (°)
Number of atoms
Average B factors (Å2)
All atoms
Protein
NADH/citrate/mevalonate
Water
Ramachandran analysis
Favored (%)
Allowed (%)
Outliers (%)
MolProbity Clashscore

NADH- and citrate-bound
DaHMGR

mevalonate-bound
DaHMGR

6DIO

6EEV

APS, 24-ID-E
0.9792
P6522

APS, 24-ID-C
0.9791
P321

113.00, 437.48
97.86–2.14 (2.18–2.14)
21.39
675,186 (34,374)
92,208 (4,476)
7.3 (7.7)
100.0 (100.00)
5.2 (2.4)
0.287 (0.843)
0.309 (0.904)
0.986 (0.40)

100.37, 75.81
57.12–1.49 (1.52–1.49)
14.85
267,310 (13,124)
70,102 (3,542)
3.8 (3.7)
97.6 (99.7)
10.5 (2.0)
0.067 (0.629)
0.078 (0.735)
0.993 (0.700)

0.1905 (0.2945)
0.2389 (0.3378)
0.007
0.905
9,429

0.1351 (0.2131)
0.1646 (0.2632)
0.005
0.821
3,228

24.23
23.27
25.48
30.11

23.73
20.14
41.4
37.3

97.14
2.86
0
5.8

97.3
2.69
0
1.41

Statistics for the highest-resolution shell are shown in parentheses.
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Table 2. Data collection and refinement statistics for SpHMGR and DaHMGR structures
that are not yet published in the Protein Database.
NADPH- and citrate-bound
SpHMGR

citrate-bound DaHMGR

Data Collection
Wavelength
0.97918
0.97918
Resolution range
57.47 - 1.92 (1.989 - 1.92)
98.41- 2.45 (2.55 - 2.45)
Space group
P 32 2 1
P 21 3
Unit cell
143.07 143.07 96.5109 90 90 120
139.17 139.17 139.17 90 90 90
Total reflections
584002 (58392)
330677 (38663)
Unique reflections
86815 (8587)
33462 (3753)
Multiplicity
6.7 (6.8)
9.9 (10.3)
Completeness (%)
99.86 (99.70)
100.0 (100.0)
Mean I/sigma(I)
7.02 (1.23)
7.9 (1.7)
Wilson B-factor
25.48
45.84
R-merge
0.1735 (1.55)
0.186 (1.377)
R-meas
0.1883 (1.683)
0.208 (1.530)
CC1/2
0.993 (0.42)
0.995 (0.469)
Refinement
R-work
0.1605 (0.2954)
0.1902 (0.2739)
R-free
0.1933 (0.3196)
0.2245 (0.2841)
Number of non7260
6322
hydrogen atoms
macromolecules
6391
6172
ligands
184
36
solvent
747
124
Protein residues
844
850
RMS(bonds)
0.007
0.002
RMS(angles)
0.91
0.49
Ramachandran
98.33
97.03
favored (%)
Ramachandran
1.67
2.97
allowed (%)
Ramachandran
0
0
outliers (%)
Rotamer outliers
0.75
1.64
(%)
Clashscore
5.8
3.22
Average B-factor
31.68
52.61
macromolecules
30.86
52.82
ligands
24.74
43.21
solvent
39.84
44
Statistics for the highest-resolution shell are shown in parentheses.
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Table 3. DaHMGR enzyme kinetic reaction mixtures. Enzyme reaction compositions for
NADH, NADPH and HMG-CoA steady-state kinetics.
Tris pH 7.4
NaCl
NADH
NADPH
Enzyme
HMG-CoA

NADH

NADPH

HMG-CoA

50 mM
50 mM
5-400 µM
20 nM
300 µM

50 mM
50 mM
10-500 µM
100 nM
300 µM

50 mM
50 mM
400 µM
20 nM
2-300 µM
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Table 4. HMGR K M values of substrates and products observed in various class II HMGRs. All values are in μM.
HMGR
DaHMGR
PmHMGR
AfHMGR
LmHMGR
SaHMGR
SpHMGR
EfHMGR

HMG-CoA
7.34 ± 0.71
20
175
19.8 ± 1.2
40
75.86 ± 4.43
20

R,S-Mevalonate

CoA

NAD+

260
620
427 ± 92
670

60
30
145 ± 19
390

210
500
25000 ± 2180

1000

230

NADH
28.5 ± 1.4
80
160
150 ± 11
100
153

NADP+
52000
1700
445 ± 89
580
250
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NADPH

Reference

500
12.9 ± 0.9
70
28.9
30

[12]
[21], [22]
[22], [23]
[22]
[22], [24]
[3], [25]

Table 5. Summary of the steady-state kinetics of DaHMGR with substrate and cofactor.
Km (µM)
kcat (s-1 )
kcat/Km

(M-1 /s-1 )

HMG-CoA

NADH

NADPH

7.34 ±0.71

28.48 ±1.39

N.D.

22.29 ±0.48

16.58 ±0.24

N.D.

3.04 x

10 6

5.82 x
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10 5

N.D.

3.8.
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Chapter IV. Altering the cofactor specificity of class II HMGR using rational
design
4.1. Summary
The prior chapters were primarily geared towards discovery where the goals were to further
characterize HMGR using several class II HMGR homologs. A variety of topics that related to the
overall structural dynamics of HMGRs as well as the atomic-level detail regarding its mechanism
were discussed. One specific topic focused on NAD(H) and NADP(H) cofactor preferences among
HMGRs with Chapter Three introducing structural features that govern cofactor specificity. A
unique structural motif, termed the cofactor helix, was proposed to be an important contributor
towards cofactor specificity. It is observed that specific interactions between the cofactor helix and
the cofactor appear to modulate the enzyme’s affinity towards either NAD(H) or NADP(H). With
the knowledge gained from those chapters, the research now branches into protein engineering,
where focus will be geared towards engineering HMGRs with modified cofactor preferences.
In these efforts, we will show successful attempts at altering the cofactor preferences of
HMGRs from Delftia acidovorans (DaHMGR) and Streptococcus pneumoniae (SpHMGR).
DaHMGR, which was characterized as an NADH-preferring HMGR in the research presented in
Chapter Three, will be modified to now have a cofactor preference for NADPH. This will be
achieved by replacing its cofactor helix, which normally contains residues that facilitate NADH
binding, with the cofactor helix of SpHMGR. This chimeric protein now prefers NADPH, which
will support the proposed work done in the Kung Lab that highlights the importance of the cofactor
helix in governing cofactor specificity. Importantly, however, a critical additional mutation will
be required to switch cofactor specificity more convincingly from NADH to NADPH in
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DaHMGR. This mutation, T189M, in addition to the cofactor helix, switches the cofactor
preference of DaHMGR, which will be assessed by kinetic analysis. Similarly, in SpHMGR, its
cofactor helix, which normally has specific interactions that facilitate NADPH binding, will be
exchanged with the cofactor helix of DaHMGR. This chimeric SpHMGR now has a higher
preference for NADH instead of NADPH. Interestingly, the analogous of the T189M mutation
which proved to be crucial in enhancing the DaHMGR chimeric protein, will be shown to not have
the same impact in SpHMGR specificity in the same manner and its implications will be discussed.
To interrogate the behavior of these chimeric proteins on a molecular level, we successfully
obtained crystal structures of the above chimeric proteins. Since these modified proteins were
generated using rationale design, we considered it essential to visualize whether the expected
mutations manifested in a predictable manner. In both the case of DaHMGR and SpHMGR, along
with the chimeric constructs, the crystal structures will provide good evidence of how switching
the cofactor helices promotes switched cofactor preferences and will be discussed in detail.
Collectively, the research presented here takes an important step forward in equipping us with the
ability to modify cofactor preferences among class II HMGRs.

4.2. Introduction

4.2.1. NAD(H) and NADP(H)
Nicotinamide Adenosine Dinucleotide (NAD(H)) and its phosphorylated version,
nicotinamide adenine dinucleotide phosphate (NADP(H)), are ubiquitous across biology. Whether
as a substrate or cofactor, NAD(P)-dependent reactions facilitate processes in a wide scope of
cellular functions ranging from redox homeostasis within pathways to immune functions to
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processes involved in aging [1]. Of its many essential redox and non-redox functions, NAD(P)(H)
has a major role in metabolism owed to its ability to work with enzymes such as oxidoreductases
to facilitate the transfer of electrons between molecules [1]. In this capacity, NAD(P)-dependent
oxidoreductase enzymes utilize NAD(P)(H) as an electron reservoir since it can accept or donate
a hydride.
Owed to their roles related to oxidative stress, aging and cell survival, it is crucial that the
redox state, which is governed by the amount of oxidized versus reduced forms of NAD and
NADP, be controlled and balanced [2]. The amount of oxidized versus reduced forms of NAD and
NADP have a major influence on the types of reactions that they facilitate. These amounts,
expressed as ratios, exist due to the observation that NAD and NADP have different physiological
roles where low NADH/NAD+ ratios facilitate oxidative reactions whereas high NADPH/NADP+
ratios facilitate reductive reactions [2]. The prevalence of a lower NADH/NAD+ ratios suggest
that NAD+ predominates in the cell and thus servers as a suitable oxidant whereas higher amounts
of NADPH over NADP+ suggests NADPH is the preferred reductant.
Compartmentalization of NAD+/NADH and NADP+/NADPH redox couples aids in the
relative localization of the various forms of these cofactors and is also regulated by, for example,
their biosynthetic enzymes[3]. If too little of these cofactors are available, or if there is an
imbalance in these ratios, the cellular redox state is altered which impacts metabolic processes that
lead to redox stress, energy stress and, consequently, pathologies that contribute towards disease
states [3]. Thus, not only are these cofactors important, but their relative abundance, and ratios are
crucial to maintaining homeostasis within the cell.
4.2.2. Structural motifs that bind NAD(P)(H)
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The binding domain of enzymes that utilize NAD(P)(H) often contain common structural
motifs. These motifs enable the enzyme to accommodate the nucleotide binding domain of
NAD(P)(H) and other nucleotides such as FAD. One such motif is the Rossmann fold which is
made up of a βαβαβ structure that includes the nucleotide binding domain[4]. For example, in
many oxidoreductases that have a Rossmann fold, a ~30 residue motif, made up of a β−α−β motif,
harbors an N-terminal dipole that coordinates the pyrophosphate of NAD(H). Additional structural
motifs that bind these nucleotides include the TIM-barrel and dihydroquinoate synthase-like
binding folds [5].
A closer look at the Rossmann fold reveals a “fingerprint” region that comprises the
nucleotide binding fold with a notable feature made up of a conserved GXGXXG motif, where X
represents variable residues, that enables phosphate binding [6]. In addition, NAD(H)-preferring
enzymes that contain a Rossmann fold have an important negatively charged residue, aspartate, or
glutamate, that informs cofactor binding. These widely conserved negatively charged residues are
able to hydrogen bond with the 2’-hydroxyl of the adenine ribose of NAD(H) [7]. This feature
helps to distinguish its preference for NAD(H) over NADP(H).
4.2.3. Structural motifs found in class II HMGRs
Friesen et al. were the first to examine the structural features that comprise cofactor binding
using the structure of HMGR from Pseudomonas mevaloni (PmHMGR)[7]. They noted, early on,
that HMGRs do not have a classical Rossmann fold and have a distinctive cofactor binding domain
however they point to a few analogous motifs between the cofactor binding domain of HMGR and
the classical Rossmann fold. Firstly, they highlight that PmHMGR does not have a GXGXXG
motif, a key motif in the fingerprint region found in a Rossmann fold, however Gly186 of a
conserved DAMG sequence is analogous to the second glycine of this motif [ 5]. This assertion
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came from observing how Gly186, which is located at the N-terminus of a helix whose N-terminal
dipole coordinates the negatively charged phosphate moieties of NADH[7]. In addition, as
discussed above, in proteins that adopt a Rossmann fold and are specific to NADH, the invariant
aspartate or glutamate coordinates the 2-hydroxyl of the adenine ribose[6]. The analogous residue
is observed in PmHMGR as Asp146 which explains why PmHMGR prefers NAD(H) over
NADP(H) [7]. Figure 1 shows a comparison between the Rossmann fold and the distinctive
cofactor binding domain of PmHMGR and notes the analogous motifs discussed above.
Friesen and colleagues further examined the role of Asp146 in governing cofactor
specificity. By mutating this aspartate to alanine or glycine, they observed a diminished catalytic
efficiency for NAD+ and an increase catalytic efficiency for NADP+ [7]. As illustrated in Figure
1, the aspartate directly coordinates the 2-hydroxyl on the adenine ribose, and thus removing this
aspartate eliminates this interaction. Moreover, Friesen et al. suggest that with the removal of the
negatively charged aspartate, the 2’-phosphate of NADP(H) is better accommodated. In their
attempts to further enhance the specificity for NADP+, they postulated that by introducing
positively charged residues downstream of Asp146, which include residues 147-149 and 192, that
these positive residues could interact the negatively charged 2’-phosphate group of NADP(H).
Indeed, they noted enhanced catalytic efficiency with NADP+ when positions Leu148 or Thr192
were mutated to arginine or lysine however they noted that this enhanced specificity was achieved
not from an increase in NADP+ catalytic efficiency but by a decrease in NAD+ catalytic efficiency
[7].

Among class II HMGRs, cofactor preferences differ among various HMGR homologs.
While class I HMGRs exclusively utilize NADP(H), in class II enzymes, HMGRs from
Pseudomonas mevalonii (PmHMGR) [7], Delftia acidovorans (DaHMGR) [8], and Burkholderia
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cenocepacia (BcHMGR) [9], all prefer NAD(H) whereas those from Enterococcus faecalis
(EfHMGR) [10] and Streptococcus pneumoniae (SpHMGR) [11] prefer NADP(H). Other HMGRs,
such as those from Archaeoglobus fulgidus (AfHMGR) [12] and Listeria monocytogenes
(LmHMGR) [13] appear to have diminished cofactor selectivity owed to their ability to utilize
either cofactor comparably. As pointed out above, Friesen et al. introduced some of the key
features that modulate cofactor specificity however in their attempts to alter cofactor specificity
they were not able to completely switch the preference from NAD+ to NADP+ and they concluded
that a necessary prerequisite to be able to achieve this required novel structures with NADP+
bound [7].
In 2018, the Kung Lab published an NADP(H)-bound HMGR from Streptococous
pneumonia (SpHMGR), the first structure of a class II HMGR with NADPH located in the cofactor
binding domain. This took an important step forward in being able to compare and contrast the
structural features that govern cofactor specificity among class II HMGRs. Historically, among
oxidoreductases, understanding the molecular determinants that govern cofactor specificity has
largely focused on the region that differentiates NAD(H) and NADP(H), namely the 2-hydroxyl
and 2’- phosphate moieties, respectively [5]. Unsurprisingly, when comparing NAD(H) and
NADP(H) binding between PmHMGR and SpHMGR, the importance of this region was
visualized. Specifically, the Kung Lab introduced the importance of a α-helix, termed the “cofactor
helix” that provides cofactor-specific binding and steric interactions that aid in cofactor selectivity
[11].

On the cofactor helix of NADPH-bound SpHMGR, a tyrosine (Tyr144) replaces the
aforementioned aspartate and is both bulkier and uncharged for specific reasons. This tyrosine no
longer interacts with the 2’-hydroxyl of NAD(H) and, instead, sterically pushes the cofactor to
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facilitate the interaction between NADP(H) and downstream residues of the cofactor helix, namely
Ser146 and Arg150 [11]. In this configuration, Tyr144 aids in sterically positioning the 2’phosphate to interact with Ser146 and positions the adenine moiety to undergo pi-pi stacking
interactions with Arg150. In contrast, NAD-bound PmHMGR contains nonpolar residues, L148
and L152, that stack up against the adenine moiety.
Along with sequence analysis of various HMGRs, Miller and Kung proposed a model that
describes how the cofactor determines cofactor specificity. This pattern, which is relatively
consistently observed among class II HMGRs is as follows: in NAD(H)-preferring HMGRs, an
aspartate begins the cofactor helix and nonpolar residues create a hydrophobic environment
downstream; in NADP(H)-preferring HMGRs, larger uncharged residues such as tyrosine or
histidine begins the cofactor helix and charged residues are positioned downstream. The published
work presented in Chapter Three served as a first testcase of this hypothesis. By solving the novel
structure of an NAD(H)-preferring HMGR, DaHMGR, we could assess whether the above model
persisted. Indeed, the interactions between NADH and the cofactor helix of DaHMGR agreed with
the above pattern.
Specifically, DaHMGR and PmHMGR, which are NAD(H)-preferring HMGRs, have
slightly different cofactor helices, 146-DKVLIGL-152 in DaHMGR and 146 – DQLLNSL-152 in
PmHMGR. The critical residues involved in governing cofactor specificity as proposed by the
model above involve the first, third and seventh residues of this helix. When comparing these
residues, we observe the conserved aspartate and note that positions 148 and 152 are made up of
hydrophobic residues. Thus, the overall pattern in the way these HMGR homologs accommodate
their preferred cofactor remains. Figure 2 shows a comparison between NAD- and NADP-
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preferring HMGRs alongside sequence analysis that shows how the cofactor helix dictates cofactor
specificity.
Apart from the cofactor helix mentioned above, there may be additional residues that are
involved in enhancing cofactor specificity. The major structural difference between NADP(H) and
NAD(H) is the additional phosphate, so it would make sense that the protein would distinguish
cofactors at the region that flanks the additional phosphate. Upon close examination, there is
indeed an additional pattern that exists in this region. Figure 3 shows the structure of SpHMGR,
an NADPH-preferring HMGR, with a methionine residue, Met185, that protrudes towards the
NADPH, possibly contributing towards pushing the adenine moiety further towards the cofactor
helix and thus facilitating the coordination of this phosphate and Arg150. In the crystal structure,
Met185 is depicted as having one conformation, but since methionine has a long flexible sidechain,
it is conceivable that this can occupy a greater region than is depicted by the crystal structure.
Tyr144, which is part of the cofactor helix, is believed to also be responsible for positioning the
cofactor and therefore both Met185 and Tyr144 may contribute towards stabilizing the NADPH
phosphate group and orientation of the adenine ring with respect to the cofactor helix. In contrast,
DaHMGR, an NAD(H)-preferring HMGR, has a threonine residue, Thr189, in place of Met185
which has a shorter side chain and capable of hydrogen bonding. It is worth noting that this
threonine is within hydrogen-bonding distance to the 2’-hydroxyl of NAD(H) in NADH-bound
DaHMGR. As a result, the ribose on NADH may swing into and occupy the region in the vicinity
of Thr189 and allow the ribose to be coordinated by Asp146 as shown in Figure 3.
When comparing only class II HMGRs, as depicted in the sequence alignment in Figure 3,
threonine is conserved across the NADH-preferring homologs, whereas methionine is conserved
across NADPH preferring HMGRs. There are other homologs, however, that either have an
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alanine or isoleucine present in place of methionine or threonine, and the cofactor preference of
some of those homologs present interesting observations. For example, Archaeoglobus fulgidus
HMGR (AfHMGR) contains an alanine and is considered a dual coenzyme specific HMGR [12].
Additionally, and interestingly, class I HMGRs which are all NADPH-preferring, have a conserved
methionine at this location, further reiterating the potential importance of this residue. While class
I HMGRs do not have a cofactor helix, which is replaced by a short loop comprised of serine,
arginine and phenylalanine that may be responsible for cofactor preference, the possible role of
methionine cannot be overlooked. The potential role of the residue at this location has not been
previously identified and may prove to be, at least in part, involved in cofactor specificity.
4.2.4. Goals of this section
NAD(P)-dependent oxidoreductases, which utilize NAD(P)(H) as the hydride reservoir
have garnered significant interest in metabolic engineering from their ability to utilize unique
substrates and synthesize products with desired stereospecific and regiospecificity under ambient
conditions [1]. Within these efforts, there is often a need to customize cofactor usage to balance
the redox requirements of respective pathways and improve product formation. Integral to
customizing cofactor usage is the need to modulate cofactor specificity, giving researchers the
ability to respond to redox requirements and ultimately to yield efficient production of desired
cofactors. To this end, a greater understanding of the structural determinants that govern cofactor
specificity in the cofactor-dependent enzymes can be leveraged in attempts at altering cofactor
specificity.
The research in this section follows this course of inquiry whereby the work presented in
the prior chapters, along with previously published worked, is leveraged in efforts at customizing
the cofactor preference of class II HMGRs. The overall goal is to further the understanding of
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cofactor preference among class II HMGRs by using protein engineering to interrogate the motifs
that govern specificity. With the knowledge that the cofactor helix dictates cofactor preference,
the first aim seeks to switch the cofactor helix between HMGRs, namely DaHMGR and SpHMGR,
to switch their cofactor preferences. The proof-of-concept is that by switching the cofactor helices,
the respective binding and steric interactions that promote cofactor preference are also switched.
A second aim is to explore the threonine and methionine residues in the vicinity of the cofactor
helix in NAD(H)- and NADP(H)-dependent HMGRs, respectively, and how they may contribute
towards cofactor specificity. The hope is to elucidate whether there are, in addition to the cofactor
helix, other residues that enhance the specificity of the non-preferred cofactor. Aims one and two
are assessed by kinetic analysis.
The third aim sought to acquire crystal structures of the above chimeric proteins. Since the
overall goal is not simply to alter cofactor specificity, but more importantly, to further understand
the structural determinants of cofactor specificity, acquiring crystal structures is critical. By
acquiring these structures, the hope is to observe whether the mutations mentioned above translate
in a predictable manner. For example, do the binding and steric interactions between the cofactor
and the cofactor helix in wildtype translate to analogous binding and steric interactions when the
cofactor is introduced into a chimeric protein?
As briefly mentioned, the benefits of such interests include being able to alter cofactor
selectivity for use in biosynthetic platforms. One such benefit is cost since NAD(H) is cheaper
than NADP(H) and is more stable [14]. For example, in one study the NADPH-dependent γDiketone Reductase that converts 2,5-hexanedione to (2S,5S)-hexanediol ((2S,5S) was engineered
to improve its NADH utility motivated by the cheaper cofactor costs associated with using NADH
cell-free biosynthetic systems [15]. Another benefit is for customizing metabolic pathways to
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optimize product formation. In another study, NADH-dependent L-alanine dehydrogenase of
Bacillus subtilis, was engineered to utilized NADPH and was incorporated as a regenerating
enzyme in coupled reactions with NADPH-dependent alcohol dehydrogenases [16]. Yet another
benefit is to enable enzymes to effectively use both cofactors instead of one. One such example
involved engineering the NAD+-dependent Pseudomonas fluorescens mannitol 2-dehydrogenase
oxidation of polyols to be able to utilize NADP(H) almost as well as NAD(H) [17]. Both the direct
applications of being able to manipulate cofactor specificity as well the value in gaining detailed
understanding of the structural features that govern HMGR functionality promise fertile
investigation.

4.3. Results
4.3.1. Kinetics
4.3.1.1. Kinetic results of DaHMGR, DaHMGR mutants and DaHMGR chimeric constructs
DaHMGR has been shown to significantly prefer NADH over NADPH [8]. This preference
is observed through the specific activities in Figure 4 which shows an ~1500-fold higher activity
using NADH over NADPH. Upon switching the cofactor helix of DaHMGR to the corresponding
helix contained in the NADPH-preferring SpHMGR –a chimera called DaHMGR_SpHMGRhelix –we observe that NADPH is now slightly preferred over NADH with an ~1.5-fold higher
specific activity. An additional mutation further enhances this switch. As previously discussed,
many NADP(H)-preferring HMGRs contain a methionine near the phosphate that differentiates
NADP(H) from NAD(H) whereas in NAD(H)-preferring HMGRs, smaller residues are observed,
as is the case with DaHMGR which contains a threonine (Thr189). After including the additional
T189M mutation alongside the SpHMGR-helix– a chimera called DaHMGR_SpHMGR156

helix_T189M –there is an even greater preference for NADPH as illustrated by a ~4-fold higher
specific activity over NADH.
Since the addition of T189M mutation to DaHMGR_SpHMGR-helix resulted in a greater
switch in cofactor specificity, we questioned whether the T189M alone could switch specificity.
To address this, we created DaHMGR_T189M, DaHMGR with only the single mutation.
DaHMGR_T189M behaves like the wildtype in that it prefers NADH however this mutant shows
both a decrease in NADH activity and an increase in NADPH activity which results in a ~680-fold
higher specific activity of NADH over NADPH as compared to ~1500-fold higher specific activity
of over NADPH in wildtype. This suggests that the T189M mutation alone cannot switch cofactor
preference but works in concert with the necessary cofactor helix to influence specificity.
Next, we questioned whether this switched preference, from NADH to NADPH, caused by
switching the respective helix, was a result of simply diminishing its ability to use NADH, or
whether the switched helix also caused an increase in NADPH activity. To do this, we investigated
how the specific activities of the various mutants compared to wildtype using both NADH and
NADPH. Figure 5 represents the specific activities of the mutants with respect to wildtype. When
assessing activity using NADH, we observe a decline in specific activity as we go from
DaHMGR_T189M, to DaHMGR_SpHMGR-helix, to DaHMGR_SpHMGR-helix_T189M,
suggesting that these mutations incrementally diminish NADH preference. When assessing
activity using NADPH, we observe an increase in specificity activity as we go from
DaHMGR_T189M, to DaHMGR_SpHMGR-helix, to DaHMGR_SpHMGR-helix_T189M
suggesting that these mutations incrementally enhance NADPH preference. Notably, we observe
higher specific activity of ~7.6- and ~19-fold respectively in NADPH activities compared to
wildtype suggesting that the switched helices markedly improved NADPH usage. Collectively,
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this suggests that these chimeric proteins, a switch that relies on switching the helix and is
enhanced by the T189M mutation, achieve their modified cofactor preference by not only
diminishing their affinity to NADH but also by gaining greater affinity to NADPH.
4.3.1.2. Kinetic results of SpHMGR mutants
SpHMGR has been shown to prefer NADPH over NADH [11]. This preference is observed
through the specific activities in Figure 6 which shows ~35-fold higher activity using NADPH
over NADH. Upon switching the cofactor helix of SpHMGR to the corresponding helix contained
in the NADH-preferring DaHMGR –a chimera called SpHMGR_DaHMGR-helix –we observed
that NADH is now preferred over NADPH with a ~28-fold specific activity.
Like the DaHMGR chimera kinetics, we questioned whether the aforementioned
methionine in proximity of the phosphate in NADPH-preferring HMGRs can be used to influence
cofactor specificity. In the case of the SpHMGR chimera, which has switched preference from
NADPH to NADH, we subsequently mutated methionine (M185) to threonine, the analogous
residue found in NADH-preferring DaHMGR, a chimera called SpHMGR_DaHMGR_M185T.
Unexpectedly, this mutation did not enhance cofactor switch from NADPH to NADH, showing
~9-fold higher specific activity as opposed to ~28-fold as seen in SpHMGR_DaHMGR-helix using
NADH.
In the same way that was done in the DaHMGR chimera kinetics, we questioned whether
this switched preference, from NADPH to NADH, caused by switching the respective helix, was
a result of simply diminishing its ability to use NADPH, or whether the switched helix also caused
an increase in NADPH activity. To do this, we investigated how the specific activities of the
various mutants compared to wildtype using both NADH and NADPH. Figure 7 represents the
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specific activities of the mutants with respect to wildtype. We observe lower specific activity of
~15 and ~29-fold respectively in NADH activities compared to wildtype suggesting that the switch
did not markedly improved NADH usage. However, NADPH specific activity was lower by
~14,000 and ~10,000 respectively, using NADPH. This suggests that while switching the cofactor
helix, which resulted in a switched cofactor preference from NADPH to NADH, lowered both
NADH and NADPH specific activities, it had a greater diminishing impact on NADPH activity.
4.3.2. X-ray crystal structures
4.3.2.1. DaHMGR mutants
4.3.2.1.1. DaHMGR_SpHMGR-helix_T189M+NADPH
This chimera crystallized with one monomer in the asymmetric unit such that its
catalytically related adjacent monomer can be generated by crystallographic symmetry. Only
density for the residues 3-376, which excludes the C-terminal domain (CTD), was observed, and
was modeled with the protein chain. The residues pertaining to the cofactor helix (R145 to L152)
and T189 were deleted from the protein chain, and the model was refined using phenix.refine [18],
which resulted in positive density that resembled the cofactor helix of SpHMGR and methionine
at position 189. Polder mFo – DFc omit density maps with respect to the cofactor helix, T189M,
and NADPH were calculated in Phenix and are shown in Figure 8.
The electron density for NADPH spanning the diphosphate moiety to the nicotinamide ring
indicates some degree of disorder, however there is good density in the region that encompasses
the adenosine portion, including the important 2’-phophsate that differentiates NADH from
NADPH. The interactions between NADPH include Asn216 forming hydrogen bonds with the
amide group of the nicotinamide ring and interactions with NADPH as it extends away from the
active site with the backbone NH groups of Met185, Gly186 as well as a backbone interaction
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between diphosphate moiety and Gly330. At the other end of NADPH, the adenosine makes
hydrogen bonds and backbone interactions with Asp183, and pi-pi interactions with Arg152. The
2'-phosphate interacts with Arg152 directly in addition to a water-mediated interaction with the
sidechain of Ser148. There are additional solvent interactions between waters and various portions
spanning the entire molecule, including the adenosine, diphosphate, and nicotinamide moieties.
4.3.2.1.2. DaHMGR_T189M+NADH
DaHMGR_T189M+NADH crystallized like the chimera above. T189 was deleted and the
model refined, which resulted in positive density that matched methionine. Positive density for
NADH was observed, although the density was not continuous. Electron density for most of
NADH was observed, however density for the 2’-hydroxyl was lacking. This appears to be
evidence of disorder in this region most likely due to the steric hindrance caused by introducing
the T189M mutation. Moreover, the ribose of NADH appears to be shifted (<1 Angstrom) away
from T189M. Overall, NADH binds DaHMGR_T189M in a similar manner retaining the
interactions found in NADH-bound DaHMGR. Unsurprisingly, T189M did not position NADH in
the “up” position, however it would presumably favor the up position to avoid steric hindrances
between the cofactor and T189M. Polder mFo – DFc omit density maps with respect to T189M,
and NADH were calculated in Phenix and are shown in Figure 9.
4.3.2.2. SpHMGR mutants
4.3.2.2.1. SpHMGR_DaHMGR-helix+NADH
This chimera crystallized with one monomer in the asymmetric unit such that its
catalytically related adjacent monomer can be generated by crystallographic symmetry. Density
for the entire chain excluding the last serine were observed and was modeled with the protein
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chain. The residues pertaining to the cofactor helix (A143 to R150) were deleted from the protein
chain, and the model was refined using phenix.refine [18], which resulted in positive density that
resembled the cofactor helix of DaHMGR. Polder mFo – DFc omit density maps with respect to
the cofactor helix and NADH were calculated in Phenix are shown in Figure 10. Density consistent
with citrate, which was part of the crystallization buffer, was observed at the active site, as
previously observed.
As it pertains to the C-terminal domain (CTD), this domain is positioned in an apparent
open conformation. While not in the exact configuration as observed in prior SpHMGR structures,
for example PDB 3QAU, the three-helical bundle is positioned away from the rest of the protein
and allows for the entry and exit of cofactor and substrate. A more detailed analysis of this
observation is outlined in Chapter Three. As it pertains to the cofactor helix, the omit density for
the sidechain of Asp144 is poor beyond the alpha carbon and suggests a measure of flexibility.
Some positive density nearby indicates that this aspartate may assume multiple conformations
which is modeled into the final structure. A water molecule positioned between this aspartate and
the 2-hydroxyl of the adenine ribose indicates the possibility of a solvent-dependent interaction
between these two moieties. As it pertains to the binding of the cofactor, NADH binds in a similar
manner to wildtype binding of NADPH with no major differences in its positioning. The
introduction of the nonpolar residues, Val148 and Leu150 appear to be positioned to hinder a
phosphate from NADPH from binding.
4.3.2.2.2. SpHMGR_DaHMGR-helix_M185T+NADH
This chimera crystallized with one monomer in the asymmetric unit in a manner like the
SpHMGR mutant above. Density for the residues 3-425 were observed and was modeled with the
protein chain. The residues pertaining to the cofactor helix (A143 to R150) and M185 were deleted
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from the protein chain, and the model was refined using phenix.refine [18], which resulted in
positive density that resembled the cofactor helix of DaHMGR and the M185T mutation. Polder
mFo – DFc omit density maps with respect to the cofactor helix, M185T, and NADH were
calculated in Phenix are shown in Figure 11. Density consistent with citrate, which was part of the
crystallization buffer, was observed at the active site, as previously observed.
Like the SpHMGR_DaHMGR-helix+NADH mutant above, the CTD is positioned in an
open configuration and is discussed in more detail in Chapter Three. Also similarly observed is a
water molecule between Asp146 and the 2’-hydroxyl of the adenine ribose that may aid in a
solvent-dependent interaction. Unlike in SpHMGR_DaHMGR-helix+NADH, density for the
sidechain of Asp146 is clear. NADH binds in the upper position, like NADPH-binding in wildtype
SpHMGR and in the chimera above.
4.3.2.2.3. SpHMGR_M185T+NADPH
This mutant crystallized with the homodimer in the asymmetric unit. In both chains, density
for residues 4-424 were observed and was modeled with the protein chain. M185 was deleted from
the protein chain, and the model was refined using phenix.refine [18], which resulted in positive
density that resembled the M185T mutation. Polder mFo – DFc omit density maps with respect to
the M185T, and NADPH for one chain were calculated in Phenix are shown in Figure 12. Density
consistent with citrate, which was part of the crystallization buffer, was observed at the active site,
as previously observed.
The CTD assumes a novel location that more resembles the “flipped” conformation as
previously observed in citrate- and NADH-bound DaHMGR. The CTD is the in the vicinity of the
closed conformation observed in the ternary complex of PmHMGR (PDB 1QAX), but the
orientation of the three helical bundle appears to be flipped. This orientation is discussed more in
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detail in Chapter Three. NADPH binds in the upper position, like NADPH-binding in wildtype
SpHMGR and in the chimeric proteins above.

4.4. Discussion
NAD(P)-dependent enzymes are utilized throughout nature to facilitate redox reactions that
span a wide range of functions. The existence of two forms of these cofactors, NAD(H) and
NADP(H), points to different physiological functions whereby NAD+ primarily serves as an
oxidant whereas NADPH as a reductant. The homeostasis of cells greatly depends on the ratio of
oxidized and reduced forms of these cofactors which highlights the importance of the relative
abundance and distribution of each of these cofactors. Due to the need to differentiate between
these two forms of the cofactor, enzymes have adopted various structural features that govern
specificity. A Rossmann fold, for example, contains a ~30 residue motif made up a β−α−β motif
that coordinates the pyrophosphate of the cofactor and in NAD-dependent enzymes a conserved
aspartate on this motif makes direct interactions with the 2-hydroxyl that distinguishes NAD(H)
from NADP(H).
Within class II HMGRs, prior research focusing on structural features that determine cofactor
specificity have revealed residues and motifs that confer specificity. The first comprehensive study
was done by Friesen et al. and studied NAD bound by PmHMGR. They noted the importance of
Asp146 in PmHMGR that coordinated the 2-hydroxyl of the adenosine ribose of NAD. Mutational
studies done on this residue and others around this region highlighted the interactions that aid in
PmHMGR’s selectivity towards NAD(H) and demonstrated how one could introduce promiscuity
between cofactors by imposing mutations that enhancing NADP(H) utility. However, with the lack
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of an NADP(H)-bound structure, these efforts were unable to completely switch cofactor
specificity. Subsequently, the Kung lab solved crystal structures of NADPH-bound SpHMGR
which aided in comparing the cofactor binding motifs between NAD(H)- and NADP(H)dependent class II HMGRs. A cofactor helix within the cofactor binding site, which flanks the
region that differentiates NAD(H) and NADP(H), was proposed as an important feature that
confers specificity. Following this discovery, the structure of NADH-bound DaHMGR was solved,
which was discussed in Chapter Three, and served to bolster the proposal that the cofactor helix
helps to govern specificity.
Now, with the above knowledge of the importance of the cofactor helix, this chapter was
geared towards furthering our understanding of the structural features that govern cofactor
specificity through protein engineering efforts. Within these efforts, the first aim was to observe if
engineering enzymes by switching the cofactor helices between HMGRs, namely NADHdependent DaHMGR and NADPH-dependent SpHMGR, also switched their cofactor specificity.
The second aim was to investigate additional residues involved in specificity. These first two aims
were primarily assessed through kinetic analysis. The third and final aim was to acquire crystal
structures of these mutants to observe if the mutations that were implemented manifested in the
way that they were designed to.
In the first aim, engineered chimeras generated by switching the cofactor helices between
DaHMGR and SpHMGR indeed switched their cofactor preferences. This is the first reported
study showing success at switching the cofactor specificity among class II HMGRs. In the case of
DaHMGR, the wildtype enzyme has a strong preference for NADH and significantly low activity
using NADPH, whereas the chimeric construct, DaHMGR_SpHMGR-helix, now prefers NADPH.
Notably, this preference is evidenced by not only a decrease in the specific activity using NADH
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but also an increase in the specificity activity using NADPH. This suggests that this chimera, with
its newly acquired cofactor helix, does not simply have diminished NADH affinity but also has
enhanced NADPH affinity.
In the case of SpHMGR, the wildtype enzyme prefers NADPH, whereas the chimeric
construct SpHMGR_DaHMGR-helix, now prefers NADH. Unlike the analogous chimera above,
however, SpHMGR_DaHMGR-helix achieves its cofactor switch by having a greater diminishing
influence on the specific activity using NADPH than NADH. This suggests that this chimera has
a low affinity for NADH but an even lower affinity for NADPH, which is the basis for its cofactor
selection. This result is not surprising. Cahn et al. point out that typically there is greater success
when switching the preferences of oxidoreductase enzymes from NAD(H) to NADP(H) than vice
versa and they reason that there is significant potential for enhancing binding that the phosphate
provides when attempting to switch from NAD(H) to NADP(H) preference[5]. Importantly,
however, switching the cofactor helix in both instances resulted in switching the cofactor
preference in the chimeras above, a pioneering effort.
The second aim of this section was to investigate additional residues implicated in cofactor
preference, specifically the threonine and methionine residues that are in the vicinity of NADHand NADPH-dependent cofactors respectively. In NADH-preferring HMGR, DaHMGR, a
threonine to methionine mutation was proposed to diminish NADH and enhance NADPH
preferences. As observed in Figure 5, this is indeed the case which validates that this region is a
hotspot related to cofactor specificity. Importantly, this residue alone was not able to switch
cofactor specificity. However, it was observed that the chimera, DaHMGR_SpHMGRhelix_T189M, which has both the newly acquired cofactor helix in addition to the T189M, had a
greater preference for NADPH than just the chimera without the T189M mutation. Therefore, these
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two modifications to wildtype DaHMGR, namely the switch in the cofactor helix and the T189M
mutation, works together in its ability to achieve its novel cofactor preference.
The results of the analogous mutation in SpHMGR and SpHMGR chimeras differed. In
NADPH-preferring SpHMGR, it was proposed that a methionine to threonine mutation would
result in diminished NADPH and enhanced NADH preference. As observed in Figure 7, this was
not the case. It appears that this mutation, M185T, diminishes the activity of both cofactors
comparably, which does not result in a marked alteration in cofactor specificity. Therefore, it was
not surprising to observe that the chimera containing this mutation alongside the newly acquired
cofactor helix, SpHMGR_DaHMGR-helix_M185T, did not have greater affinity for NADH than
without this mutation. This chimera still had a switched preference towards NADH but introducing
the M185T minimized this switch instead of enhancing it. This was unexpected, and therefore it
was highly desirable to visualize the structural underpinning of this observation. The third aim of
this section was to solve crystal structures of the above chimeras to understand how these
mutations manifested. Especially considering some of the differences in the way DaHMGR and
SpHMGR chimeras behaved, this final aim was of paramount importance.
It is worth pointing out that while the above mutations, namely the switch in cofactor
preference because of the switch in cofactor helices, were successful, the overall activity of these
modified enzymes were significantly lower than wildtype enzymes when they function in their
native capacity. In the process of altering cofactor specificity, overall catalytic activity is
compromised. This is not an unexpected result. Cahn et. al, who have done the most
comprehensive overview of engineering NAD(H)/NADP(H) cofactor preferences among
oxidoreductases, point out that even minor changes to the cofactor binding site can have a dramatic
effect on overall activity despite the hydride transfer at the catalytic site being distal from the
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region that differentiates NAD(H) and NADP(H) binding[5]. To this end, additional work must be
done to recover activity.
Concerning the cofactor switch associated with DaHMGR, kinetic analysis revealed that the
cofactor switch, from NADH to NADPH, achieved by the chimeric protein, DaHMGR_SpHMGRhelix_T189M, was the most effective compared to the chimera without T189M. Thus, we
crystallized the former chimera bound to its preferred cofactor, NADPH. The crystal structure of
this chimera shows how the binding and steric interactions introduced by engineering DaHMGR
to have an NADPH-associated cofactor helix aided in its newly acquired selectivity towards
NADPH. Notably, NADPH is bound “higher” up in the cofactor binding than the way wildtype
DaHMGR is bound to NADH as will be discussed below.
With the NADPH-associated cofactor helix, the tyrosine lacks the ability to interact with the
2’-hydroxyl of NADH, as illustrated in Figure 13, an overlay of NADH bound in wildtype
DaHMGR and NADPH bound in the chimera. Additionally, this tyrosine sterically pushes up the
cofactor to facilitate the interaction between the ribose phosphate of NADPH and Arg152, the
ribose phosphate and Ser148 through a water molecule, as well as pi-pi stacking interactions
between the adenine moiety and Arg152. In addition, there is a second hydrogen bonding
interaction between Arg152 and the ribose phosphate as well as a solvent-mediated interaction
between the ribose hydroxyl group of NADPH and Ser148. As previously noted, the introduction
of the interaction between Arg152 and Ser148 and the phosphate has a major influence on binding.
This would explain how this chimera achieves its newly acquired preference by not only
diminishing the wildtype preference for NADH but also by increasing its affinity for NADPH.
These interactions are very similarly observed in the wildtype NADPH-bound SpHMGR. An
overlay of NADPH-bound SpHMGR with this DaHMGR chimera, Figure 14, shows how
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remarkably conserved the binding and steric interactions in the NADPH-associated cofactor helix
are when translated into DaHMGR.
When

examining

the

role

of

the

T189M

mutation,

the

structure

of

DaHMGR_T189M+NADH hints at the role of methionine in influencing selectivity. Without the
NADPH-dependent helix, the cofactor binds “lower” in the binding pocket much like the wildtype
configuration. However, in this orientation, the methionine creates a less favorable spatial
arrangement of the ribose of the cofactor as illustrated Figure 15. This is observed in the omit
density maps pertaining to NADH binding, where density for the 2-hydroxyl is lacking and the
ribose appears to be shifted (<1 Angstrom) away from T189M (Figure 9). Moreover, the removal
of the threonine, eliminates the possible hydrogen bond between the threonine side chain and the
2’-hydroxyl of NADH. With the NADPH-associated cofactor helix, however, the cofactor binds
“higher” up in the binding pocket, thus leveraging methionine’s steric role in stabilizing the
cofactor in this position. These observations agree with the kinetic analysis which shows that the
introduction of T189M reduces NADH activity and enhances NADPH specific activity. Therefore,
the structures portray the NADPH-associated cofactor helix being crucial to selecting towards
NADPH which is further aided by the T189M mutation.
Concerning the cofactor switch associated with SpHMGR, kinetic analysis revealed that the
cofactor switch, from NADPH to NADH, achieved by the chimeric protein SpHMGR_DaHMGRhelix was the most effective compared to the chimera with the M185T mutation. Thus, we
crystallized the former bound to its preferred cofactor, NADH. The crystal structure of this chimera
shows how the binding and steric interactions introduced by engineering SpHMGR to have an
NADH-associated cofactor helix aided in its newly acquired selectively towards NADH. However,
unexpectedly, NADH is still bound higher up in the cofactor binding site which is discussed below.
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With an NADH-associated cofactor helix we expect to see the following: the aspartate
directly coordinates the 2’-hydroxyl on the adenine ribose of NADH, non-polar residues creating
a hydrophobic environment which would be less favorable for the 2’-phosphate of NADPH, and
importantly the lack of a tyrosine to sterically push up the cofactor would allow the cofactor to
bind lower in the binding pocket. We do, indeed, observe the hydrophobic residues near adenine
ribose of NADH which creates a less favorable spatial arrangement for a phosphate. This likely
explains how, with the newly acquired NADH-associated cofactor helix, the kinetic results show
this chimera to prefer NADH, and is depicted Figure 16, an overlay of NADPH-bound SpHMGR
and NADH bound in this SpHMGR chimera. However, because the cofactor binds higher up in
the binding pocket, the aforementioned aspartate does not interact directly with the cofactor. The
aspartate, with poor electron density for the side chain possibly indicating multiple conformations,
is ~6.5A away from the hydroxyl of NADH. While there is a possibility that there is a watermediated interaction between these two moieties, this interaction is different than what was
observed in wildtype NADH-bound DaHMGR as shown in Figure 17, an overlay of NADH-bound
DaHMGR and this SpHMGR chimera. This may explain why the kinetic results show that while
this chimera indeed has a switched cofactor preference, it is primarily achieved by having a greater
diminishing influence on NADPH binding than NADH.
As explained above, due to the cofactor binding higher up in the binding pocket, the expected
aspartate did not directly coordinate the 2’-hydroxyl of NADH. One hypothesis was that the
methionine (M185) could be preventing the cofactor from binding lower. The reasoning for this
hypothesis came from the observation that in the analogous DaHMGR chimera, methionine
favored the binding of the cofactor in the higher position. However, the structure of
SpHMGR_DaHMGR-helix_M185T+NADH, with both the DaHMGR helix and the methionine
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to threonine mutations, shows that NADH still binds higher up in the binding pocket. Figure 18,
shows an overlay of these two novel structures with other structures that depict the cofactor in the
higher and lower positions. This figure shows how, despite mutating methionine to threonine in
NADPH-bound SpHMGR_M185T, the cofactor still binds in the upper position. This agrees with
the kinetic results which shows that the M185T does not improve cofactor selectivity towards
NADH. Instead, since the cofactor still binds higher up in the binding pocket, a methionine and
not a threonine, in this position, helps to stabilize the cofactor. The structure of
SpHMGR_M185T+NADPH, which only has the M185T mutation, corroborates this observation
by showing that even in wildtype SpHMGR, mutating the methionine to threonine still allows the
cofactor to bind in the upper position as illustrated by Figure 18, but due to the lack of the larger
sidechain of methionine, this mutant has lower kinetic activity.
To summarize the protein engineering related to DaHMGR, the structural and funct ional
manifestations of the respective mutations can be explained relatively easily. With the introduction
of the NADPH-associated cofactor helix, tyrosine aids in pushing the cofactor higher up in the
binding pocket where the 2’-phosphate of the cofactor interacts with charged residues. Since the
cofactor binds higher in the binding pocket, the threonine to methionine mutation aids in stabilizing
the cofactor. Moreover, this configuration no longer possesses the native aspartate to coordinate
the 2’-hydroxyl of NADH and the hydrophobic residues to deter phosphate, selectively towards
NADPH is achieved.
To summarize the protein engineering related to SpHMGR, the structural and functional
manifestations of the respective mutations explain how cofactor selectivity is achieved, but also
points to greater complexity. Without additional NADP(H)-bound class II HMGRs structures, it
is difficult to draw conclusions, however in the case of SpHMGR, it appears that nature has created
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the binding pocket to favor cofactor binding in the higher position. This is likely to accommodate
phosphate from its preferred cofactor, NADP(H), requiring additional space. During mutagenesis,
aspects of the introduced NADH-associated cofactor helix are translated in SpHMGR, specifically
the introduction of hydrophobic residues to deter NADPH binding, and kinetic results agree with
this. However, the complete influence of the cofactor helix is diminished since the cofactor helix
binds higher up, independent of the cofactor helix.
In this chapter, NADH- and NADPH- selective class II HMGRs were engineering to have
altered cofactor specificity, which was assessed by kinetic analysis and visualized using crystal
structures. To our knowledge, while many studies attempted cofactor switch in oxidoreductase
enzymes, crystal structures of the resultant chimeras are lacking. In a comprehensive review of
protein engineering efforts aimed at coenzyme specificity in oxidoreductases, the authors maintain
that crystal structures that depict the enzyme with its corresponding cofactor is of significant
importance in rational cofactor engineering [19]. The value in crystal structures is to not only
validate how these mutations manifest, but to understand how they may behave differently than
expected, as was the case in the SpHMGR chimeras. The results of this section provide the first
successful attempts at switching the cofactor preferences in class II HMGRs and take a significant
step forward in understanding the structural determinants of cofactor selectivity.

4.5. Future work
4.5.1. Improving overall catalytic activity
As previously mentioned, modifications to the cofactor specificity in oxidoreductases,
including the attempts in this research, results in diminishing the overall catalytic activity of the
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enzyme. Cahn et al. propose that following such mutagenesis, it is necessary to recover activity by
means of incorporating additional mutations. These mutations serve to “restabilize and reactivate”
the protein by compensating for the diminishing effects of the mutations introduced above [5]. The
authors note that while the approach to use random mutagenesis screening of various residues even
distal to the above mutations result in an effective recovery of activity, it requires significant
resources. Instead, based on a database of structural information, they have produced a
computational approach whereby one can input their amino acid sequence, and receive
recommended residues to target. They note that the most effective mutations are prominently
featured in the vicinity of the adenine ring[5].
This computational tool, called Cofactor Specificity Reversal Structural Analysis and
Library Design (CSR-SALAD), was used to analyze SpHMGR_DaHMGR-helix, the SpHMGR
chimera which now prefers NADH. CRS-SALAD recommended that the following residues be
investigated to aid in recovery of activity: medium priority residues including Thr177, Gln178,
Glu179, Ala180, Lys325 and low priority residues, Asp144, Asp176 and Glu179. When analyzing
DaHMGR_SpHMGR-helix_T189M, the following residues were recommended: medium priority
residues Arg182, Asp183, Ala184, and Val328, and low priority residues, Lys151, Arg182,
Lys333. Future work can be done in this regard, by introducing mutations with the hope of
improving the overall activity of these novel enzymes.
4.5.2. Investigating the structural features that facilitate the cofactor binding in the upper
position in SpHMGR constructs
In the case of the DaHMGR chimeric constructs, NADH is bound lower in the binding
pocket in the wildtype structure. Upon switching the cofactor helix to an NADPH-associated helix,
there are unique interactions that aid in pushing the cofactor higher up in the binding pocket, which
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in turn helps to facilitate interactions between the 2’-phosphate and residues of the cofactor helix.
In the case of the SpHMGR chimeric constructs, NADPH is bound higher in the binding pocket in
the wildtype structure. However, upon switching the cofactor helix to an NADH-associated helix,
the cofactor still binds higher, and this prevents, for example, a direct interaction between the
aspartate of the cofactor helix and the 2’-hydroxyl of the adenine ribose. It remains unclear why
the cofactor still prefers to bind in the upper position.
To this end, it would be valuable to investigate the structural features that govern this
phenomenon. If one can modify this region such that the cofactor binds lower in the binding
pocket, it is probable that the influence of the cofactor helix will be even more pronounced, thus
improving the switching of cofactor preference more convincingly. If it is determined that the
cofactor helix in the upper configuration is necessary, then the cofactor helix will need to be
modified accordingly. For example, one could attempt using glutamate instead of aspartate to help
coordinate the 2’-hydroxyl of the adenine ribose. Since NADH binds higher in the binding pocket,
the distance between aspartate and the 2-hydroxyl moieties would be greater when aspartate is
used versus glutamate.
4.5.3. Translating and optimizing the helices between additional class II HMGRs
In this research the cofactor helices of two HMGRs were switched resulting in switched
cofactor preferences that are determined by the cofactor helix. One could also investigate how the
helices of DaHMGR and SpHMGR translate into other class II HMGRs. Does introducing an
NADH-associated helix into other NADH-preferring HMGRs retain their cofactor preferences for
NADH? Does introducing an NADPH-associated helix into other NADH-preferring HMGRs
switch their cofactor preferences to NADPH? Which switches result in more convincing outcomes
and what are the structural reasons behind this? This research takes the first significant step in
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altering cofactor specificity among class II HMGRs, however, as was demonstrated in the cases of
DaHMGR and SpHMGR, each switch needs to be interrogated on a case-by-case basis. Despite
this observation, the cofactor helix appears to be the most influential structural feature that governs
specificity and thus further work in exchanging and optimizing cofactor-related protein
engineering should continue to focus on this motif.

4.6. Materials and methods

4.6.1. Designing DaHMGR and SpHMGR mutants
The codon-optimized mva gene for DaHMGR and SpHMGR wildtype constructs were
cloned as previously reported in Chapter Two which contains the nucleotide and amino acid
sequences. Round-the-horn PCR mutagenesis was used to insert the cofactor helices to generate
the switched-helix mutant constructs. Primers encoding for the SpHMGR cofactor helix (142AYPSIVKR-150) were used to generate the DaHMGR_SpHMGR-helix gene and primers
encoding

for the DaHMGR cofactor helix

(145-RDKVLIGL-152) were used

for

SpHMGR_DaHMGR-helix. Initially, only the last seven residue were considered part of the
cofactor helix however initial kinetic studies showed that eight residues were required. Site
directed mutagenesis was utilized

to insert

the methionine and threonine in

the

DaHMGR_SpHMGR-helix_T189M and SpHMGR_DaHMGR-helix_T185M genes respectively.
The plasmids were transformed into E. coli DH10B cells, and the gene sequences were confirmed
(Quintara Biosciences) before transformation into BL21(DE3) cells for protein expression.
4.6.2. Expression and purification of DaHMGR and SpHMGR mutants
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All DaHMGR and SpHMGR constructs were expressed and purified as reported in their
respective wildtype conditions found in Chapter Two. Briefly, cells were grown in lysogeny broth
supplemented with kanamycin and was grown at 37°C with shaking until OD 600 ~0.6-0.8, induced
with 0.5 mM isopropyl β- d-1-thiogalactopyranoside, and allowed to express at 16-20°C at 220
RPM for 16-18 hours. Cells were harvested by centrifugation at 5,000 RPM for 12 minutes, flash
frozen with liquid nitrogen, and stored at -80°C. Cells for DaHMGR constructs were sonicated in
lysis buffer [50 mM Tris (pH 7.8), 400 mM NaCl, 1 mM tris(2-carboxyethyl) phosphine (TCEP),
10% glycerol, and 10 mM imidazole], clarified, and the supernatant as applied to a Ni-NTA
column. DaHMGR constructs were eluted with 250 mM Imidazole, and highest concentration
fractions were pooled together, and buffer exchanged in storage buffer [50 mM Tris (pH 7.4), 400
mM NaCl, 1 mM TCEP, and 10% glycerol] using a PD-10 desalting column (GE Healthcare).
SpHMGR constructs were purified similarly with the following modifications: lysis buffer [50
mM Tris (pH 7.8), 200 mM NaCl, 10% glycerol, and 10 mM imidazole]; storage buffer [50 mM
Tris (pH 7.8), 200 mM NaCl, 10% glycerol]. Protein purity was assessed by SDS-PAGE, with
varying concentrations as determined by absorbance at A280 nm using a calculated extinction
coefficient, flash-frozen in liquid nitrogen, and stored at −80 °C.
4.6.3. Kinetic Characterization
Enzyme activity was measured by monitoring the rate of NAD(P)H oxidation by
absorbance at A340 nm using a NanoDrop 2000 with an extinction coefficient of 6200 M −1 cm−1 .
Reaction mixtures contained 50 mM Tris (pH 7.8), 50 mM NaCl, 5 mM DTT, 300 μM HMGCoA, 200 μM NAD(P)H, and enzyme. Change in absorbance over time of the initial rates per mg
of protein was used to determine the specific activity. Assays were performed in triplicate and the
values reported are the means ± the standard error of the mean (SEM).
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4.6.4. Crystallization of DaHMGR and SpHMGR mutants
The crystallization condition for Da-SpHelix_T189M+NADPH was optimized from the
wildtype condition previously reported (PDB 6EEU) to contain 100 mM Bis-Tris pH 6.0, 11%
PEG, 500 mM LiSO 4 and 10 mM NADPH. Crystals, which looked like the initial condition
described in Chapter Two, were grown overnight by sitting-drop vapor diffusion, soaked in a cryo
solution containing well solution supplemented with a 51% of a cryo solution containing 16%
ethylene glycol, 16% glycerol, 18% sucrose, and 4% glucose (called “magic cryo”) and 20 mM
NADPH, and flash-cooled using liquid nitrogen. Crystals for DaHMGR_T189M+NADH were
grown similarly with the addition of 20 mM NADH instead of NADPH.
The crystallization condition for SpHMGR_DaHMGR-helix+NADH was optimized from
an initial hit (C5 of PEG RX screen from Hampton Research) obtained via sparse-matrix screening
by sitting-drop vapor diffusion using a Crystal Gryphon (Art Robbins Instruments) to contain 100
mM Sodium Citrate pH 5.0, 19% PEG 3350 + 20 mM NADH. Crystals, which looked like
rectangular sheets, were grown overnight by sitting-drop vapor diffusion, soaked in a cryo solution
containing well solution supplemented with 30% glycerol and 20 mM NADH, and flash-cooled
using liquid nitrogen. Crystals for SpHMGR_DaHMGR-helix_M185T+NADH were grown
similarly with the cryo solution contained 35% magic cryo instead of 30% glycerol.
Crystals for SpHMGR_M185T+NADPH were grown under similar conditions as the
SpHMGR constructs above but assumed a different morphology. These crystals, which looked like
hexagonal prisms, were grown overnight by sitting-drop vapor diffusion, soaked in a cryo solution
containing well solution supplemented with 35% of a solution containing magic cryo and 20 mM
NADH.
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4.6.5. X-ray data collection, structure determination, and refinement of DaHMGR and SpHMGR
mutants
X-ray diffraction experiments were conducted at the Advanced Photon Source (APS)
beamline 24-ID-E and were indexed, merged, and scaled using iMOSFLM. DaHMGR and
SpHMGR structures were solved using apo DaHMGR (PDB 6EEU) and one monomer of a
structure of SpHMGR (PDB 5WPJ), respectively, by molecular replacement using Phaser in the
Phenix suite. In all cases, ligands and the C-terminal domain were removed from search models.
Iterative rounds of model building in Coot and reciprocal refinement in phenix.refine were
performed. Where electron density for ligands and CTD were observed, they were modeled in
using Coot. Final data collection statistics are listed in Table 1.
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4.7. Tables and figures

Figure 1. Comparison between canonical Rossmann nucleotide binding motif versus the
nucleotide binding motif of class II HMGR. On the left are cartoon depictions of the respective
nucleotide binding motifs colored by secondary structure. In the middle are schematics of these
secondary structures with the α-helices and β-sheets labeled. On the right are close-ups of the
nucleotide binding region showing similarities between the Rossmann fold and the motif found in
class II HMGRs that pertain to cofactor selectivity. NAD is shown as sticks and colored as follows:
N colored blue, O colored red, P colored orange, C colored green. A) Rossmann binding motif as
observed in a lactate dehydrogenase structure from Squalus acanthias (PDB 1LDM). B) The
unique binding motif as observed in a class II HMGR structure from Delftia acidovorans (PDB
6DIO).
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Figure 2. NAD versus NADP associated cofactor helices. On top, is an overlay of the cofactor
helices of NAD-preferring DaHMGR (in green) and NADP-preferring SpHMGR (in cyan) shown as
cartoon representation with the cofactors as sticks colored as follows: N colored blue, O colored red,
P colored orange, C colored with respect to the color of the cartoon. The first, third, and seventh
residues of the cofactor helices are shown in sticks. On the bottom, is a table containing the species,
its corresponding cofactor helix, and its cofactor preference. In the table, the first, third and seventh
residues of the cofactor helix are highlighted and correspond to the residues depicted as sticks in the
diagram above as they are observed in DaHMGR and SpHMGR.
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Figure 3. Overlay of the structures of NAD-bound DaHMGR and NADP-bound SpHMGR
highlighting residues implicated in cofactor selectivity. On top, is an overlay of the crystal
structures of NAD-bound DaHMGR (in cyan) and of NADP-bound SpHMGR (purple) shown in
cartoon representation. The cofactors are shown as sticks as well as the methionine and threonine
residues implicated in cofactor selectivity. The sticks are colored as follows: N colored blue, O
colored red, P colored orange, C colored according to its cartoon coloring. The methionine appears
to push up NADP to facilitate the interaction between the phosphate of NADP and Arg150 (shown
as sticks) whereas the overlay suggests that NAD in this position would favor the smaller threonine
residue as it is positioned lower in the binding pocket. On the bottom, is a table depicting the
organism, cofactor helix and respective cofactor preference of various class II HMGRs showing
how larger residues predominate in NADP-preferring HMGRs whereas smaller ones in NADpreferring HMGRs in the highlighted region that pertain to the methionine and threonine residues
depicted in the structures above.
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Figure 4. Kinetics of DaHMGR and DaHMGR mutant constructs. Specific activity using
NADH versus NADPH in A) wildtype, B) DaHMGR_SpHMGR-helix, C) DaHMGR_T189M,
and D) DaHMGR_SpHMGR-helix_T189M. Assays were performed in triplicate and the values
reported are the means ± the standard error of the mean (SEM).
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Figure 5. Comparing activity of DaHMGR mutants versus wildtype with respect to NADH
and NADPH. The specific activities of the various mutants with respect to wildtype DaHMGR
are shown on the left, using NADH, and on the right, using NADPH. This was calculated by taking
the ratio of the specific activity over the wildtype specific activity and presenting it in a logarithmic
scale.
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Figure 6. Kinetics of SpHMGR and SpHMGR mutant constructs. Specific activity using
NADH versus NADPH in A) wildtype, B) SpHMGR_DaHMGR-helix, C) SpHMGR_M185T, and
D) SpHMGR_DaHMGR-helix_M185T. Assays were performed in triplicate and the values
reported are the means ± the standard error of the mean (SEM).
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Figure 7. Comparing activity of SpHMGR mutants versus wildtype with respect to NADH
and NADPH. The specific activities of the various mutants with respect to wildtype SpHMGR
are shown on the left, using NADH, and on the right, using NADPH. This was calculated by taking
the ratio of the specific activity over the wildtype specific activity and presenting it in a logarithmic
scale.
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Data Collection
Wavelength
Resolution range
Space group
Unit cell
Total reflections
Unique reflections
Multiplicity
Completeness (%)
Mean I/sigma(I)
Wilson B-factor
R-merge
R-meas
R-pim
CC1/2
Refinement
Reflections used in refinement
Reflections used for R-free
R-work
R-free
Number of non-hydrogen atoms
macromolecules
ligands
solvent
Protein residues
RMS(bonds)
RMS(angles)
Ramachandran favored (%)
Ramachandran allowed (%)
Ramachandran outliers (%)
Rotamer outliers (%)
Clashscore
Average B-factor
macromolecules
ligands
Solvent

NADPH-bound
DaHMGR_SpHMGRhelix_T189M

NADH-bound
DaHMGR_T189M

NADH-bound
SpHMGR_DaHMGR-helix

NADH-bound
SpHMGR_DaHMGRhelix_M185T

NADPH-bound
SpHMGR_M185T

0.97918
75.6 - 1.881 (1.948 - 1.881)
P321
100.22 100.22 75.6 90 90
120
384483 (25342)
35971 (2298)
10.7 (11.0)
100.0 (100.0)
11.9 (1.7)
31.53
0.105 (1.518)
0.116 (1.679)
0.049 (0.712)
0.999 (0.683)

0.97911
56.94 - 2.24 (2.32 - 2.24)
P321
100.21 100.21 75.4504 90 90
120
105932 (10048)
20273 (1875)
5.2 (5.4)
94.61 (97.43)
4.5 (1.5)
26.13
0.234 (0.987)
0.284 (1.204)
0.156 (0.676)
0.974 (0.276)

0.97918
57.03 - 1.66 (1.719 - 1.66)
C 2 2 21
73.91 89.6501 147.66 90 90
90
716151 (35873)
58349 (2826)
12.3 (12.7)
99.90 (99.95)
12.8 (2.5)
18.62
0.110 (1.052)
0.120 (1.145)
0.047 (0.449)
0.998 (0.858)

0.97911
53.55 - 1.8 (1.864 - 1.8)
C 2 2 21
73.55 90.29 155.82 90 90 90
263185 (15494)
48006 (2827)
5.5 (5.5)
99.15 (99.54)
6.9 (1.5)
20.33
0.146 (1.155)
0.178 (1.413)
0.100 (0.798)
0.993 (0.444)

0.97911
76.13 - 1.53 (1.585 - 1.53)
P 32 2 1
141.69 141.69 97.0612 90 90
120
1948175 (98616)
168298 (8315)
11.6 (11.9)
99.86 (100.00)
9.5 (1.5)
15.61
0.151 (1.783)
0.165 (1.952)
0.066 (0.782)
0.997 (0.527)

35955 (3558)
1990 (197)
0.1726 (0.3158)
0.2063 (0.3493)
3024
2751
108
205
375
0.011
1.14
97.32
2.68
0
0.36
4.09
40.36
39.3
71.09
44.3

20264 (2051)
958 (88)
0.1705 (0.2603)
0.2116 (0.3017)
3010
2732
44
234
374
0.008
1.08
98.12
1.88
0
0.72
4.69
30.93
29.9
65.15
36.47

58087 (5706)
2841 (274)
0.1504 (0.2350)
0.1742 (0.2723)
3536
3216
102
257
427
0.009
1.04
98.12
1.88
0
0.91
4.14
29.53
29.28
22.53
34.32

47984 (4751)
2385 (228)
0.1671 (0.2954)
0.1943 (0.3418)
3576
3195
57
324
423
0.007
0.86
97.62
2.38
0
0.3
2.63
29.82
28.87
33.88
38.39

168248 (16706)
8189 (867)
0.1456 (0.2724)
0.1787 (0.3036)
7304
6425
132
757
842
0.014
1.23
98.57
1.43
0
0.74
4.68
25.72
24.7
19.71
35.3

Table 1. Data collection and refinement statistics pertaining to the various structures in this chapter.
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Figure 8. Polder omit density maps calculated from NADP-bound DaHMGR_SpHMGRhelix_T189M. Polder mFo – DFc omit density contoured at 3.0σ shown surrounding A) NADP,
B) the NADP-associated cofactor helix from SpHMGR, and C) the T189M mutation introduced
colored orange. Each of the respective moieties are shown in cartoon representation or sticks with
the following coloring: N colored blue, O colored red, P colored orange, C colored green.
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Figure 9. Polder omit density maps calculated from NAD-bound DaHMGR_T189M. Polder
mFo – DFc omit density contoured at 3.0σ shown surrounding A) NAD, B) the T189M mutation
introduced colored magenta. Each of the respective moieties are shown in cartoon representation
or sticks with the following coloring: N colored blue, O colored red, P colored orange, C colored
green.
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Figure 10. Polder omit density maps calculated from NAD-bound SpHMGR_DaHMGRhelix. Polder mFo – DFc omit density contoured at 3.0σ shown surrounding A) NAD, B) the NADassociated cofactor helix of DaHMGR colored red. Each of the respective moieties are shown in
cartoon representation or sticks with the following coloring: N colored blue, O colored red, P
colored orange, C colored green.
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Figure 11. Polder omit density maps calculated from NAD-bound SpHMGR_DaHMGRhelix_M185T. Polder mFo – DFc omit density contoured at 3.0σ shown surrounding A) NAD, B)
the NAD-associated cofactor helix of DaHMGR, and C) the M185T mutation colored purple. Each
of the respective moieties are shown in cartoon representation or sticks with the following coloring:
N colored blue, O colored red, P colored orange, C colored green.
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Figure 12. Polder omit density maps calculated from NADP-bound
SpHMGR_M185T. Polder mFo – DFc omit density contoured at 3.0σ shown surrounding
A) NADP, B) the M185T mutation colored green. Each of the respective moieties are
shown in cartoon representation or sticks with the following coloring: N colored blue, O
colored red, P colored orange, C colored green.
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Figure 13. Overlay of NAD-bound DaHMGR and NADP-bound DaHMGR_SpHMGRhelix_T189M.
Overlay
of NAD-bound DaHMGR (grey)
and
NADP-bound
DaHMGR_SpHMGR-helix_T189M (green) shown in cartoon representation with the cofactor
helices and cofactors in sticks colored as follows: N colored blue, O colored red, P colored orange,
C colored according to its cartoon coloring.
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Figure 14. Overlay of NADP-bound DaHMGR_SpHMGR-helix_T189M and NADP-bound
SpHMGR. Overlay of NADP-bound SpHMGR (grey) and NADP-bound DaHMGR_SpHMGRhelix_T189M (green) shown in cartoon representation with the cofactor helices and cofactors in
sticks colored as follows: N colored blue, O colored red, P colored orange, C colored according to
its cartoon coloring. Interactions between Arg152 and the adenine moiety, the 3’-phosphate and
Arg152, and the 3’-phosphate and Ser148 through a water molecule are depicted using yellow
dashed lines in NADP-bound DaHMGR_SpHMGR-helix_T189M.
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Figure 15. Overlay of NAD-bound DaHMGR and NAD-bound DaHMGR_T189M. Overlay
of NAD-bound DaHMGR (green) and NAD-bound DaHMGR _T189M (cyan) shown in cartoon
representation with T189 and M189 shown in sticks, respectively, and the cofactors in sticks
colored as follows: N colored blue, O colored red, P colored orange, C colored according to its
cartoon coloring.
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Figure 16. Overlay of NAD-bound SpHMGR_DaHMGR-helix and NADP-bound SpHMGR.
Overlay of NAD-bound SpHMGR_DaHMGR-helix (cyan) and NADP-bound SpHMGR (grey)
shown in cartoon representation the cofactor helices and cofactors in sticks colored as follows: N
colored blue, O colored red, P colored orange, C colored according to its cartoon coloring. D144
appears in alternate conformations as depicted.
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Figure 17. Overlay of NAD-bound SpHMGR_DaHMGR-helix and NAD-bound DaHMGR.
Overlay of NAD-bound SpHMGR_DaHMGR-helix (cyan) and NAD-bound DaHMGR (grey)
shown in cartoon representation the cofactor helices and cofactors in sticks colored as follows: N
colored blue, O colored red, P colored orange, C colored according to its cartoon coloring. D144
appears in alternate conformations as depicted and a water molecule is represented by a red sphere.
Interactions are depicted as dashed lines and colored based on interactions formed from its
respective protein structure.
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Figure 18. Overlay of various DaHMGR and SpHMGR wildtype and mutant proteins
showing the higher and lower binding of the cofactor. Cartoon representation of wildtype
DaHMGR, wildtype SpHMGR, and mutant SpHMGR structures colored according to the key. The
cofactor and the corresponding methionine/threonine residue is shown in sticks and colored as
follows: N colored blue, O colored red, P colored orange, C colored according to its cartoon
coloring.
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Chapter V: Applications for HMGR in natural product, drug design, and
metabolic engineering research

5.1.

Summary
In Chapters Two through Four, experiments in several class II HMGRs were aimed at

characterizing various biophysical characteristics, including solution-state studies (Chapter Two),
characterizing the affinity of substrate and cofactor and related structural dynamics (Chapter
Three), and modifying its cofactor preference (Chapter Three). Throughout these endeavors, there
were discussions of how these characteristics manifest and their immediate significance in light of
prior work on class II HMGRs. In this final Chapter, we utilize this knowledgebase to inform
future avenues of interest by looking at specific experimental results and how they might
contribute towards new research.
Three major avenues of research will be discussed: 1) HMGR’s role in natural product
synthesis, 2) metabolic engineering involving HMGR, and 3) drug development targeting HMGR.
The specific experimental results that pertain to the structural basis of cofactor preference,
oligomerization, and substrate affinity, will inform efforts at understanding and exploiting HMGR
in natural product biosynthesis and drug discovery with specific focus given towards efforts at
being able to fine-tune DaHMGR activity with respect to overall activity and cofactor utility. A
paradigm that relates cofactor preference, reaction direction, oligomerization and the nature of
products formed will be proposed. Unique ways of modulating or inhibiting HMGR activity which
include unique hotspots at the active site as well as allosteric sites will be discussed. In sum, this
closing chapter extrapolates the efforts of the previous sections and propels exciting areas of
research that pertain to this biologically important enzyme.
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5.2.

Introduction
As pointed out in Chapter One, natural products continue to be an exciting reservoir of

compounds that have benefit in a wide range of industries. It is, therefore, remarkable to consider
that only a small fraction of the world’s biodiversity has been evaluated for its potential, leaving a
majority of the natural products available in nature open for discovery [1]. Equally exciting as the
prospect of discovering new compounds from nature for society’s benefit, is the research and
development into the proteins that perform the necessary steps within the pathways that generate
these compounds. By expanding our understanding of the way these proteins work there will be
greater insight into the biosynthesis of these commodity compounds. Moreover, elucidating the
mechanisms of how these proteins from different kingdoms end up producing often the exact same
compound is an intriguing undertaking for the evolutionary biologist. Likewise, there is ripe
opportunity for the structural biologist to discern the structural traits that result from these
evolutionary processes which equips the synthetic biologist with the tools needed to engineer
desired commodity compounds. The limiting step, therefore, is the research and development into
these endeavors.
We begin this concluding chapter by first fixing HMGR as an important enzyme in the
field of natural products. This will allow us to return to Chapter One and re-introduce an important
observation: natural products are a promising field for prod ucing compounds of interest. The
implication of the current study expands our understanding of not only HMGR itself, but on
HMGR-dependent reactions in natural product discovery. Secondly, following this discussion on
HMGR and natural products, we consider metabolic engineering, and how the research done here
can contribute towards HMGR-dependent production of natural products. Through insight gained
into how HMGR cofactor specificity is governed and by being able to modulate its behavior, we
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will explore how one can customize metabolic pathways in metabolic engineering efforts. Lastly,
in the third section, we move away from natural products and metabolic engineering and look at
HMGR itself as a potential drug target for antibiotics. Considering HMGRs from specific
homologs on a molecular level, one can design inhibitors that are specific to a particular HMGR,
and by extension, specific to the respective pathogen.
In sum, in this final chapter, with the knowledge gained from the research presented thus
far, we begin to extrapolate how these efforts could be applied in natural products, metabolic
engineering, and drug development and will be addressed as follows:
HMGR and natural products:
❖ Why are natural products important?
❖ What is the significance of HMGR-dependent reactions in natural product research?
HMGR and metabolic engineering:
❖ What does metabolic engineering offer?
❖ How can we utilize intrinsic HMGR activity or modify it for synthetic biology efforts?
HMGR and drug design:
❖ What makes a good drug?
❖ How can a drug target class II HMGRs?

5.3.

HMGR and natural products

5.3.1. Why are natural products important?
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Throughout history, creating compounds for medicinal use has always been of great
interest. Research and development into drug design have since spanned the globe motivated by
the need to generate safe and life-sustaining medicine often with enormous financial incentives.
When assessing the strategies of drug development, while in recent years a substantial amount of
drugs are made from purely synthetic approaches, an even larger amount of drugs are inspired by
what is already available in nature in the form of natural products [2]. As it pertains to drug
development, these secondary metabolites can either have activity in its original form, are
synthetically modified to an improved version, or they provide scaffolds for natural product
models that offer medicinal benefits [1]. A popular example of a natural product derivative that
was discovered to comprise medicinal use is the ubiquitous pain and anti-inflammation medicine,
aspirin. Its active ingredient, acetylsalicylic acid, was synthesized based on the natural product,
salicin, isolated from the bark of the willow tree Salix alba [1].
As a source for medicine, natural products offer the highest success rate in producing
potential drug leads [1]. As pointed out by Newman and Cragg, in the almost four decades
spanning Four Decades from 01/1981 to 09/2019, natural products have contributed, in some
fashion, towards about half of all small molecules approved for medicinal purposes in the USA
[3]. Figure 1 illustrates the proportionally sizable percentage of compounds that constitute drug
sources implicated by natural products, demonstrating just how much influence these compounds
have had on drug development. In their comprehensive review, Newman and Cragg give much
attention to anticancer agents and infectious disease related drugs, with natural products featuring
prominently among the approved medicine aiming to cure or treat these illnesses.
In addition to their roles in medicine, the use of natural products extends to other fields
such as the production of biofuels, essential oils, nutrition and fragrances [4]. Such endeavors not
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only prove beneficial to society but offer a lucrative industry to explore. For example, one estimate
suggests that globally, the market for flavor and fragrances approaches ~40 billion dollars and
cosmetics will reach over 800 billion dollars by 2023[5]. The demand for natural and sustainable
products underscores the importance of finding efficient ways to produce these natural products
[5]. Microbial production of natural products in these efforts has become increasingly popular [4].
Needless to say, the field of natural products, whether it be for the benefit of medicine or for the
production of other chemicals of interest, is an attractive area of study and underscores the
importance of research aiming to shed light on the biosynthesis of these important biomolecules.

5.3.2. What is the role of HMGR-dependent reactions in natural product research?
As pointed out in Chapter One, isoprenoids constitute the largest and most structurally
diverse class of natural products. Despite its expansive presence across biology, the biosynthesis
of isoprenoids is channeled through two major pathways, the DXP and mevalonate pathway.
HMGR, is the first-committed step of one of these obligate pathways, thus fixing HMGR as a key
enzyme across a substantial proportion natural product biosynthesis. As such, any investigation
into HMGR contributes towards our growing understanding of how these important, often lifesustaining molecules, are made.
As it pertains to natural products, one important insight gained from this research involves
looking at the preferred direction of HMGR activity. The forward direction is the reductive
reaction, converting HMG-CoA to mevalonate. The reverse direction is the oxidative reaction.
Knowing the preferred direction of an HMGR homolog has implications on the types of molecules
that are made in its native context. As described in Chapter One, in the mevalonate pathway, when
the forward reaction is considered, HMG-CoA is converted to mevalonate which goes on to
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produce isopentyl pyrophosphate (IPP) and dimethylallyl pyrophosphate (DMAPP), the building
blocks for isoprenoid biosynthesis. However, this assumes that the forward reaction is preferred in
its physiological context. An example of this is seen in archaea where the forward reaction leads
to the production of isoprenoids that are important for the synthesis of, among other things, its
membranes which are made up of glycerol ether linked to isoprenoid alcohols[6]. In contrast,
HMGR from Pseudomonas mevalonii prefers to work in the reverse direction. Instead of using
HMGR to produce the precursors for isoprenoids, it uses mevalonate as the sole source of carbon
and energy, converting it to HMG-CoA to be eventually converted to acetyl-CoA, a central
metabolite [6], [7]. Moreover, research into inhibitors that target HMGR activity would benefit
from such knowledge since inhibiting HMGR activity also prevents the formation of HMGRdependent downstream products. Therefore, the preferred direction of HMGR in its native context
has major implications on the molecules being generated.
One way to assess preferred reaction directionality is to observe which cofactor is
preferred. NADP(H) and NAD(H) often have different roles in the cell where NAD+ is primarily
used as an oxidant and NADPH as a reductant as discussed in Chapter Four [8]. This is revealed
in low values, 0.001 to 0.01, of NADH/NAD+ ratios in contrast to higher values, 15-60, in
NADPH/NADP+ ratios in various cellular environments[9]. In the context of HMGR, if an enzyme
prefers NADP(H), it is likely that the forward reaction is preferred . For example, Streptococcus
pneumoniae HMGR is an NADP(H)-dependent HMGR, and one study showed that the production
of isopentyl pyrophosphate via the mevalonate pathway was essential for survival in Streptococcus
pneumoniae, substantiating the claim that the forward reaction is preferred [10], [11]. In contrast,
as mentioned above, PmHMGR, which prefers the reverse direction, is an NAD(H)-preferring
HMGR [12]. Hence, with mounting evidence of this pattern, one could reasonably posit the types
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of molecules HMGR predominantly generates, be it natural product or metabolic precursors, in its
physiological context, by ascertaining its cofactor preference.
The research revealed in Chapter Three reveal DaHMGR as an NAD(H)-preferring
HMGR. Using steady-state kinetics, we observe a significant preference for NAD(H). This
preferred cofactor was subsequently used for crystallization experiments where NAD(H)-bound
HMGR showed the important interactions that favor NAD(H). As highlighted, an important
cofactor helix, which contains an aspartate (Asp146) coordinates the hydroxyl groups on the
adenine-ribose moiety thus facilitating the cofactor preference towards NAD(H). This suggests
that DaHMGR prefers the reverse direction and, therefore, will have implications on the
physiological relevance of mevalonate acquisition and utility in the cell as well as HMG-CoA
production.
A related phenomenon to which this research contributes towards involves the relationship
between oligomerization and cofactor preference. There appears to be a developing paradigm
within class II HMGRs where HMGRs that prefer NADP(H) as its cofactor manifest as a dimer
whereas HMGRs that prefer NAD(H) are able to form hexamers. The work in Chapter Two agrees
with this paradigm showing that NADPH-preferring SpHMGR exists as a dimer in solution as
revealed by Size Exclusion Chromatography, with no higher order oligomerization evident. A
predominately single peak in the expected dimer size is observed. This is also reflected in the
crystal structure of SpHMGR where SpHMGR is revealed as a homodimer in the crystal lattice.
In contrast, the crystal lattice of the crystal structure of DaHMGR can create a hexamer in the
crystal lattice. Upon further solution-state analysis performed using Size Exclusion
Chromatography and Small-Angle X-ray Scattering, DaHMGR exists in equilibrium between a
hexamer and dimer. Its ability to form the hexameric assembly is noteworthy in the context of
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oligomerization and its respective cofactor preference. Thus, the work here further supports the
developing paradigm that NADP(H)-preferring HMGRs and NAD(H)-preferring organisms exist
in different oligomeric states in its native environments and more specifically points to the ability
of NAD(H)-preferring HMGRs to form higher order oligomerization.
In the context of natural product biosynthesis, the ramifications of these observations are
noteworthy. Further work needs to be done in this regard, but so far, it appears that cofactor
preference, preferred reaction direction in its respective cell, and oligomerization are related . Their
does not appear to be causative influences between cofactor preference and oligomerization, but
the correlation exists. Therefore, it may be possible to look at any given one of these aspects, in an
uncharacterized HMGR, and predict the remaining unknowns. For example, it may become
possible to simply look at the sequence of the cofactor helix, predict its cofactor preference based
on the structural residues that constitute the structural determinants that govern cofactor
specificity, and thereby classify its preferred directionality, its oligomerization preference, and
ultimately the types of molecules it generates in the cell. One could assess whether HMG-CoA or
whether mevalonate are preferred products which has major implications on the types of
downstream products that can be generated in the context of natural product biosynthesis.
For example, in the case of Staphylococcus aureus, based on the observation that
mevalonate production is required for survival[13], the HMGR reaction probably favors the
forward direction, converting HMG-CoA to mevalonate. The cofactor helix, made up of residues
AYPSIKAR, lacks the conserved aspartate that would coordinate the 2’-hydroxyl of NAD(H) and
instead has the bulkier tyrosine that helps to sterically position the phosphate of NADP(H) to
coordinate the charged residues found later in the cofactor helix. This suggests that it would be
NADP(H)-dependent which agrees with the above assumption that the preferred direction is the
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reductive reaction. However, the oligomeric state of HMGR remains unknown. Using the
developing model proposed here, we can predict it to be a dimer. As such, the work done here has
the potential to inform aspects of individual HMGRs as well as class II HMGRs in general and
offers insight into HMGR-dependent natural product biosynthesis.

5.4.

HMGR and metabolic engineering

5.4.1. What does metabolic engineering offer?
Metabolic engineering provides the opportunity for researchers to investigate methods of
producing a wide range of compounds with uses as fuels, medicine, and other commodity
chemicals spanning both commercial and health-related industries. These methods involve
harnessing or modifying the metabolism of a host in order to leverage the production of native or
non-native metabolites[14]. These techniques not only offer ways to produce novel compounds for
use in new ways, but also offer alternative ways of producing existing chemicals. Earlier in this
section, we highlighted the importance of natural products in producing chemicals of interest.
Thus, it comes as no surprise that metabolic engineering of natural products is revealing itself as a
promising approach to acquiring compounds for benefit to society [15].
To this end, there are efforts towards producing compounds such as fossil fuels that are in
jeopardy of being depleted, or greener alternatives in response to climate change and
environmental pollution [16]. These methods can involve using cell-based systems where, for
example, living microbes are modified to produce desired compounds. They can also involve cell-
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free systems where specific proteins are isolated and incorporated into a synthetic pathway that
leads to the production of desired compounds.
In a cell-based biosynthetic platform, a common host used in metabolic engineering is the
bacterium Escherichia coli (E. coli). Since E. coli is such a malleable and efficient host,
biosynthetic pathways found elsewhere in nature can be inserted into E. coli, allowing the abundant
production of desired products. As depicted in Figure 2, the exogenous pathway becomes
incorporated into the machinery of the host cell in a way that does not drastically disrupt the
survival of the host and is able to perform targeted reactions to produce highly specific products.
In one study, researchers were able to generate a modified strain of E.coli that could produce a
class of branched-chain fatty acids that constitute precursors for renewal fuels[17]. Normally,
E.coli does not naturally produce branched chain fatty acids, however by customizing the supply
of branched-chain amino acids in the growth medium and by modifying the amino acid
biosynthesis pathways, which included upregulating certain enzymes, they were able to generate
branched-chain fatty acids [17].
There are, however, limitations to using cell-based systems which revolve around the need
to maintain homeostasis within the host that prevents adequate product formation. For example,
microbes are usually only able to perform optimally at certain temperatures, or the implicated
pathways end up creating toxic amounts of products or intermediates [16]. Thus, one alternative
relies on a cell-free system where enzymes are isolated, combined, and incorporated into a
synthetic pathway, in vitro, to generate a desired product. In one study, researchers were able to
design an entirely artificial glycolytic pathway that converts glucose to pyruvate using only four
enzymes [16]. The pathway, made of enzymes from a variety of different source organisms,
eliminated phosphorylation and dephosphorylation steps required in typical glycolytic pathways,
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and used only NAD+ as a molecular shuttle. The researchers took this concept further and utilized
two enzymes to convert pyruvate to ethanol, and five enzymes to convert pyruvate to isobutanol.
Of importance, is that in order to be selective towards a specific intermediate in the pathway, one
of the enzymes, NADPH-dependent aldehyde dehydrogenase, was engineered to have greater
affinity for NADH since the pathway already utilized NAD(H) [16].
In both the above approaches, cell-based and cell-free biosynthetic platforms, a more
complete understanding of the pathways that are implicated in product formation, as well intimate
knowledge of the individual enzymes involved, are prerequisites of being able to utilize these
platforms effectively. For example, in cell-based systems, good understanding of the aspects that
limit and regulate the pathway, the types of intermediates that are generated, and how enzymes
exist in its cellular environment, are vital. In a cell-free system, it will be advantageous to know
the kinetic parameters such as catalytic efficiency, specific activity, and substrate affinity of
enzymes within the synthetic pathway to be able to predict and control the flow of product
formation. It would also be highly beneficial to have available the means to modify the behavior
of proteins in a predictable manner as was the case of the cell-free system discussed above.
5.4.2. How can we exploit intrinsic HMGR activity?
5.4.2.1.The feasibility of exploiting HMGR activity
There have already been numerous cell-based and cell-free platforms that have exploited
HMGR activity. The research from this study adds to and extends our understanding of some of
the ways in which HMGR has been and can be used. For example, in the cell-based biosynthetic
study where researchers developed an E.coli strain to express the mevalonate pathway from
Saccharomyces cerevisiae, they interchanged the gene encoding HMGR with those from various
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organisms and found that when HMGR from Delftia acidovorans (DaHMGR) was used, there was
higher product formation, amorphadiene, the antimalaria precursor [18]. In Chapter Three,
DaHMGR was kinetically characterized and, as pointed out in Table 1, DaHMGR has the lowest
KM out of various class II HMGRs. This suggests that DaHMGR has a comparably higher affinity
for HMG-CoA than other HMGRs and might account for the reason DaHMGR was the most
effective at producing the most amorphadiene.
However, this interpretation is complicated by the observation that in the study mentioned
above, Staphylococcus aureus HMGR (SaHMGR) showed the highest mevalonate-producing rate
–the forward reaction –and DaHMGR had the highest HMG-CoA producing rate –the reverse
reaction –when assessed in vitro with their preferred cofactor and in vivo under aerobic conditions.
Under anerobic conditions, this pattern was reversed revealing higher mevalonate production using
DaHMGR than SaHMGR. As the authors point out, concentrations of NADH in E. coli are higher
under anerobic conditions. Thus, the work in Chapter Three which characterizes DaHMGR as an
NADH-specific HMGR aids in our interpretation of this phenomenon. As depicted in Chapter
Three, DaHMGR has significantly lower activity when using NADPH and strongly prefers
NADH. Of note is that DaHMGR also has the lowest KM for NADH of the homologs represented
in Table 1. Therefore, under anerobic conditions, with higher concentrations of NADH present in
E. coli, DaHMGR which has a high affinity to HMG-CoA and prefers NADH, can perform the
forward reaction producing HMG-CoA at high rates.
This does not, however, explain why DaHMGR eventually went on to produce more
amorphadiene since the experiment relied on the forward reaction under aerobic conditions.
HMGR is often considered the rate-limiting step, and as such, under aerobic conditions, one would
expect SaHMGR, which had the highest forward reaction rate under aerobic conditions, to be the
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most efficient enzyme to produce larger quantities of amorphadiene. Further investigation into this
apparent contradiction led the researchers to observe the amount of unused mevalonate present
during in vivo production of amorphadiene and determined that there was unused mevalonate in
extracts from SaHMGR experiments. This suggested to them that, while SaHMGR was effective
at making high amounts of mevalonate, the subsequent enzyme in the mevalonate pathway, namely
mevalonate kinase, which converts mevalonate to mevalonate-5-phoshate, was being inhibited by
high concentrations of mevalonate.
Now that DaHMGR has been studied more rigorously in the present research, the work
done here provides a quantitative characterization of how it may function in vivo. More
specifically, one could look at the kinetic parameters and enable a quantitative approach at
metabolic engineering geared towards HMGR-dependent reactions. Beyond explaining and
understanding, metabolic engineering aims to modify behavior for desired outcomes.
5.4.2.2. Modifying HMGR activity
In the study above, when trying to explain how DaHMGR is able to produce more
amorphadiene than when other HMGRs were used, the authors proposed that DaHMGR is able to
balance HMG-CoA levels below the threshold that would lead to cellular toxicity while also
balancing mevalonate levels below concentrations that would inhibit mevalonate kinase activity
[18]. This balancing act is directly related to the affinity of substrates and products as well as
activity, where fine-tuning allows for optimal function in the specific pathway it is incorporated in
to. This fine-tuning of DaHMGR activity can be further exploited and can be investigated in vitro
by modulating its activity. This modulation can involve enhancing affinity, with the hope of
enhancing catalytic efficiency, or it can involve attenuating affinity resulting in diminished
activity. Especially in the case of attenuating binding, one must be careful not to totally destroy
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affinity and instead make finer adjustments that lead to controlled modulation of activity. Thus, a
highly nuanced approach, where intimate knowledge of the enzyme dynamics, is warranted. The
hope is that one can fine tune, in a controlled manner, the various factors, such as substrate and
product affinity and enzyme activity, for optimal product formation.
One approach to modulating activity would be to examine the importance of higher order
oligomerization. As mentioned in Chapter Two, DaHMGR exists as a hexamer made of trimers of
homodimers. In light of the fact that only the homodimer is required for activity in many class I
and class II HMGRs, it is likely that homodimers of DaHMGR would still be active. And since,
as pointed out in Chapter Two, oligomerization often has implications on the activity of the protein
which is most commonly observed by revealing higher activity with higher order oligomerization,
one could potentially modulate DaHMGR activity by enhancing or preventing the formation of
the hexamer. This can be achieved by exploring the hexameric interface and homing in on residues
that can be mutated. These mutations could be aimed at furthering the interactions that stabilize
this interface or they can disrupt of the formation of the hexamer. Equipped with the structures of
DaHMGR and the biophysical approaches investigated in Chapter Two, the prospect of this
approach is promising.
To disrupt the hexameric interface of DaHMGR, there are several residues already being
investigated in the Kung Lab. Glu308 and Gln133 are examples of residues that can be targeted
(Ashley Yang and Yan Kung, unpublished). Glu308 makes interactions with the backbone His125
and Gly126 of a neighboring molecule. Gln133 interacts with the backbone of Thr105, and with
the sidechain of Q104. As pointed out in Chapter Two, Peacock et al. suggest that DaHMGR also
has a potential salt bridge between Glu320 and the side chain of Arg128, and another potential salt
bridge exists between Asp123 and Arg226

[19]. In all the instances, mutating glutamate,
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glutamine, aspartate or arginine, to alanine will prevent these interactions. In addition, at the
hexameric interface, the helix containing residues Gln133 to His125 spans across a series of antiparallel B-sheets. By mutating Gly126 to a glutamine, it is possible that the large side chain
introduced through this mutation would prevent the helix from interfacing with the B-sheets
(Ashley Yang and Yan Kung, unpublished.) Figure 3 shows images of these various interactions
at this interface. Towards the goal of disrupting the hexameric interface, it seems highly likely that
a combination of a variety of the above mutations would prove successful to this end . Size
Exclusion Chromatography can be used to characterize the oligomeric state of the expressed
proteins, and kinetic analysis can be performed to assess the resulting catalytic activity.
In addition, Peacock et. al., analyzed the interfaces of the three NAD-preferring class II
HMGRs whose structures have been deposited in the Protein Data Bank, all of which appear to
form hexamers, PmHMGR, DaHMGR and BcHMGR, and they note that the hexameric interface
of DaHMGR is the strongest with two potential salt bridges and eight hydrogen bonds at the
DaHMGR interface, one salt bridge and seven hydrogen bonds at the PmHMGR interface, and
one salt bridge and two hydrogen bonds at the BcHMGR interface [19]. With such information,
one could vary the strength of the interface in a rational way to either increase or decrease the
strength of the interactions. In doing so, one could influence the equilibrium of oligomerization in
solution such that increasing or decreasing the number and strength of these interactions could lead
to greater or lesser proclivity to form hexamers. It remains to be determined, however, if and how
oligomerization influences activity, but the crystal structures provided in this study, in addition to
the structures already available in the Protein Data Bank, provide ample room for metabolic
engineering efforts.
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Another metabolic engineering approach of modulating activity would be to increase or
decrease the affinity of substrate, intermediates, and products, thus influencing the rate at which
the forward or reverse reaction occurs. An overlay of apo DaHMGR and HMG-CoA bound
SpHMGR show a highly conserved binding pocket. However, one interesting difference exists at
the solvent exposed region of HMG-CoA. A serine instead of an arginine flanks the adenine
portion of HMG-CoA. In HMG-CoA bound PmHMGR, this arginine interacts with the adenine
moiety through cation-pi stacking interactions as shown in Figure 4, similarly observed in CoAbound-BcHMGR [19].
Further analysis into the sequence alignment of various class II HMGRs reveal that this
residue is either aromatic –tyrosine or histidine—or arginine, but in SpHMGR this residue is a
serine. Figure 4C shows a sequence alignment at this region. It is probable, that the aromatic side
chains also undergo pi-pi stacking interactions between the ring structures and the adenine moiety
in a similar manner as arginine where it is observed in the case of HMG-CoA-bound PmHMGR.
Consequently, one could assess if and how these residues, namely tyrosine, histidine, arginine and
serine, influence HMG-CoA affinity, and could rank these mutations in order of its influence on
activity. Using this unique site is advantageous because it is likely that mutating other residues
within the binding pocket would result in more drastic changes to HMG-CoA affinity as is
emphasized by the highly conserved architecture. In contrast, this site already has some variability,
and affords flexibility in metabolic engineering to be able to fine tune substrate affinity.
5.4.2.3. Modulating HMGR cofactor preference
The entire of Chapter Four is dedicated to HMGR cofactor preference, and as pointed out,
being able to control cofactor affinity and preference is valuable in the metabolic engineering
arena. To this end, researchers could either enhance or diminish the affinity of a cofactor to an
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HMGR, make an HMGR more promiscuous towards NAD(H) and NADP(H), or switch the
cofactor preferences entirely. In the previous section, the importance of cofactor requirements
within the context of the forward or reverse reaction within aerobic or anerobic conditions was
proposed and emphasizes the importance of being able to control this feature.
The results of Chapter Four set forth a promising path towards modulating cofactor
preference not only in DaHMGR and SpHMGR, which were the HMGRs investigated in that
chapter, but also across class II HMGRs. The patterns observed and utilized, namely the residues
that constitute the cofactor helix that is believed to dictate cofactor preference, is a potentially
translatable approach where this paradigm could inform a variety of engineering efforts in
HMGRs. However, as also discussed in Chapter Four, while there are some approaches that are
translatable, it may be necessary to take each HMGR on a case-by-case basis.
In the case of NADH-preferring DaHMGR, for example, one could compare its cofactor
helix, RDKVLIGL, with that of another NADH-preferring HMGR, PmHMGR, which has the
cofactor helix of KDQLLNSL in an attempt to investigate which helix would provide better
cofactor affinity. From this scaffold, additional modifications to the cofactor helix could be made
to influence cofactor affinity. It is conceivable that one could create a highly efficient DaHMGR
based on its engineered ability to use very small amounts of NAD(H) which would be useful in a
biosynthetic platform that needs to optimize cofactor requirements. If, on the other hand, one
desires to diminish activity, to prevent the reaction from producing toxic amounts of the product,
one could alter the cofactor helix accordingly.
In a biosynthetic platform that has both NAD(H) and NADP(H) it may also be
advantageous to be able to modify DaHMGR with the ability to use both cofactors. This would be
particularly important in a platform where the availability of either of these cofactors is of
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importance. Chapter Four revealed a chimeric DaHMGR, DaHMGR_SpHMGR-helix, which is
able to use both NADH and NADPH comparably. While this chimeric construct has a slightly
higher preference for NADP(H), it is significantly more promiscuous than wildtype DaHMGR. If,
however, one desires to switch the cofactor preference of DaHMGR entirely, one could modify
DaHMGR_SpHMGR-helix with the addition of the T189M mutation discussed in Chapter Four.
This chimeric DaHMGR, DaHMGR_SpHMGR-helix+T189M, has a new preference for
NADP(H) and can be used in a pathway where NADP(H) is the most abundant cofactor available.
While work still needs to be done to improve the overall efficiency of the chimeric enzymes
mentioned above, it is exciting to consider the successful proof-of-concept already demonstrated
in the research presented here.
One could make the argument, that instead of engineering an existing HMGR to have
different activity, whether it be for the purpose of exploiting oligomerization dynamics, substrate
binding, or cofactor affinity, that one could simply use a different HMGR homology instead.
However, this is not always a feasible option. As pointed out in the study that began this section,
a variety of factors need to be considered when interchanging HMGRs. Examples of some of these
factors include cofactor preference, its rates for the forward or reverse reactions, and how the
HMGR performs under aerobic versus anerobic conditions. Ultimately balancing of all these
factors in the context of the specific pathway would benefit from being able to customize them.
For example, in the amorphadiene study, SaHMGR had the highest forward reaction rate,
producing the most mevalonate under aerobic conditions with its preferred cofactor. This would
suggest that SaHMGR would be the ideal HMGR to use. However, as already pointed out,
DaHMGR was able to balance the aforementioned factors that resulted in the more effective
amorphadiene production. Thus, while the intrinsic activity of each HMGR is valuable, the
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importance of rationale-based engineering of HMGRs to be able to fine tune a particular HMGR
for desired outcomes is a noteworthy pursuit which makes the work presented here valuable.

5.5.

HMGR and drug design

5.5.1. What makes a good drug?
In a general, yet concise description, a good drug needs to be safe and effective; it needs to
be safe with minimal side-effects, and effective at feasible dosages. In contrast to its concise
aspirations, the complexity of achieving these standards is immense and requires a good
understanding of parameters such as bioavailability, drug affinity, drug potency, and efficacy.
Bioavailability refers to the amount of drug present in the blood supply after the drug is
administered and is represented as a fraction of the original amount given [20]. Drug affinity is a
measure of how strongly a drug binds its target and is often expressed in terms of the dissociation
constant Kd, the concentration of one binding partner (A) required for 50% of the other binding
partner (B) to become bound in an AB complex [20]. A related term is IC 50 which is a measure of
the concentration of a drug inhibitor that prevents 50% of the native substrate from being bound
to the target [20]. Efficacy is a measure of the maximum possible effect of the drug in its
physiological context, and potency, which is noted in terms of EC 50 , is the concentration of drug
required to produce 50% of the maximum effect [20].
A majority of drug compounds target proteins, in the form of receptors, enzymes and
transport proteins, as a means of performing its therapeutic outcome [20]. In this context, good
drug design requires interrogation of the drug-protein complex such that the quantity, position, and
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strength of the interactions can all be modulated with flexibility which is a result of intimate
knowledge of the structure and function of the protein. Typically, a high-throughput screen is used
to identify lead compounds with a crude Kd to measure affinity of the drug to the target. From this
scaffold, additional functional groups are removed, modified, or added, to increase the drugs
therapeutic outcome.
What makes drug development increasingly complex, however, is that some of the above
parameters –bioavailability, affinity, efficacy, and potency –can be mutually exclusive. For
example, one could discover a compound that binds very tightly to the target protein, but it is
possible that due to the makeup of the compound, the drug is unable to pass through the various
metabolic routes to enter the blood at high enough doses. Thus, if its bioavailability is poor, then
the overall effect of the compound is severely hampered. In this example, researchers could
consider modifying the lead compound, by removing, modifying, or adding functional groups that
aid in the drug’s bioavailability. There is also the concern that the drug could interact with other
proteins in the body causing toxicity issues. Again, the strategy could be to introduce structural
features onto the compound that retain its binding affinity to the original target while disrupting
its binding to unwanted alternative targets. As such, it is insufficient to simply screen for
compounds that have high affinity to its target. Instead , it requires substantial downstream
optimization to balance strong binding of the drug to the target as well as other factors that
ultimately contribute towards its safety and effectiveness.
The types of drug-target interactions pertinent to drug design are as follows: electrostatic
interactions, which are the strongest of interactions applicable to drug design, and are notably
inversely proportional to distance and highly dependent on the nature of the environment;
hydrogen bonds vary in strength and is dependent on the angle at which the electron-rich and
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electron-deficient atoms interact; Van der Waals interactions are considered weak, highly distancedependent interactions, but in greater quantity can be crucial in binding, such as those between a
carbon skeleton of a drug and parts the enzyme; other interactions include dipole-dipole, ion-dipole
and repulsive interactions[20]. Armed with high resolution crystal structures of the target protein,
a researcher can utilize the above knowledge of the quantity, position, and strength of the
interactions, in developing a drug that is finely tuned to exploit these interfaces while also
balancing factors such as bioavailability and minimizing non-specific binding that collectively
contributes towards favorable therapeutic outcomes.
In addition to understanding the drug-target complex, further knowledge about the
protein’s manifestation within the cell and body need to be considered. For example, there needs
to be a good understanding of the relative expression and abundance of the protein within the cell
and localization of the target protein in various parts of the host[21]. Furthermore, the way a protein
presents itself in the cell, as compared to in vitro, is an important consideration. As outlined in
Chapter Two, the way a protein presents itself in its native context can often be studied using
solution-state techniques and include topics such as its dynamic three-dimensional constitution
and its oligomerization states. Additionally, crystal structures of the target protein are vital in drug
design efforts. Therefore, while substantial research and development is emphasized during the
later drug approval processes, namely pre-clinical to approval phases, drug research relies on the
work of basic research in studying the structure and function of the protein in isolation[22].
5.5.2. How can we target class II HMGRs at the active site?
5.5.2.1. The feasibility of targeting class II HMGRs
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It is not within the scope of this study to pursue drug design. On a drug research and
development spectrum ranging from a concept to FDA approval, the data from the research
presented here humbly positions itself at the earliest of stages. However, the results provided here,
namely the solution-state studies in Chapter Two, and the relatively high-resolution structural data
and kinetic parameters revealed in Chapter Three, provide a feasible foundation of basic research
from which to work from. The overall aim would be to identify HMGRs from specific pathogens
and observe if inhibiting HMGR from those pathogens would result in depriving the organism of
necessary metabolites required for survival. This concept has already been explored as was
demonstrated in one study where researchers showed that HMGR was essential for survival in
Staphylococcus aureus by genetically perturbing the gene that encodes HMGR [13]. An inhibitor
designed to prevent HMGR activity in Staphylococcus aureus, a bacteria that can sometimes cause
serious infections with the concern of growing multi-drug resistant strains [23], could lead to the
development of a novel antibiotic.
An important observation worth noting is that class I inhibitors, namely statins, are highly
effective at disrupting class I HMGR activity which serves as the basis for modulating cholesterol
synthesis as pointed out in Chapter One. However, statins do not bind to class II HMGRs as well
as class I HMGRs with one study showing over 104 -fold higher Ki values for Lovastatin inhibiting
class II HMGR over class I HMGR[24]. There are specific interactions between the drug and the
residues of class I HMGRs that are lacking in class II HMGR which contribute towards the
differences in inhibition profiles [24]. Of importance is that class I and class II HMGRs reveal
changes in the residues that are crucial for catalytic activity as well as in regions that promot e
oligomerization as elaborated in Chapter Two[25].
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Herein lies an important observation: the above data suggests that there are substantive
differences between the active site architecture between both classes of HMGR. So, it is feasible,
and in the case of statins, already shown that a drug can be specific to either class I or class II
HMGR. This is advantageous because if the purpose of inhibiting HMGR is to disrupt HMGR
from a pathogen, it would necessarily want to avoid targeting the host HMGR. Thus, the
differences between the three-dimensional structural determinants that result in the varying HMGR
inhibition profiles between classes of HMGRs aids in the feasibility of being able to select between
the host HMGR and pathogenic HMGR.
To date, there lacks a comprehensive comparison of the functional differences between
various homologs with respect to inhibition. Most studies assess inhibition with regards to a
specific HMGR without comparing inhibition across HMGRs. There are, however, kinetic studies
done using HMG-CoA for a variety of class II HMGRs. In Table 1, the KM values of various class
II HMGRs are shown in increasing order. These values range from 7.34 to 175 μM HMG-CoA.
This variation reveals that in some instances, the differences in KM are small, for example, 19.8
versus 20 μM HMG-CoA for LmHMGR and EfHMGR respectively. However, differences
between DaHMGR and SpHMGR, for example, differ by 10-fold with values of 7.34 versus 75.86
μM HMG-CoA.
This would suggest that there might be structural differences not only between classes of
HMGR but also within class II HMGR that may facilitate drug design that is selective towards
specific pathogens. One could interpret the kinetic values above as reason to suggest that ultimately
drug design needs to be taken on a case-by-case basis considering that many of the KM values vary
only by 3-6-fold. Working with the exact structural and functional characteristics of a particular
HMGR is warranted.
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5.5.2.2.Targeting HMGR at the active site
The crystal structures of DaHMGR described in Chapters Two and Three represent the first
crystal structures of HMGR from Delftia acidovorans. In addition, at the time of publication, there
were crystal structures of only two other class II HMGR homologs, namely PmHMGR and
SpHMGR, and as such the publication of DaHMGR structures increased our ability to ascertain
differences and similarities between HMGR homologs. Since then, the structure of BcHMGR has
also been published. In addition to DaHMGR, high resolution structures of SpHMGR and
SpHMGR mutant constructs were presented in this research. While structures of SpHMGR already
exist, obtaining higher resolution structures, with novel insight, enhances our understanding on a
molecular level. However, considering how ubiquitous HMGR is in biology, the need for
additional crystal structures of various HMGR homologs still persists.
The catalytically important residues at the active site of class II HMGRs are highly
conserved among class II HMGRs. Figure 5, an overlay of the active site of several class II
HMGRs, illustrates how well conserved the residues and their respective positioning are. As such,
it would be particularly difficult to design a drug that differentiates between species using
rationale-based structural analysis. In practice, a highly effective method of finding compounds
that bind uniquely to the active site is to use a high-throughput screen, and specifically, a highthroughput screen that reveals drugs that not only bind the active site but also inhibit the function
of the enzyme. From this screen, compounds can be further investigated. To this end, there have
already been some efforts which have revealed important findings that would facilitate future drug
design that will be discussed here.
Prior investigations have suggested that a drug that targets class II HMGRs must include
the -CH 3 and -OH groups on the β-carbon and the carboxyl group of mevalonate[26], [27], [24].
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The importance of these functional groups makes sense considering that the substrates,
intermediates, and products of this reaction, namely HMG-CoA, mevaldyl-CoA, mevaldehyde and
mevalonate, all contain these moieties. It was shown that exchanging these functional groups with
others resulted in a loss of inhibition[24]. The work presented in Chapters Three and Four,
containing several structures of DaHMGR and SpHMGR with citrate bound in the active site,
directly relates to this phenomenon. Citrate was introduced during crystallization experiments by
using crystallization solutions with citrate as a buffering component. Citrate contains the -OH on
the β-carbon and the carboxyl group of mevalonate, however it has a -CO2 group instead of a -CH3
on the β-carbon of mevalonate. This seemingly small difference in functional groups showed a
correspondingly low citrate inhibition with a Ki of 170 mM. This inhibition is weak despite
showing that citrate competitively binds with respect to the substrate by occupying the mevalonate
binding site with some of the expected substrate interactions. This further emphasizes the
importance of each of the above functional groups. If, for example, high-throughput screening of
drug candidates reveal new compounds that lack some of the above structural characteristics, the
initial drug lead can be modified to include these functional groups to enhance drug-HMGR
interactions.
In Chapters Two and Three, there was an analysis of the various conformations the Cterminal domain (CTD) assumes at various points in the mechanism. Of importance is that the
CTD interfaces with the rest of the protein differently through these various conformations such
that different residues are presented to the active site at various points in the mechanism. For
example, in the ternary structure of PmHMGR bound to HMG-CoA and NAD+ where the CTD
adopts a closed conformation, His381, Leu372 and Ile377 all of which are from the CTD, are
implicated near the active site and proposed to be catalytically important [28]. His381 is the
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catalytically important histidine described in Chapter Three. It also proposed that Leu372 and
Ile377, form a part of a hydrophobic pocket along the inner face of the first helix of the CTD which
may help to shield the hydride transfer reaction from solvent and create a favorable hydrophobic
environment for the nicotinamide moiety[28]. In the HMG-CoA-bound SpHMGR structure which
positions the CTD in a partially closed conformation, Lys380 and Lys384, both of which are from
the CTD, directly interact with the diphosphate moiety of HMG-CoA. In both above instances, the
position of the CTD introduces new interactions at the active site along the substrate-binding motif
that provides additional hot spots to target which are beyond the conserved active site residues.
For example, the hydrophobic residues offer the medicinal chemist the opportunity to utilize Van
der Waals interactions using carbon skeletons as previously mentioned.
In this research, novel locations of the CTD are revealed. One structure of DaHMGR
reveals the CTD in a flipped conformation with citrate bound in the active site. Citrate mimics the
binding of mevalonate and the HMG moiety of HMG-CoA. While there are no specific interactions
between residues of this CTD in the flipped conformation and citrate, the second helix, instead of
the first helix mentioned above, lays adjacent to the active site. In this orientation, residues of the
second helix can be exploited as drug targets. One example is Arg405 which is in reasonable
proximity to the substrate and cofactor. Figure 6 shows the positioning of the second helix and the
location of the Arg405 with respect to the substrate and cofactor. Arginine offers the medicinal
chemist the opportunity to create ionic interactions which are the strongest drug-protein
interactions as previously mentioned.
Targeting specific HMGRs will be effective using high-throughput screening of small
molecules. After this initial phase of finding promising leads, rationale-based optimization of drug
design will be enhanced by our understanding of the structural insight obtained from the
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aforementioned structures. New insight obtained from relatively high-resolution structures of
DaHMGR and SpHMGR with regards to interactions at the active site and substrate binding sites
offer additional opportunity to strengthen drug-protein interactions. These additional hot spots are
important when considering how similar the active sites between HMGRs are and may be
necessary when trying to design drugs that are highly specific.
5.5.2.3.Targeting allosteric sites of HMGR
In the previous section, the CTD was discussed in the context of generating drugs that
target the residues that exist on the CTD that interface with the active site. The goal was to design
substrate inhibitors that exploit CTD interactions near the active site. However, in this section, we
continue exploring the role of the CTD by proposing ways to target the CTD at other locations. As
pointed out in Chapter Three, the CTD is required for catalysis, so it seems plausible that designing
a drug that prevents the activity of the CTD offers an opportunity to halt the entire reaction by
allosterically regulating the enzyme.
The CTD plays at least two important roles. First the role is to position the catalytically
important histidine at the active site at a precise step in the reaction mechanism. The second role
is to allow substrates, intermediates, and products to enter, be retained, or leave, at the appropriate
step within the reaction mechanism. By performing its catalytically important duties, the CTD
traverses through various conformations, including being in an open conformation that may exist
like an extended arm that is able to move freely, to then interfacing with the rest of the protein in
partially closed, closed, and flipped conformations. It is possible, then, to create a small molecule
that prevents the CTD from being able to adopt one or more of the catalytically important
conformations. As expected, HMGR mutants where the CTD was completely truncated showed
no activity (Edwin Ragwan and Yan Kung, unpublished).
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There are several key positions on the CTD that would be good targets and involve the two
important roles previously mentioned. One target would be the catalytically important histidine.
The structures of the various conformations of the CTD presented in this research emphasize the
inherent flexibility of the CTD. In the DaHMGR structure containing the CTD in the flipped
conformation, the catalytically important histidine points away from the protein and are exposed
(see Figure 7). Furthermore, the open conformations of the CTD in SpHMGR discussed in Chapter
Four shows that there are multiple possible open conformations. Thus, in an open conformation,
the CTD is vulnerable to being targeted by small molecules at various locations along the peptide
chain. Therefore, either in the flipped conformation or in the open conformations, a small
molecule, such as a peptide fragment, designed to target the catalytically important histidine and
flanking residues could function as an effective antagonist to overall protein activity.
Additional targets of the CTD include the regions that interface with the protein. By
generating compounds that prevents the closure of the CTD one could kill both roles of the CTD,
namely the positioning of the histidine at the active site and the controlling the flux of substrates,
intermediates, and products. Prior to this research, these interfaces were limited to closed and
partially closed conformations, but the novel flipped conformation revealed through structural
analysis of DaHMGR provides additional approaches. A related target would be the flexible linker
that joins the CTD with the rest of the protein. A peptide fragment designed to immobilize this
linker, or one that would sufficiently disrupt its flexibility, will prevent the overall movement of
the CTD.
Yet another allosteric target would involve preventing oligomerization of HMGR. HMGR
is catalytically active as a dimer where the substrate of one monomer interacts with the cofactor of
its adjacent monomer. The dimerization interface, as discussed in Chapter Two, is extensive and
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well conserved, and requires a well-orchestrated interlocking between the N-terminal domains of
each monomer. It is unknown how and when this dimerization event takes place. It does, however,
open the possibility of designing a small molecule that would prevent this dimer from forming.
Moreover, solution-state studies of DaHMGR revealed in Chapter Two suggests that it exists as a
hexamer made up of a trimer of dimers. It remains to be investigated how the activity of the
hexameric structure compares to a dimer. If the hexamer is more catalytically active, one could
target this higher order oligomerization motif.
Most drugs that work on proteins directly bind to the active site however this allows for
the drug to bind to the active sites of proteins that have related functionality which results in nonspecific interactions leading to side effects [29]. A marked advantage of targeting allosteric sites,
therefore, is the ability to be highly selective towards regions of a protein that do not necessarily
share conserved motifs, thus allosteric regulation offers a new paradigm for drug discovery [30].
In the case of HMGR, while the catalytic histidine is well conserved, the residues flanking the
histidine are not. Therefore, generating a peptide fragment that targets a unique motif
encompassing the histidine of a specific HMGR homolog offers the opportunity to be highly
specific towards that homolog. Similar to traditional drug design and development that targets the
active site, the proof-of-concept of using allosteric regulation still requires further scrutiny into the
effects of using allosteric modulators, but the basic science research presented here provides some
of the foundations of these approaches.
In this section, we discussed the importance of understanding the basic biochemistry of
proteins in order to exploit them as drug targets. More specifically, by having intimate knowledge
of the active site, allosteric sites, oligomerization motifs, and CTD dynamics, of HMGRs, one
could design drug compounds that perturb activity as a means of inhibition. Greater understanding
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of these endeavor’s provides flexibility in drug design to be able to modify drug leads by balancing
important drug efficacy parameters that eventually contribute towards its safety and effectiveness.
The kinetic, biophysical, and crystallographic data presented in the earlier chapters were discussed
in this context and proved valuable in expanding the preliminary work needed to exploit HMGR
as a drug target.

5.6.

Conclusion
In sum, this study adds to and extends our understanding of class II HMGR, an enzyme

that is implicated across biology as well as in synthetic endeavors. This research has elucidated
some of nature’s terrific strategies in being able to generate unique structural features that give
HMGR its ability to carry out its mechanism. It also offers biochemists the opportunity to harness
these strategies for numerous benefits. Chapter Two highlighted the importance of biophysical
characteristics such as oligomeric state in solution and overall three-dimensional dynamics.
Chapter Three investigated the atomic-level detail of the mechanism and paid specific attention to
the mobile C-terminal domain that directly aids in catalysis. Chapter Four focused on the structural
determinants of cofactor specificity with protein engineering that utilized nature’s design to
rationally alter cofactor preferences. Despite significant strides being achieved, this study unearths
further opportunities for inquiry and warrants ongoing investigation into this biologically
important enzyme. Its direct applications are abundant, but, importantly, the advancement in our
understanding of the way evolution has developed this fascinating protein continues to be
scientifically fruitful and is valuable as we pursue deeper understanding of nature’s grand design.
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5.7.

Tables and Figures

Figure 1. Small-molecule drugs approved from 01/1981 to 09/2019. Newman and Cragg
highlight the small molecules that were approved based on their source in their pie chart in this
figure. The categories as outlined by the authors are as follows: B = Biological, N= Natural
product, NB= Natural product "Botanical", ND = Derived from a natural product, S = Totally
synthetic drug, S* = Made by total synthesis, but the pharmacophore is/was from a natural product,
V = vaccine. (Newman and Cragg, J. Nat. Prod. 2020, 83, 3, 770–803)
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Figure 2. Cell based versus cell-free based metabolic engineering. Cell based metabolic engineering (left),
utilizes endogenous and exogenous enzymes of a pathway within a host, to convert selective feedstock to a
desired product. The host cell can be grown in large amounts and may require supplementation with reaction
intermediates such that large-scale production of the desired product is obtained and subsequently extracted.
Cell-free based metabolic engineering (right) is done in vitro where isolated proteins are incorporated into a
synthetic pathway, that utilizes the selective feedstock as a substrate, to create the desired product. Largescale synthesis can be obtained and may require supplementation of necessary metabolites to creat e large
amounts of the desired product that can subsequently be extracted.
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Figure 3. Hexameric interface interactions. Various interactions between adjacent monomers at
the hexameric interface of DaHMGR. These interfaces appear to stabilize the hexameric formation
and are candidates for site-directed mutagenesis when trying to modulate the formation of the
hexamer. One monomer is colored orange, and the adjacent monomer is colored green. When
depicted, residues and backbone are shown as sticks, with the following coloring: O = red, N = blue
and carbons colored the same as its respective monomer. A) Glu320 makes backbone interactions
with His125 and Gly126. B) Gln133 makes interactions with the side chain of Gln104 and with the
backbone of Thr105. C) Glu320 makes electrostatic interactions with Arg128. D) A potential side
chain interaction between Asp123 and Arg226. A) and B) are being investigated in the Kung Lab
(Ashley Yang and Yan Kung, unpublished). C) and D) have been proposed by Peacock et al.
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Figure 4. Variance in residues that appear to interact with the solvent exposed adenine
moiety of HMG-CoA in various HMGR homologs. A) and B) show residues flanking the
adenine moiety of HMG-CoA. A) HMG-CoA-bound SpHMGR (PDB 5WPK) shown in cartoon
representation in purple with Ser9 and HMG-CoA shown as sticks. B) HMG-CoA-bound
PmHMGR (PDB 1QAX) shown in cartoon representation in green with Arg11 and HMG-CoA
shown as sticks. Sticks are colored as follows: O = red, N = blue, C = colored according to the
cartoon representation. C) A sequence alignment at the N-terminal region of various HMGR
homologs, with the highlighted residue being the one that appears to flank the adenine moiety of
HMG-CoA. The residue that appears to interact with the adenine appear to be either aromatic
(tyrosine or histidine), arginine, or serine.
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Figure 5. Overlay of the active site of several class II HMGR homologs. Two different views
of an overlay showing the active site of HMGR ofrom various class II HMGRs. Side chains of
residues in the active site are shown as sticks with the following coloring: PmHMGR in green
(PDB 1QAX), SpHMGR in magenta (PDB 5WPJ), BcHMGR in yellow (PDB 6P7K), and
DaHMGR in light pink (6EEU). HMG-CoA is shown as spheres and are colored as follows: C =
gray, O = red, N = blue, S = yellow, P = orange.
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Figure 6. Arg405 introduced near the active site as a result of the flipped conformation found in citrateand NAD-bound DaHMGR. Citrate- and NAD-bound DaHMGR shown in cartoon representation colored
gray, with the first, second and third helices of the CTD in the flipped conformation colored cyan, magenta,
and yellow respectively. Arg405, which is part of the second helix, is now in the vicinity of the active site,
closer to the cofactor. HMG-CoA is modelled in from HMG-CoA-bound PmHMGR (PDB 1QAX). Worth
noting is that due to the large sidechain of Arg, this residue can be exploited as a drug target beyond its specific
positioning above. Ligand sticks are colored as follows: C = green, O = red, P = orange, N = blue, S = yellow.
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Figure 7. Flipped versus closed conformation of the CTD. On the right, is an overlay of the flipped
and the closed conformations. The CTD of citrate- and NAD-bound DaHMGR (PDB 6DIO) in the flipped
conformation is shown in cartoon representation with helices 1, 2, and 3 colored in dark green, dark
orange, and dark blue respectively. The CTD of HMG-CoA- and NAD-bound PmHMGR (PDB 1QAX)
in the closed conformation is shown in cartoon representation with helices 1, 2 and 3 colored light green,
light orange, and light blue respectively. The rest of the protein of DaHMGR and PmHMGR is depicted
in gray surface representation. NAD and HMG-CoA from HMG-CoA- and NAD-bound PmHMGR
(PDB 1QAX) is modeled in. The catalytical histidines, His381, of each CTD is shown in sticks. On the
left, is a close-up view of the flipped and closed conformations, highlighting the location of His381 in
each CTD. In the flipped conformation, His381 is solvent exposed and away from the active site. In the
closed conformation, His381 is buried and directed towards the active site. Sticks are colored as follows:
C = green, N = blue, O = red, P = orange, and S = yellow.
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Table 1. Km values for various class II HMGRs shown.

HMGR homolog
DaHMGR
LmHMGR
EfHMGR
SaHMGR
PmHMGR
SpHMGR
AfHMGR

KM HMG-CoA (μM)
7.34
19.8
20
40
50
75.86
175
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KM NADH (μM)
28.5
150
ND
100
80
153
160
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